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Abstract 
Eye disorders are on the rise as a result of an ageing population, an increasing 
obesity problem and a growth in the number of diabetic patients. Conventional 
ophthalmic formulations do not maintain therapeutic drug concentration in the 
target tissues for a long duration due to the physiological and anatomical eye 
barriers. Novel delivery systems such as nanoparticles have been explored to 
enhance the delivery of therapeutic agents to the eye. These delivery systems 
have in general been assessed using in-vivo animal models, despite ethical 
concerns for animal wellbeing. 
The aims of this thesis were to synthesise and characterise four amphiphilic 
polymers, subsequently prepare and characterise four nano sized polymeric self-
assemblies loaded with triamcinolone acetonide (TA), develop an in-vitro porcine 
eye model and to evaluate the permeation of nano sized self-assemblies using the 
developed model. 
Four comb-shaped amphiphilic polymers (Pa5, Pa5-MPEG, Ch5 and Da10) were 
synthesised with a high yield (>81%) and good reproducibility. These polymers 
formed spontaneous positive self-assemblies in aqueous media (114-314 nm). 
The mean hydrodynamic diameters of the positive spontaneous self-assemblies 
entrapping TA were in the range of 200–334 nm loading high concentrations (455-
1263 µg mL-1) of TA, much greater than the TA inherent aqueous solubility or 
concentrations achieved using conventional solubilisers.  
A porcine in-vitro eye model was developed to assess drug permeation through 
anterior and posterior ocular tissues. The model was partially validated using 
tritiated water and a series of hydrophilic markers with increasing molecular 
weights. The integrity of porcine ocular tissue was checked by monitoring the 
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permeation of tritiated water to ensure the membrane intactness. Tritiated water 
permeation at 15 min was exploited as a potential method to normalise drug flux, 
as tritiated water percentage permeation at 15 min had an inverse relationship with 
tissue thickness (R2 = 0.66), to reduce the inherent variability between tissue 
samples thus increasing the accuracy of the in-vitro eye model. Four markers 
(fluorescein sodium salt, 4, 10 and 20 kDa FITC-dextran) were used for the 
purpose of investigating the effect of increasing molecular weight on ocular tissue 
permeability. The permeability of the markers displayed an inverse relationship 
and abrupt decline with Mw in terms of the permeability through scleral and 
corneal tissues of human and porcine and the molecular weight of the markers. 
The developed porcine in-vitro eye model showed good correlation with the human 
in-vitro model providing strong evidence it can be used to screen potential 
formulations before testing in-vivo.  
The TA loaded self-assemblies and a few chemical enhancers (glutamic acid, 
tween 80, chitosan, Pa5 and elevate temperature (45 °C)), selected to assist drug 
delivery via two routes (paracellular and transcellular), were tested using the 
developed in-vitro eye model. The results showed there was no marker 
permeation enhancement effect in porcine and human ocular tissues using 
chemical enhancers. 
In summary, a porcine in-vitro eye model was developed to assess hydrophobic 
and hydrophilic penetrant permeation across anterior and posterior ocular tissues. 
The porcine in-vitro eye model showed good correlation with the human in-vitro 
model providing strong evidence that the porcine in-vitro eye model can be used to 
screen potential formulations before testing in-vivo using the porcine model which 
ultimately might correlate well with the in-vivo human responses. Although TA self-
assemblies did not significantly increase drug flux through human or porcine 
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scleral tissues, it might be of interest for ophthalmic topically administered 
formulations due to their positive charge and small nano size. 
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1.1 Introduction 
Profound changes in modern life style over the past decades have led to an 
increase in the prevalence of obesity, diabetes and an ageing population (Amos, 
McCarty & Zimmet, 1997; Office for National Statistics, 2002; The NHS 
Information Centre, 2012). A significant risk factor to major eye diseases such as 
age related macular degeneration (AMD, posterior eye disease) and glaucoma 
(anterior eye disease) are associated with obesity (Cheung & Wong, 2007; Habot-
Wilner & Belkin, 2005), diabetes (Bonovas, Peponis & Filioussi, 2004; 
Chronopoulos, Trudeau, Roy, Huang & Vinores, 2011; Wong, Bui & Vingrys, 2011) 
and ageing (Cedrone, Mancino, Cerulli, Cesareo & Nucci, 2008; Klein et al., 2010). 
In the United States alone, due to a rapidly ageing population, the number of 
people affected by AMD is estimated to increase by 50% to three million by 2020 
(Yorio, Clark & Wax, 2011). Worldwide there are 70 million patients who are 
suffering from AMD or glaucoma (Yorio, Clark & Wax, 2011). In 2010 it was 
estimated that the medicines targeting these eye diseases have a projected 
market of 1.8 and 4 billion US dollars, respectively (Yorio, Clark & Wax, 2011).  
Anterior and posterior eye diseases such as glaucoma, proliferative diabetic 
retinopathy and AMD are the main causes of visual impairment, deterioration in 
visual acuity and blindness in developed countries (Antonetti et al., 2006). Patients 
with anterior or posterior eye diseases are commonly treated by surgery, laser 
treatment and medicines (Del Amo & Urtti, 2008). However, these treatments, 
especially those targeting posterior eye diseases are associated with many 
complications such as inflammation, toxicity, side effects and pain (Del Amo & 
Urtti, 2008). 
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Despite the accessibility of the eye and the ease of instilling topical dosage 
forms, the delivery pathways of drugs through ocular tissues is undoubtedly a 
complicated process in which drugs encounter many barriers (Willoughby et al., 
2010). These barriers hinder the delivery of drugs to the targeted tissue through 
the most convenient route i.e. the trans-corneal route (Willoughby et al., 2010). To 
understand the barriers and how to improve ocular drug delivery, it is crucially 
important to be familiar with the structure of the eye. 
1.2 Human Eye Structure  
The human eye is composed of two different sized anterior and posterior 
spherical segments that are connected by circular tissue called the limbus (Moore, 
Dalley & Agur, 2009). A schematic diagram of the main components of the human 
eye is shown in Figure ‎1.1. 
The anterior segment is the smaller of the two (one-sixth of the whole eye, 
8 mm radius) with an outer focal component that is a multilayer transparent tissue 
called the cornea. The posterior segment is the larger of the two segments (12 mm 
radius) with an outer white opaque collagen layer called the sclera. The eye weight 
in a human adult is approximately 7.5 grams, has a volume of 6.5 cm3 and a 24 
mm vertical diameter which is usually less than the horizontal diameter (Rogers, 
2010). The aqueous humour is a solution filling the anterior and posterior 
chambers (anterior: space between the cornea and the iris, posterior: space 
between the iris and the lens), whereas the vitreous humour is a clear gel filling 
the vitreous chamber (space between the retina and the lens) (Rogers, 2010). The 
anterior segment of the eye consists mainly of the cornea, iris, ciliary body and the 
lens while the posterior segment consists of sclera, choroid and the retina (Yanoff, 
Duker & Augsburger, 2004). The retina (inner component of the posterior 
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segment) consists mainly of light sensitive photocells which are responsible for 
converting observed light to electrical signals (Yanoff, Duker & Augsburger, 2004).  
 
 
Figure ‎1.1: Human eye structure and main components. The anterior segment consists mainly of 
the cornea, iris, ciliary body and the lens. The posterior segment consists of sclera, choroid and the 
retina (Myles, Neumann & Hill, 2005). 
 
The eye is a complex collective organ, composed of many tissues, each 
designed to perform a specific function. Detailed description of each tissue is 
beyond the scope of this general introduction, hence, some of the tissues and 
layers have been briefly mentioned (sections ‎1.2.1.4 and ‎1.2.2.2). 
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1.2.1 Anterior Eye Segment 
1.2.1.1 The Conjunctiva 
The conjunctiva is a transparent vascularised mucous membrane covering 
the anterior surface of the eyeball and the inner surface of the eyelids (Figure ‎1.1, 
(Cummings, 2012). The conjunctiva can be divided into three morphologically 
distinct areas: bulbar (covering the anterior part of the eyeball), palpebral (covering 
the inside of the eyelids) and fomix or the conjunctival cul-de-sac (a transition zone 
between the bulbar and the palpebral conjunctivas) (Hoang-Xuan, Baudouin & 
Creuzot-Garcher, 1998; Lens, Nemeth & Ledford, 2008). The conjunctival tissue 
consists of two to three layers of epithelial cells with tight junctions only on the 
apical surface layer and cuboidal basal cells (Hornof, Toropainen & Urtti, 2005). 
The conjunctival tissue also contains mucous goblet cells which are responsible 
for secreting the mucus required for the tear film stability and corneal transparency 
(Holland, Mannis & Lee, 2013). This tissue has a rich supply of blood vessels, and 
plays a significant role in systemic clearance of topically administered formulations 
(Hamalainen, Kananen, Auriola, Kontturi & Urtti, 1997).  
1.2.1.2 The Cornea 
The cornea is an avascular transparent tissue covering approximately 15% 
of the surface area of the eye (Pathak & Thassu, 2009). It is primarily responsible 
for focusing light and protecting internal ocular tissues from xenobiotics (foreign 
materials) (Thassu & Chader, 2013). Due to the absence of vasculature in the 
cornea, the corneal tissue receives nourishment from the tear film, aqueous 
humour and limbal vessels (Wilson, Semenova, Hughes & Olejnik, 2006). The 
cornea in an adult human has an average dimension of 11.5 mm horizontally, 10.5 
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mm vertically (Rufer, Schroder & Erb, 2005) and an average central corneal 
thickness of 0.53 mm (Doughty & Zaman, 2000).  
The cornea is composed of five layers (Figure ‎1.2) namely the corneal 
epithelium (the outer layer), Bowman's layer, corneal stroma, Descemet's 
membrane and corneal endothelium (Li et al., 1997; Yanoff & Duker, 2008). The 
epithelium layer consists of 5-7 layers of superficial, wing and basal epithelial cells 
(Hao, Li, Kao & Liu, 2010) that form a major barrier to ophthalmic topical 
formulation due to the tight junctions between the cells; especially in the superficial 
cells (Willoughby et al., 2010). The thickness of the human epithelial layer is 
approximately 50 µm (Li et al., 1997; Patel, McLaren, Hodge & Bourne, 2001). The 
stroma mainly consists of an extracellular matrix, stromal cells and approximately 
4% glycosaminoglycans (Akhtar et al., 2002) with an approximate thickness of 500 
µm which accounts for >90% of the corneal thickness (Willoughby et al., 2010). 
The endothelium layer consists of a monolayer of cuboidal cells with an 
approximate thickness of 5 µm (Wilson, Semenova, Hughes & Olejnik, 2006). The 
main function of this monolayer is to regulate fluid and solute transport between 
the aqueous humour and the corneal stroma. In contrast to the corneal epithelium 
the endothelium cells do not regenerate (Bourne, Nelson & Hodge, 1997) and 
upon cell death in the endothelium layer the cells flatten and enlarge in volume, 
covering the space occupied by the dead cell (Bourne, Nelson & Hodge, 1997). 
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Figure ‎1.2: Cross sectional view of the corneal tissue depicting  the five layers of the cornea 
adapted from Willoughby et al (Willoughby et al., 2010). 
 
1.2.1.3 Aqueous Humour  
Aqueous humour is a clear fluid filling the anterior inner space of the eyeball 
(approximately 250 µL); it is contained in the anterior and posterior chambers. The 
aqueous humour has a pH of 7.2 and it contains low levels of proteins, glucose, 
various ions and high levels of ascorbic acid and lactic acid in comparison to the 
blood plasma (Crooke, Guzman-Aranguez, Peral, Abdurrahman & Pintor, 2008). 
This fluid nourishes the cornea and the lens and gives the front of the eye (cornea) 
its shape. The aqueous humour drains out of the anterior chamber by the 
trabecular meshwork (spongy tissue near the ciliary body) through a set of 
channels called Schlemm's canal to the episcleral venous system (Thassu & 
Chader, 2013). The turnover and drainage of the aqueous humour (2.75 µL.min-1 
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(To, Kong, Chan, Shahidullah & Do, 2002)) plays an important role in the 
clearance of instilled topical formulations (Thassu & Chader, 2013). 
1.2.1.4 The Iris and Ciliary Body 
The iris is a circular tissue which controls the amount of light entering the 
eye by regulating the diameter of the pupil (an aperture at the centre of the iris) 
and divides the anterior and posterior chambers (Lens, Nemeth & Ledford, 2008). 
The ciliary body is responsible for the production of the aqueous humour and for 
changing the shape of the lens through a connective tissue called the zonule of 
Zinn (Figure ‎1.1) (To, Kong, Chan, Shahidullah & Do, 2002). 
1.2.2 Posterior Segment 
1.2.2.1 The Sclera 
The sclera is a vascular, tough and opaque white-yellow protective layer 
consisting of collagen, elastic fibres and proteoglycan (Watson & Young, 2004). 
The main purpose of the sclera is to maintain the shape of the eyeball and to 
provide resistance to internal and external forces (Lens, Nemeth & Ledford, 2008). 
The sclera is composed of four layers; 1) Tenon’s capsule, 2) episclera, 3) scleral 
stroma and 4) lamina fusca layers (Maza, Tauber & Foster, 2012). The Tenon’s 
capsule layer is a hypocellular layer which contains arranged compact collagen 
bundles (Maza, Tauber & Foster, 2012). The episclera layer is a well-vascularised 
layer which contains elastic tissue and macrophages (Maza, Tauber & Foster, 
2012). The scleral stroma has interwoven dense collagen fibre bundles and 
lamellae with scattered elastic fibres present within (Watson & Young, 2004). The 
innermost layer of the sclera (lamina fusca) has collagen bundles smaller than 
those that exist in the scleral stroma and branch extensively to blend with the 
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underlying choroidal tissue (Curtin, 1969; Komai & Ushiki, 1991a). This layer has a 
noticeable increase in cell numbers (sclerocytes and melanocytes) in comparison 
to the scleral stroma (Watson & Young, 2004). 
The sclera covers approximately 80% of the eye surface and varies in 
thickness (Maza, Tauber & Foster, 2012; Olsen, Aaberg, Geroski & Edelhauser, 
1998). The thickness of sclera in an adult human is thickest at the posterior pole 
(1-1.18 mm), decreasing progressively to the equator (0.4-0.6 mm) and 
progressively increasing towards the limbs (0.8 mm). The thinnest part of the 
sclera is immediately behind the recti muscles (0.3 mm) (Maza, Tauber & Foster, 
2012; Norman et al., 2010; Vannas & Teir, 1960; Watson & Young, 2004). Besides 
not having epithelium and endothelium cell layers, the scleral tissue differs 
primarily from the corneal tissue in the uniformity of the arrangement of the 
collagen fibres and the degree of hydration (Watson & Young, 2004). Relative to 
the cornea, the sclera has irregular collagen fibres (scleral collagen fibrils diameter 
25-230 nm, corneal collagen fibrils diameter approximately 25 nm) and a four fold 
lower concentration of proteoglycans resulting in  a lower water content (68% in 
comparison to 78% in the corneal stroma) (Komai & Ushiki, 1991b; Watson & 
Young, 2004). In addition, the sclera is perforated by blood vessels and has an 
extensive nerve supply (Watson & Young, 2004). 
1.2.2.2 The Choroid 
The choroid, ciliary body and iris form the vascular middle layer of the 
human eyeball. The choroid is a dark reddish brown layer, which lies between the 
sclera and retina. The choroid thickness in human eyes is approximately 220 µm 
at the posterior pole and 100 µm at the anterior (Touitou & Barry, 2007). Within 
this vascular layer, large vessels are located near the sclera (vascular lamina) and 
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extended smaller vessels (choriocapillaris) are pressed against the light sensitive 
layer of the retina. These capillaries provide oxygen and nourishment to the outer 
layers of the retina (Lens, Nemeth & Ledford, 2008; Touitou & Barry, 2007). 
1.2.2.3 The Retina 
The innermost layer of the posterior segment of the eyeball consists of the 
retina (approximately 32 mm diameter, (Kolb, Fernandez & Nelson, 2007)). The 
retina is a complex part of the eye and consists of ten layers which are depicted in 
Figure ‎1.3. The retinal tissue is divided into two segments namely, the retinal 
pigmented epithelium (RPE) and the neural retina (the rest of the cell layers). The 
RPE is a tight barrier separating the neural retina from the choroidal circulation 
(Kolb, Fernandez & Nelson, 2007). It regulates nutrients supply to the retina and 
removes metabolic end products from the retina (Yanoff, Duker & Augsburger, 
2004). 
The innermost layer (inner limiting membrane) of the retina is in contact 
with the vitreous body, while the outermost layer (RPE) is in contact with the 
choroid. The retinal thickness across mammalian species has been reported to be 
around 217 µm (Buttery, Hinrichsen, Weller & Haight, 1991; Duong et al., 2008). In 
humans the retina is thinnest at the fovea centre (approximately 178 µm) and 
thickest at the foveal rim (approximately 320 µm), beyond the fovea the retina 
progressively thins until the equator (approximately 120 µm) (Landau, 
Schneidman, Jacobovitz & Rozenman, 1997). The retina is packed with 
photosensitive cells called rods and cones (photoreceptor outer segment in 
Figure ‎1.3). There are three kinds of cone cells each responding to different 
wavelengths of light, namely, red, green and blue. Rod cells are responsible for 
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nocturnal vision and are sensitive to light but insensitive to colour (Yanoff, Duker & 
Augsburger, 2004).  
 
 
Figure ‎1.3: A schematic diagram illustrating the layer structure of the retina (neural retina and 
RPE). 
 
Near the centre of the retina there is a highly pigmented yellow spot called 
the macula. Close to the macula centre is the fovea, the fovea is a small pit (5-6 
mm in diameter (Rogers, 2010)) dominated by tightly packed cone cells 
responsible for central vision. The rest of the retina (peripheral) consists of rod 
cells responsible for nocturnal vision (Yanoff, Duker & Augsburger, 2004). The 
retina is considered as one of the most metabolically active tissues in the body 
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(Yanoff, Duker & Augsburger, 2004). Therefore, the functional integrity of the 
retina depends on the supply of nutrients and the removal of waste. This is 
achieved through the inner retinal blood and choroidal circulations (Yanoff, Duker 
& Augsburger, 2004). 
1.2.2.4 Vitreous Humour 
The vitreous humour is an acellular (apart from a few phagocyte cells) 
transparent gel (approximately 4 mL) that fills the space between the lens and the 
retina (vitreous chamber). The constituents of the vitreous body are approximately 
98-99% water (the water percentage increases with age), collagen and natural 
macromolecules such as hyaluronic acid (HA) (Yanoff, Duker & Augsburger, 
2004). The collagen confers the gel-like property of the vitreous, whereas the HA 
stabilises the collagen network (Bos et al., 2001). Unlike the aqueous humour 
which is continuously secreted and drained, the vitreous humour is undynamic. 
Therefore, any haemorrhage and inflammation in the vitreous cavity will cause 
vision obstruction and surgical intervention might be necessary to remove the 
debris (blood and cells). The vitreous humour is targeted as a drug depot for 
retinal drug delivery. 
1.3 Eye Diseases 
There are a number of diseases concerned with the eye varying in severity, 
prevalence and in duration. A brief description of some of the common eye 
diseases (anterior and posterior), pathogenesis and treatments are discussed in 
sections ‎1.3.1.1-‎1.3.2.3. 
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1.3.1 Anterior Eye Diseases 
1.3.1.1 Glaucoma 
Glaucoma is a condition where the eye trabecular meshwork becomes 
slightly blocked resulting in an increased intraocular pressure (IOP) (Edward & 
Vajaranant, 2012). Untreated glaucoma might causes damage to the optic nerve 
(Edward & Vajaranant, 2012). There are two types of glaucoma (chronic and acute 
glaucoma), both types can be considered as a type of optic neuropathy (Rogers, 
2010). The increased IOP can be reduced by means of medical intervention such 
as laser or surgery and by drugs. The drugs work by increasing the flow of 
aqueous humour (prostaglandin analogues e.g. tafluprost), decreasing the 
production of aqueous humour (beta-blockers and carbonic anhydrase inhibitors) 
or opening up the blocked trabecular meshwork (miotics e.g. pilocarpine) (Edward 
& Vajaranant, 2012; Fogagnolo & Rossetti, 2011). 
1.3.1.2 Endophthalmitis 
Endophthalmitis is an inflammatory condition of the internal ocular structure 
caused by bacterial or fungal microorganisms (Scott, Loo, Flynn & Miller, 2003; 
Shen, Wang, Tsai & Lee, 2010). It often occurs due to complications in intraocular 
surgery, particularly cataract surgery or intravitreal injections (Shen, Wang, Tsai & 
Lee, 2010). Endophthalmitis is often accompanied by severe pain, and in extreme 
cases it can result in vision loss (Scott, Loo, Flynn & Miller, 2003). Endophthalmitis 
can be treated using antibiotic (intravitreal or topical) and corticosteroids 
(intravitreal or topical) reducing the inflammation and swelling to the affected 
tissues (Das, Jalali, Gothwal, Sharma & Naduvilath, 1999; Pijl, Theelen, Tilanus, 
Rentenaar & Crama, 2010). 
Chapter 1: General Introduction 
14 
 
1.3.2 Posterior Eye Diseases 
1.3.2.1 Age Related Macular Degeneration (AMD) 
Age related macular degeneration (AMD) is a disease that affects the 
photoreceptor cells in the retina, especially the macula; the exact cause of this 
disorder is still unknown (Prasad, Schwartz & Hubschman, 2010). Generally AMD 
is painless, and progresses slowly until the central vision is lost due to the 
degeneration of photoreceptor cells and RPE (Birch & Liang, 2007). There are two 
types of macular degeneration, namely atrophic or non-exudative (dry form) and 
neovascular or exudative (wet form) (Prasad, Schwartz & Hubschman, 2010). The 
wet form is the most severe of the two and the least common (Prasad, Schwartz & 
Hubschman, 2010). The vision of patients suffering from this form degenerates 
more rapidly than the dry form (Prasad, Schwartz & Hubschman, 2010). In the wet 
form, abnormal blood vessels grow behind the retina resulting in bleeding and 
scarring that lead to the distortion or loss of central vision (Prasad, Schwartz & 
Hubschman, 2010). The dry form is less severe and it develops very slowly 
(gradual cell death of the cone and rod cells) causing gradual loss of central vision 
(Birch & Liang, 2007). 
Currently, there is no conclusive evidence to demonstrate that medical 
treatment can reverse the damage caused by this disease. Nevertheless, in 2008 
the National Institute for Health and Clinical Excellence (NICE) ("National Institute 
for Health and Care Excellence," 2013) approved the use of an anti-vascular 
endothelial growth factor (anti-VEGF) drug, ranibizumab (Lucentis®, Genentech) 
for the treatment of AMD ("National Institute for Health and Care Excellence," 
2013). The approved treatment does not reverse the damage but slows the 
progression of the disease by selectively binding with VEGF and inhibiting the 
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vascular leakage and growth of blood vessels ("National Institute for Health and 
Care Excellence," 2013). The wet form of the disease can also be treated with 
laser photocoagulation, photodynamic therapy and surgical intervention (Prasad, 
Schwartz & Hubschman, 2010). 
1.3.2.2 Macular Oedema 
Macular oedema (MOD) is a painless disease, in which swelling or 
thickening of the macula occurs, due to an increase in retinal blood vessel 
permeability (Cummings, 2012). This leads to the retention of fluid and protein 
deposits collected on or under the macula (Cummings, 2012). Macular oedema is 
a common posterior eye disease causing blurred and/or distorted vision (Dartt, 
Dana, D'Amore & Niederkorn, 2011). It can be classified as macular oedema 
caused by systemic diseases such as diabetes or chronic renal failure, or macular 
oedema caused by vein occlusion or surgical procedure e.g. cataract or retinal 
surgery. The standard treatment of macular oedema is laser photocoagulation, in 
which the laser cauterises the abnormal ocular blood vessels and thus reduces the 
swelling and improves the visual acuity in some cases. Other treatments include 
vitreous surgery, anti-VEGF and the use of corticosteroids (Jonas, Kreissig & 
Degenring, 2002; Kuppermann et al., 2007; Sivaprasad, McCluskey & Lightman, 
2006). 
1.3.2.3 Diabetic Macular Oedema 
Diabetic macular oedema (DMO) retinopathy is a condition caused by 
complications of diabetes mellitus. Diabetic retinopathy is the most common 
diabetic eye disease and is a leading cause of severe vision loss or even 
blindness (Dartt, Dana, D'Amore & Niederkorn, 2011). Hyperglycemia leads to 
high intracellular levels of glucose, oxidative stress (formation of free radicals), and 
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the activation of protein kinase C; these factors ultimately disrupt the blood retinal 
barrier (BRB) (Antonetti et al., 2006; Bhagat, Grigorian, Tutela & Zarbin, 2009). In 
non-proliferative diabetic retinopathy, blood vessels may swell and leak fluid 
whereas in proliferative diabetic retinopathy abnormal new blood vessels grow on 
the surface of the retina (Cunha-Vaz, 2010).  
Diabetic retinopathy has four stages mild, moderate, severe non-
proliferative retinopathy and proliferative retinopathy (Cunha-Vaz, 2010). The 
earliest stage is the mild non-proliferative retinopathy in which a microscopic 
aneurysm occurs. These microscopic aneurysms are blood-filled dilatations of 
blood vessels (balloon-like swelling) in the retina. The second stage of this 
condition is the moderate non-proliferative retinopathy where some blood vessels 
nourishing the retina are blocked (Cunha-Vaz, 2010). These blocked blood 
vessels lead to blood supply deprivation in several areas of the retina, which 
triggers signals to the body to grow new blood vessels, this is the last stage before 
the proliferative stage (Severe non-proliferative) (Cunha-Vaz, 2010). The disease 
progresses to the proliferative retinopathy as the starved retina triggers VEGF to 
grow new blood vessels to supply nutrients (Cunha-Vaz, 2010). These new blood 
vessels are abnormal; they are fragile and grow along the retina and into the 
vitreous body. The newly grown blood vessels do not cause symptoms or vision 
loss (Cunha-Vaz, 2010). However if blood leaks out of these vessels, this may 
cause severe vision loss and even blindness in some cases (Cunha-Vaz, 2010). 
The main way of treating proliferative retinopathy is by laser surgery and 
vitrectomy (removal of the vitreous humour). This laser surgery is called scatter 
laser photocoagulation treatment where the laser is used to shrink the abnormal 
blood vessels by placing burns in the areas of the retina away from the macula, 
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causing them to shrink. In recent years, anti-VEGF and corticosteroids have been 
shown to be effective in treating diabetic retinopathy (Avery et al., 2006; Isaac, 
Abud, Frantz, Rassi & Avila, 2012). 
1.3.3 Ocular Drug Delivery Routes 
There are four ocular drug delivery routes, namely topical, systemic, 
transscleral and intravitreal which have been employed to treat various eye 
diseases (Mitra, 2003). A summary of the four ocular drug delivery routes is 
illustrated in Figure ‎1.4. The most effective and convenient route of drug delivery 
to the anterior segment of the eye is the topical route (section ‎1.3.3.1) (Wilson, 
Zhu, Kurmala, Rao & Dhillon, 2001). However, this is not an effective way of 
delivering drugs to the posterior segment of the eye due to the obstructive nature 
of the eye barriers toward xenobiotics (foreign materials) (Wilson, Zhu, Kurmala, 
Rao & Dhillon, 2001). The systemic, transscleral and intravitreal routes 
(sections ‎1.3.3.2-‎1.3.3.4) are used in treating posterior eye segment diseases. 
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Figure ‎1.4: Schematic representation of drug distribution pathways from the four drug delivery 
routes. Colour code: Blue line = transscleral route, Red line = intravitreal route, Green line = 
corneal route, Black line = conjunctival and systemic route. 
 
1.3.3.1 Topical Drug Delivery  
This is the most convenient route, due to the accessibility of the eye and 
ease of instilling the dosage form. However, this route suffers from many 
disadvantages such as vision distortion, systemic clearance and frequent 
application that may cause inconvenience and disruption to the patient’s daily life 
(Wilson, Zhu, Kurmala, Rao & Dhillon, 2001). In addition, it is an ineffective route 
for chronic and posterior segment diseases due to the short drug contact time with 
the cornea (precorneal barriers). In addition to the corneal barrier, the aqueous 
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humour circulation and the long distance between the anterior segment and the 
retina (approximately 23 mm) are some of the main barriers limiting the access of 
topically applied drugs to posterior segments of the eye (Urtti, 2006).  
1.3.3.2 Systemic Drug Delivery  
Ophthalmic drugs delivered through the systemic route are generally 
delivered via intravenous injection (e.g. Visudyne®, Novartis AG (Prasad, Schwartz 
& Hubschman, 2010)). This route is the least desirable route in ophthalmology due 
to the high drug concentrations needed to overcome the blood retinal barriers and 
due to the toxicity that might occur in other organs in the body (Wilson, Zhu, 
Kurmala, Rao & Dhillon, 2001).  
1.3.3.3 Transscleral Drug Delivery 
In recent years, scleral drug delivery for various posterior disorders has 
attracted attention among academics and the pharmaceutical industry. The 
transscleral delivery route offers many advantages over other routes such as the 
corneal route: relative high scleral surface area (potential drug depot), high degree 
of hydration (enhanced diffusion of hydrophilic molecules), metabolically inactive 
and relatively high permeability to macromolecules (Ambati et al., 2000; 
Ayalasomayajula & Kompella, 2004; Bourges et al., 2006; Kim et al., 2009; Olsen, 
Edelhauser, Lim & Geroski, 1995). 
Drug delivery through the transscleral route is normally achieved via 
periocular injections. Periocular Injections (subconjunctival, subtenon, peribulbar 
and retrobulbar) are administered in the cavities around the eye or under the 
conjunctiva (Janoria, Gunda, Boddu & Mitra, 2007). Figure ‎1.5 illustrates the 
periocular injection positions around the eye. Periocular injections can provide 
high retinal and vitreous humour drug levels (approximately 0.01–0.1% of the 
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applied dose) in comparison to topically administered eye drops (approximately 
0.001% or less) (Thassu & Chader, 2013). 
Subconjunctival injections (volume up to 500 µL) are used to deliver drug to 
the anterior (through systemic circulation, transcorneal and transscleral diffusion) 
and posterior segment of the eye (through transscleral route). The subtenon (1-5 
mL), peribulbar (8-10 mL), retrobulbar (2-3 mL) and posterior juxtascleral (0.5 mL) 
injections are mainly used to deliver injected drug to the posterior segments 
through the transscleral route. These injections allow the dosing of large volumes 
and can be repeated as necessary (Thassu & Chader, 2013).  
 
Figure ‎1.5: Schematic representation of periocular routes of administration (Janoria, Gunda, 
Boddu & Mitra, 2007). 
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1.3.3.4 Intravitreal Drug Delivery 
The intravitreal injection (maximum 0.2 mL volume) penetrates the sclera, 
choroid and retina, this route delivers the drugs directly to the vitreous humour 
(Figure ‎1.5). However, it is associated with many disadvantages such as 
endophthalmitis, retinal detachment, haemorrhage and the need for repetitive 
treatments. The puncture point of the needle is usually at the par planar which is 
about 1.5 mm from the limbus. The par planar is the ideal point for intravitreal 
injections and implants as the peripheral retina is less vascular at this point and it 
enables the needle to deliver the drug/implant deep in the vitreous humour 
(Kompella & Edelhauser, 2011). Despite all the associated disadvantages of the 
intravitreal technique, it is the most common route of delivery to the posterior 
segment of the eye (Kompella & Edelhauser, 2011).  
1.4 The Ocular Physiological Barriers 
In order to understand the challenges and formidable obstacles facing 
ocular drug delivery to the anterior and posterior segments of the human eye, the 
eyes physiological barriers must be explained. The next two sections (‎1.4.1 
and ‎1.4.2) describe the precorneal and corneal barriers that any drug applied to 
the anterior segment of the eye must overcome, whereas sections ‎1.4.2 and ‎1.4.3 
detail the conjunctival and systemic barriers associated with drug delivery to the 
posterior segment of the eye. 
1.4.1 Lacrimal Fluid and Eye Movement (Precorneal) Barriers 
The tear film and eye lids are the first defensive barrier against any foreign 
materials entering the eye. Tear film (lacrimal fluid) is composed of three layers 
namely, lipid, aqueous and mucin, it has an approximate 3 µm thickness, 6-8 µL 
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volume and 1.2 µL min-1 turnover volume (Järvinen, Järvinen & Urtti, 1995; Thassu 
& Chader, 2013). The lipid layer is the superficial layer consists of wax esters, 
diglycerides, triglycerides and hydrocarbons. This layer reduces the surface 
friction related to blinking and eye movement and prevents the evaporation of the 
aqueous layer (Thassu & Chader, 2013). The aqueous layer consists of mainly 
water, proteins, glycoprotein, electrolytes and peptides (Touitou & Barry, 2007). 
The mucin layer consists of glycoproteins which prevent bacterial adhesion, 
provide lubrication and function as antioxidants (Touitou & Barry, 2007).  
The eye cul-de-sac can accommodate approximately 30 µL of administered 
drug without overflow. Drugs applied topically to the surface of the eye (typical eye 
drop volume 25-56 µL (Brown & Lynch, 1986)) are subjected to rapid elimination 
via the lacrimal fluid and eye lid movement. The lacrimal fluid shows a quick 
restoration time (typically 2–3 min) to its original volume (6-8 µL) (Maurice, 1973), 
and the majority of the topically administered dose is washed away within just 15-
30 s after instillation due to lacrimal turn over, blinking (every 2-10 s (Rogers, 
2010)) and induced lacrimation (Gaudana, Ananthula, Parenky & Mitra, 2010; 
Thassu & Chader, 2013). 
1.4.2 Corneal and Conjunctival Barriers 
Topically administered drugs to the front of the eye can penetrate by two 
routes, namely the corneal and non-corneal pathways. The non-corneal route 
involves drug penetration across the conjunctival and scleral tissues before 
permeation into the inner intraocular tissues (Thassu & Chader, 2013). Drugs 
penetrating through the corneal route encounter the lipophilic corneal epithelial 
and endothelial layers and the hydrophilic stroma layer (Wilson, Zhu, Kurmala, 
Rao & Dhillon, 2001). The epithelium and endothelium cell layers contain a 100-
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fold higher lipid content per unit mass than the corneal stroma (Cogan & Hirsch, 
1944) and the apical corneal epithelial cells have tight junctions (the estimated 
intercellular pore size is 60 Ǻ or less (Lee, 1990)). The epithelial layer is a rate 
limiting barrier for transcorneal diffusion of small ionic and hydrophilic drugs, as a 
result of the presence of tight junctions which retard paracellular drug permeation 
of these molecules (Klyce & Crosson, 1985). The endothelium layer is not a rate 
limiting barrier as it is approximately 200 times more permeable than the 
epithelium (Touitou & Barry, 2007). After the epithelial layer drugs encounter the 
stroma (500 µm thick) which is hydrophilic in nature and acts as a major barrier for 
highly lipophilic drugs (Urtti, 2006).  
The conjunctiva has 5-15 layers of epithelia cells with tight junctions at the 
apical end (Aulton & Cooper, 1988). Although the conjunctival tissue have more 
epithelia cell layers than the corneal tissue, it has two times larger pores and 
sixteen times higher pore density than the cornea (Hamalainen, Kananen, Auriola, 
Kontturi & Urtti, 1997). Hence, the conjunctiva is more leaky and permeable to 
hydrophilic and large molecules than the cornea and allows drugs to permeate 
through both paracellular and transcellular routes (Mitra, Velagaleti & Grau, 2010). 
In humans, the conjunctiva possesses a relatively large surface area (16-18 cm2) 
in comparison to the cornea (1 cm2) (Järvinen, Järvinen & Urtti, 1995). Due to the 
large surface area, the high vascularisation and lymphatics of the conjunctiva, 
topically applied drugs are quickly cleared into the blood circulation resulting in 
systemic distribution of the drug away from the eye (Mitra, 2003). 
The precorneal barriers and the short drug-cornea contact time is 
considered to be the primary reason for the low percentage (typically 1%) of the 
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topically administered drug to reach the intraocular tissues (Lee & Robinson, 
1986). 
1.4.3 Blood Retinal Barriers 
This barrier affects drug delivery targeting the posterior segment of the eye. 
Passive diffusion of materials into the retinal tissue is restricted by the blood retinal 
barrier (BRB) (Ranta et al., 2010). The BRB can be divided into an inner and an 
outer BRB as depicted in Figure ‎1.6. The inner BRB is located near the vitreous 
humour and is formed by endothelial capillary cells which have tight junctions. The 
outer BRB consists of the RPE and choroidal circulation. 
 
 
Figure ‎1.6: Schematic presentation of the inner and the outer blood–retinal barrier (BRB) (Hornof, 
Toropainen & Urtti, 2005).  
 
The inner two thirds of the retina obtains nourishment from the retinal blood 
vessels which branch from the ophthalmic artery (inner BRB). These blood vessels 
are not fenestrated, similar to the vessels of the brain and have tight junctions in 
between retinal capillary endothelial cells. The other third of the retina obtains its 
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nourishment from the choroidal circulation (outer BRB). The choroidal capillaries 
(choriocapillaries) have fenestrations of approximately 60 nm in diameter. They 
are leaky and relatively permeable allowing the exchange of nutrients and waste 
products (Thassu & Chader, 2013). 
Despite the high blood flow of the retinal and choroid (the average rate of 
the entire retina blood flow is 80 mL min-1, whereas the choroidal flow is ten times 
the retinal blood flow (Thassu & Chader, 2013; Yanoff, Duker & Augsburger, 
2004)). The tight junctions in the RPE and in the retinal capillaries restrict the 
movement of many substances and form a formidable barrier for drugs 
administrated systemically or periocularlly (injections in the cavities between the 
eyeball and the eye orbit, Figure ‎1.5) (Urtti, 2006).  
1.5 Ocular Drug Permeation Pathways 
1.5.1 Anterior Segment 
Drug transport across corneal epithelial cells occurs via two pathways 
namely, transcellular and paracellular. The transcellular involves cell membrane 
diffusion, channel diffusion and carrier-mediated transport through the cells. The 
paracellular involves diffusion through intercellular spaces and tight junctions. The 
passive transcellular pathway, in which molecules diffuse through the lipid matrix 
of the epithelial cells membrane, is believed to be the major mechanism of corneal 
absorption of topically applied ocular drugs (Macha & Mitra, 2003). The molecules’ 
ability to diffuse across epithelial cells through the transcellular pathway depends 
upon the molecules interaction with the constituents of the cell plasma membrane 
(lipids, cell receptors). The partitioning of molecules into the cornea is a crucial 
step to enter the cell. Consequently, the partition coefficient is a major factor in 
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determining the transport across the epithelium and stroma. A parabolic 
relationship between the partition coefficient (octanol/water) and the corneal 
permeability has been reported for many molecules (Kishida & Otori, 1980; 
Mosher & Mikkelson, 1979; Schoenwald & Huang, 1983; Schoenwald & Ward, 
1978). As a result of the lipophilic and hydrophilic nature of the corneal barriers 
(corneal epithelium and stroma), the optimal corneal permeability was reported to 
be in the range of 1-3 log partition coefficient (Lee, 1990; Mitra, 2003; Mosher & 
Mikkelson, 1979) indicating the absorption of neither extremely hydrophilic nor 
extremely lipophilic compounds is favoured. Nonetheless, other factors such as 
molecular size and charge influence the corneal permeability (Lee, Carson & 
Takemoto, 1986; Mitra, 2003). Liaw et. al. reported cationic molecules such as L-
lysine and benzylamine had 2-3 fold higher rabbit corneal permeability than 
negatively charged molecules such as L-glutamic acid and salicylic acid (Liaw, 
Rojanasakul & Robinson, 1992). The author also reported a decrease in 
polyethylene glycol (200-1000 Da) rabbit corneal permeability with increasing 
molecular weight (Liaw & Robinson, 1992). 
The paracellular pathway is the preferred route of diffusion for small 
hydrophilic molecules through the corneal epithelium. However, the existence of 
three forms of junctional complexes namely, tight junctions (zonula occludens), 
intermediate junctions and spot desmosomes hinders the transport of the 
hydrophilic molecules (Macha & Mitra, 2003). 
The two major barriers encountered in topical ocular drug delivery are the 
precorneal short residence time and the poor permeability of the cornea. 
Prolonged topical drug residence time is achieved using inserts (Jain, Carvalho & 
Banerjee, 2010; Salminen, Urtti, Kujari & Juslin, 1983), bioadhesives (Kaur & 
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Smitha, 2002) and via vehicle modification (Diebold et al., 2007). Reportedly the 
poor corneal permeability can be altered by modifying the integrity of the corneal 
epithelium either by using chemical penetration enhancers or physical 
enhancement techniques (e.g. iontophoresis) or by altering the physicochemical 
properties of the drug (prodrug) (Hao, Li, Liu & Kao, 2009; Järvinen & Järvinen, 
1996). 
Ocular penetration enhancers used topically affect either the paracellular or 
the transcellular route. The paracellular enhancers alter reversibly the corneal 
epithelial tight junction, increasing paracellular transport. Many ocular paracellular 
enhancers have been reported in the literature, most commonly calcium chelating 
agents and cytochalasins (group of small molecules which bind to the actin 
microfilaments rendering the permeability of the tight junctions). The chemical 
transcellular enhancers disrupt the cell membrane lipids and protein components, 
increasing drug transcellular permeability (Mitra, 2003; Zambito, Zaino & Di Colo, 
2006).  
A prodrug is an inactive form of the drug, which is enzymatically 
metabolised (esterases, ketone reductase, and steroid 6-hydroxylase) to the active 
parent compound in ocular tissues (Patel, Shastri, Shelat & Shukla, 2010). The 
prodrug approach has been reported to enhance corneal permeation. For example 
dipivefrine a prodrug of epinephrine (used in the treatment of glaucoma) was 
shown to have 17 fold higher corneal permeability than epinephrine in human 
(Järvinen & Järvinen, 1996; Mandell, Stentz & Kitabchi, 1978). The disadvantage 
of the prodrug approach is that it is considered as a new drug entity and hence 
extensive pharmacokinetic information is required. 
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1.5.2 Posterior Segment 
As scleral tissue is acellular and does not have epithelium and endothelium 
cell layers, the transcellular drug permeation pathway is absent. Scleral drug 
permeation can occur via the perivascular and the collagen network spaces and 
via the aqueous media of the mucopolysaccharides (Wilson, Zhu, Kurmala, Rao & 
Dhillon, 2001). Due to the structure of the scleral tissue (mainly the absence of the 
tight junctions), large molecules can passively diffuse via the tissue. Molecules of 
size up to 120 kDa have been reported to diffuse into human sclera (Nicoli et al., 
2009). Due to the porous nature of the sclera and the passive diffusion of 
penetrants in between the free spaces of the collagen bundles, scleral drug 
permeability is influenced by drug properties such as lipophilicity and solubility 
(Thakur, Kadam & Kompella, 2011). An inverse correlation between the drug 
lipophilicity of six corticosteroids (triamcinolone, prednisolone, dexamethasone, 
fluocinolone acetonide, triamcinolone acetonide, and budesonide) and bovine 
scleral transport has been reported (Thakur, Kadam & Kompella, 2011). The latter 
study also reported a strong positive correlation between drug solubility and tissue 
concentration, which affected free drug levels and scleral drug transport. 
Similar to the cornea, the drug permeability through the sclera can be 
enhanced using the prodrug approach. Malik et al. reported the permeation of 
celecoxib prodrug (celecoxib succinamidic acid) to be eight fold higher than 
celecoxib through bovine scleral tissue due to the increase in the solubility of the 
prodrug (the aqueous solubility of the prodrug was 300 fold higher than celecoxib) 
(Malik, Kadam, Cheruvu & Kompella, 2012). The alteration of the BRB 
permeability is another method to enhance posterior drug delivery. The BRB 
permeability can be altered using a hyperosmotic solution (e.g. mannitol) which 
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prompts shrinkage of the RPE cells and retinal capillaries ultimately causing the 
opening of tight junctions (Mitra, 2003). However, the aforesaid method is non-
specific, prompting shrinkage to all blood capillaries and hence rendering them 
more permeable, making this method unsuitable for specifically enhancing ocular 
drug delivery (Mitra, 2003). 
1.6 Conventional Ophthalmic Drug Delivery Systems  
There are various conventional ophthalmic formulations that have been 
developed to overcome the ocular barriers and target the internal tissues of the 
eye. The following sections (‎1.6.1 and ‎1.6.2) will briefly describe the most common 
formulations used in treating anterior and posterior segment diseases.  
1.6.1 Anterior Segment 
1.6.1.1 Topical Formulations (Eye Drops, Suspensions, Ointments and 
Gels) 
The current treatment for most anterior segment diseases is topically 
administered drugs. The topically applied formulations can be liquids, 
suspensions, creams or gels.  
Examples of eye drops solutions are antibiotics (e.g. Chloramphenicol 0.5% 
w/v), antihistamines (e.g. Azelastin Hydrochloride 0.05% w/v) and lubricants (e.g. 
Hypromellose 0.5% w/v) (British National Formulary 2013). Despite the ease and 
convenience of self-application of eye drops, conventional eye drops are inefficient 
(Siepmann, 2012) as they suffer from rapid elimination through the precorneal 
barriers (i.e. eye blinking and tear flow) resulting in a short duration of drug effect 
and hence the requirement for a more frequent dosing regimen (Siepmann, 2012). 
The actual dose penetrating into the eye from topical eye drops is estimated to be 
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less than 5% of the total administered dose (Urtti, 2006). To improve drug contact 
time, permeation and bioavailability; viscosity enhancers, such as methylcellulose, 
polyvinyl alcohol, polyvinylpyrrolidone and carbomers can be added to topical eye 
drops (Bartlett & Jaanus, 2008). Viscosity enhancers improve precorneal 
residence time and bioavailability by enhancing formulation viscosity resulting in a 
slower dose elimination from the precorneal area and hence a greater 
transcorneal penetration of the drug into the anterior chamber (Bartlett & Jaanus, 
2008).  
Ophthalmic suspensions contain solid micron sized particles of hydrophobic 
drugs suspended in aqueous medium (e.g. Betaxolol Hydrochloride 0.5% w/v, 
99.5% of the particles are less than 25 µm in size) (British National Formulary 
2013; "British Pharmacopoeia Volume III," 2012). The solid micron sized particles 
are retained in the precorneal pocket and thus improve drug contact time and 
duration of action relative to drug solution. The drug contact time and duration of 
action for a suspension is particle size dependent in which larger sized particles 
can be retained in the precorneal area for longer time and show slower drug 
dissolution compared to smaller size particles (Remington, Troy & Beringer, 2006). 
The disadvantages of ophthalmic suspensions include coagulation and 
disturbance in vision.  
Ophthalmic ointments are composed of a mixture of solid hydrocarbons 
(paraffin) which have a melting point close to the physiological ocular temperature 
(34 °C) (Bartlett & Jaanus, 2008). The drug is added to the ointment mixture either 
as a solution or as a micro sized powder. Upon administration to the precorneal 
area, the ointment can break up into small droplets forming a depot of drug in the 
cul-de-sac for extended periods. Ophthalmic ointments, such as betamethasone 
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sodium phosphate 0.1% w/v (British National Formulary 2013), are indicated for a 
range of inflammatory conditions of the eye, such as blepharitis (inflammation of 
the eyelid). Due to the viscous nature of such formulations, they provide prolonged 
therapeutic action relative to eye drops. This can be particularly beneficial for 
nocturnal use and may also enhance patient compliance due to a reduced number 
of applications. The main disadvantage of ointments is that they cause blurred 
vision due to the refractive index difference between tears and the non-aqueous 
ointment (Bartlett & Jaanus, 2008). 
Ophthalmic gels form as a result of high concentration of viscosity 
enhancers (e.g. carbomers). Viscotears® and GelTears® are two examples of 
ophthalmic gels containing carbomer 980 (British National Formulary 2013). The 
main advantage of ophthalmic gels is that they prolong precorneal residence time 
and reduce systemic clearance (Bartlett & Jaanus, 2008). Despite the high 
viscosity, a gel achieves only a limited improvement in bioavailability, and the 
administration frequency can be reduced to once a day at most. The high viscosity 
gel might results in blurred vision and matted eyelids, which reduce patient 
compliance (Bartlett & Jaanus, 2008). A newer development in ophthalmic gels is 
the use of polymers that exhibit solution-gel phase transition in the precorneal area 
(mainly cul-de-sac) in response to environmental stimuli such as pH, ion strength 
or temperature. This new development allows ophthalmic gel formulation to be 
applied using eye drops, which is simple, convenient and able to dispense precise 
volume. Timoptol® LA (British National Formulary 2013) and Lizmon TG® 
(Shibuya, Kashiwagi & Tsukahara, 2003; Yamamoto, Kitazawa, Azuma, 
Tsukahara & Nakashima, 1997) are two commercially marketed gel-forming 
ophthalmic solutions, the first changes to gel in the presence of sodium ions (ion 
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strength), whereas the latter forms gel upon changes in temperature 
(thermosetting gel) (Shibuya, Kashiwagi & Tsukahara, 2003). 
1.6.1.2 Cul-de-sac Inserts 
The cul-de-sac of the eye is situated between the palpebral or bulbar 
conjunctiva and either the lower or the upper eyelid (Lens, Nemeth & Ledford, 
2008). Ocusert® is a cul-de-sac non-bioerodible (ethylene–vinyl ester) insert 
developed for glaucoma. It provides uniform controlled release of pilocarpine over 
a seven day period (20 or 40 µg/h of pilocarpine). This product was introduced to 
the market in 1974 (Macoul & Pavanlangston, 1975), but soon after, Ocusert® was 
shown to have unsatisfactory intraocular pressure (IOP) control due to difficulty of 
insertion, irritation of the eye and displacement of the device (Sihvola & Puustjarvi, 
1981). The insert is no longer marketed due to side effects of pilocarpine, such as 
a miosis and brow ache (Molokhia, Thomas, Garff, Mandell & Wirostko, 2013). 
Lacrisert® is a rod shaped (1.27 mm diameter, 3.5 mm long) water soluble 
cul-de-sac insert introduced in 1981 (Lee, Hughes, Ross & Robinson, 2010). It is 
composed of 5 mg of hydroxypropyl cellulose without any additives (McDonald et 
al., 2009). The insert is designed to treat moderate to severe dry eye syndrome. It 
works by breaking down into cellulose, which stabilizes and prolongs the tear film 
breakup time, it also serves as an eye lubricant (Lee, Hughes, Ross & Robinson, 
2010).  
1.6.1.3 Implants 
SurodexTM is a rod shaped biodegradable poly(D,L-lactide-co-glycolide) 
(PLGA) anterior chamber implant. The implant is inserted into position (anterior 
chamber) after cataract surgery to control postoperative inflammation (Lee, Chee, 
Balakrishnan, Farzavandi & Tan, 2003). It is a matrix implant consisting of 
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dexamethasone (60 µg) and PLGA with hydroxypropyl methylcellulose. The 
implant has 1.0 x 0.5 mm dimension and provides sustained dexamethasone 
release over 7-10 d at a constant rate (Lee, Hughes, Ross & Robinson, 2010).  
1.6.2 Posterior Segment 
1.6.2.1 Systemic, Intravitreal and Transscleral formulations 
Currently, the treatment of posterior segment disease is still significantly 
limited to intravitreal and periocular injections. However, there are treatments 
which use other delivery routes (i.e. systemic) such as Visudyne®. Visudyne® is a 
photodynamic therapy (photosensitizer) developed as an alternative to thermal 
laser photocoagulation for the treatment of subfoveal choroidal neovascularization 
due to AMD. The photodynamic therapy is a two phase treatment and employs 
photosensitizer (verteporfin®) administered intravenously (systemic) followed by 
activation with a laser which emits light having the same wavelength of light 
absorption as the photosensitizer. Unlike thermal laser photocoagulation, the 
photodynamic therapy allows selective damage of tissue containing the 
photosensitizer (Prasad, Schwartz & Hubschman, 2010). 
Periocular corticosteroid injections for control of intraocular inflammation 
(e.g. uveitis) are well established clinical practice. For example TA sub-Tenon’s 
injections have been reported to be effective in the treatment of uveitis (Salek et 
al., 2013). 
More recently the majority of treatments have shifted in favour of intravitreal 
injections. Lucentis® (anti-VEGF drug) became the first-line therapeutics in wet 
AMD treatment. It is an intravitreal injection approved in the United Kingdom in 
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January 2013. NICE also approved Lucentis® for the treatment of diabetic macular 
oedema (DMO) ("National Institute for Health and Care Excellence," 2013).  
1.6.2.2 Implants 
Posterior implants are often too big to be delivered through needles and 
surgical operations have to be performed. However, recently smaller injectable 
implants have been commercialised (Sanford, 2013). Vitrasert® is a Food and Drug 
Admistration (FDA) approved implant for the treatment of AIDS-related 
cytomegalovirus infection. It requires a 4-5 mm sclerotomy (surgical incision of the 
sclera) to implant inside the human eye. It releases ganciclovir (4.5 mg) over a 6 
month period (Choonara, Pillay, Danckwerts, Carmichael & Du Toit, 2010). 
Another implant named Retisert® is an FDA approved treatment for chronic non-
infectious posterior uveitis (an inflammation of the interior tissues of the eye). 
Retisert®  is surgically implanted in the eye through a small 3-4 mm incision. The 
implant is a reservoir insert (disc shaped 3 x 2 x 5 mm) containing 0.49 mg of 
fluocinolone which releases the drug over 30 months (Nicholson, Singh, Sears, 
Lowder & Kaiser, 2012). Similarly, Iluvien® is also an intravitreal implant providing 
a sustained dose of fluocinolone acetonide to treat diabetic macular oedema. It 
has been approved in several European countries including the United Kingdom 
(Sanford, 2013). This implant is delivered through an applicator employing a 25-
gauge needle and the implant can last up to 36 months (Sanford, 2013). 
1.7 Novel Drug Delivery Systems and Methods 
Topical and conventional ophthalmic formulations do not maintain 
therapeutic drug concentration in the target tissues for a long duration due to the 
unique physiological and anatomical eye barriers (Kompella & Edelhauser, 2011). 
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Researchers and the pharmaceutical industry are still in pursuit of novel drug 
delivery systems to overcome ocular barriers and to provide prolonged drug 
therapeutic concentration by the least invasive method possible. The following two 
sections (‎1.7.1 and ‎1.7.2) describe novel drug delivery systems in various clinical 
stages and novel ocular drug delivery methods. 
1.7.1 Novel Drug Delivery Systems in Clinical Trials 
For the treatment of chronic eye diseases, various formulations are at 
different stages of clinical trial to prolong and maintain therapeutic drug 
concentration in the target tissues. The urgent need to develop novel ophthalmic 
drug delivery systems for chronic diseases arises from the necessity to increase 
the convenience for the patient, reduce the dosing frequency of both anterior and 
posterior formulations and to reduce the invasiveness of treatment targeting the 
posterior segment. 
1.7.1.1 Anterior Segment 
A subconjunctival insert developed by Pfizer, Inc. containing latanoprost 
(glaucoma treatment) is in Phase I clinical trials. The insert is composed of a 
latanoprost core contained in a poly (DL-lactide-co-glycolide) (PLGA) tube. An 
impermeable polymer caps one end of the tube, whilst a permeable polymer caps 
the other. Latanoprost is released across the permeable end and the drug release 
duration is designed to be 3-6 months (ClinicalTrials.gov Identifier: 
NCT01180062). 
IBI-10090 is a dexamethasone biodegradable product for injection into the 
anterior chamber to treat inflammation associated with cataract surgery 
(ClinicalTrials.gov Identifier: NCT01606735). IBI-10090 will be Icon’s first product 
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to reach the market using the Verisome® technology (a novel drug delivery system 
in which the final product can be manufactured in a biodegradable solid, gel or 
liquid form capable of releasing drug in a controlled manner for extended periods 
of time). Icon Bioscience also plans on using Verisome® technology for the delivery 
of therapeutic levels of latanoprost to the anterior chamber (IBI-60089) as a Phase 
I/II clinical trial will be launched in the second quarter of 2013 ("Icon Bioscience, 
Inc. (IBI)," 2013).  
1.7.1.2 Posterior Segment 
Eye drops to target the posterior segment of the eye have not yet been 
commercially introduced. However, a few eye drop formulations targeting posterior 
eye diseases are in clinical trials. 
A topical dexamethasone cyclodextrin microparticle eye drop was applied 
topically into DMO patients three or six times a day for 4 weeks. Interestingly, the 
eye drops have been shown to decrease central macular thickness and improve 
visual acuity after 4 weeks (Tanito et al., 2011). A Phase II/III clinical trial for DMO 
is currently undergoing (ClinicalTrials.gov Identifier: NCT01523314). 
Triamcinolone acetonide (TA) has been used extensively in treating various 
posterior ocular disorders such as: macular oedema, DMO and AMD using 
intravitreal or periocular injection. Despite the apparent established efficacy of 
corticosteroids, disadvantages such as the relative short half-life of drugs in their 
free form for intravitreal use and frequent dosage related problems 
(inconvenience, vitreous hemorrhage, endophthalmitis, and retinal detachment) 
has led researchers to develop a variety of sustained release drug delivery 
systems to overcome the aforementioned drawbacks. 
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Cardillo et al. designed PLGA microspheres encapsulating TA (RETAAC 
system). The efficacy of intravitreally RETAAC (1 mg) was compared to a TA 
suspension (4 mg) in DMO patients. RETAAC demonstrated a superior 
performance compared to the TA suspension in decreasing the retinal thickness 
and improving visual acuity after 12 months (Cardillo, Souza-Filho & Oliveira, 
2006). The formulation is currently undergoing Phase I/II (ClinicalTrials.gov, 
NCT00407849). 
Icon Bioscience, Inc. is also using Verisome® drug delivery platform 
technology to deliver TA via intravitreal injection (IBI-20089). The IBI-20089 is 
designed to last up to six months (6.9 mg, 25 µL) or one year (13.8 mg, 50 µL). A 
Phase I study of IBI-20089 for chronic cystoid macular oedema has been 
completed ("Icon Bioscience, Inc. (IBI)," 2013). Cohort 1 and 2 (five patients each) 
received an intravitreal injection of 6.9 and 13.8 mg of TA, respectively. The 
central subfield thickness (CST) decreased significantly from the baseline in cohort 
1 and 2 at day 1, 30 and 360 after receiving the TA intravitreal injection (Lim, 
Fung, Wieland, Hung & Wong, 2011). The IBI-20089 is now being tested in a 
Phase II clinical study adjunctively with 0.5 mg of ranibizumab (Lucentis®) for 
choroidal neovascular AMD (ClinicalTrials.gov Identifier: NCT01175395). 
Cortiject® is a preservative and solvent free emulsion encapsulating a target 
tissue-activated corticosteroid prodrug developed by Novagali Pharma 
("Cortiject®," 2013). Although a Phase I study is currently ongoing in the United 
States in patients suffering from diabetic retinopathy, to date there are no details 
disclosed about the efficacy of the trial nor about the duration of the drug release 
from the formulation (ClinicalTrials.gov Identifier: NCT00665106). 
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1.7.2 Novel Drug Delivery Methods 
1.7.2.1 Anterior Segment 
 Drug Loaded Contact Lenses 1.7.2.1.1
Recently, a drug loaded contact lens has been investigated as a potential 
technology for delivering drugs to the anterior segment of the eye. This route has 
the advantage of minimising the frequency of administration and is non-invasive. 
Costa et. al. showed the possibility of impregnating commercially available silicon-
based contact lenses with two anti-glaucoma drugs without altering important 
features of the contact lenses, such as O2 permeability (Costa et al., 2010). A 
silicone hydrogel contact lens loaded (pre-soaked) with ketotifen fumarate (allergic 
conjunctivitis treatment) sustained the drug release for more than 24 h in rabbits 
eyes (Xu, Li & Sun, 2011).  
 Capsule Drug Ring 1.7.2.1.2
The capsule drug ring (13 mm outside diameter, 0.1 mm thickness and 
volume of 50 µL) is a novel intraocular insert inserted in to the lens capsule during 
cataract surgery (placed on the empty circumferential space around the intraocular 
lens) (Molokhia et al., 2010). This implant is a non-biodegradable refillable 
reservoir capable of delivering multiple drugs to either the anterior or posterior 
segment of the eye. Molokhia et al. produced prototypes using poly methyl 
methacrylate sheets as the reservoir material with silicon valves for refilling. The 
device has shown near-zero-order release kinetics of Avastin as a model drug in 
in-vitro studies (Molokhia et al., 2010). 
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1.7.2.2 Posterior Segment 
 Drug Delivery through Suprachoroidal Space 1.7.2.2.1
The suprachoroidal space is a virtual space between the choroids and 
sclera. This space becomes real when fluid accumulates resulting of detachment 
of the choroid from the sclera. Delivery to the suprachoroidal space via 
microcannulation is a prospective route of drug delivery to the posterior segment 
of the human eye, especially to target the macular region and optic nerve (Olsen 
et al., 2006). A research team reported the use of microcannulation to deliver TA 
to the suprachoroidal space (Olsen et al., 2006). It is shown to be safe and 
reproducible in primates and pigs. Furthermore, the study demonstrated steady 
delivery of triamcinolone acetonide to the posterior tissue for at least 120 days with 
the advantage of very low systemic levels of TA, thus reducing side effects (Olsen 
et al., 2006). 
 Intrascleral Drug Delivery through Hollow Microneedles 1.7.2.2.2
A novel approach has been attempted where hollow microneedles are used 
to deliver drugs to the sclera. Microneedles can penetrate into scleral tissue 
without completely crossing or rupturing the sclera and hence they can diminish 
the side effects associated with intravitreal injections, such as pain, retinal 
detachment and haemorrhage. Microneedles can be coated with a therapeutic 
agent or used to deliver a therapeutic agent in a solution form (Jiang, Moore, 
Edelhauser & Prausnitz, 2009). The novel approach of intrascleral drug delivery 
through individual microneedles has been shown to deliver 10-35 µL of solutions 
to an approximate circular area of diameter 1-10 mm in human cadaver scleral 
tissue (Jiang, Moore, Edelhauser & Prausnitz, 2009). This novel approach 
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bypasses the conjunctival and episcleral barriers (well-vascularised tissue) and 
deposit drugs directly in the scleral tissue.  
1.8 Nano Size Drug Delivery Systems  
The European commission define nano-materials as “A natural, incidental 
or manufactured material containing particles, in an unbound state or as an 
aggregate or as an agglomerate and where, for 50 % or more of the particles in 
the number size distribution, one or more external dimensions is in the size range 
1 nm - 100 nm.” ("European Commission ", 2013). However, the range of nano-
size drug delivery systems (NDDS) in nano-pharmaceuticals according to the 
European Science Foundation ranges from 1 to 1000 nm  ("Nanomedicine," 2005; 
Volker, Bärbel & Sibylle, 2008). NDDS, broadly referred to as nanocarriers, have a 
number of exploitable properties for drug delivery, due to their small relative size 
such as, high surface area to volume ratio, the effects of Brownian motion and low 
settling velocity (Gupta & Kompella, 2006). Aqueous NDDS below 1000 nm in size 
have higher Brownian motion velocity (a 1000 nm particle has a speed of 1716 
nm.s-1) than the settling velocity (a 1000 nm particle has a speed of 430 nm.s-1) 
and hence the colloidal solutions are stable and have a long shelf-life (Gupta & 
Kompella, 2006). Colloidal solutions precipitate upon agglomeration or the 
formation of particles larger than 2 µm (Hsu, 2007; Yasukawa et al., 2004). 
NDDS have been prepared from various materials such as synthetic 
polymers (e.g. PLGA), natural polymers (e.g. chitosan), proteins (e.g. human 
albmuine serum), lipids and even metals (e.g. gold). The variation of used 
materials and different preparation methods results in numerous types of NDDS 
such as liposomes, solid lipid nanoparticles, dendrimers, polyelectrolyte 
complexes, nanoemulsions, and polymeric nanoparticles, nanospheres or micelles 
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(Badawi, El-Laithy, Qidra, Mofty & Dally, 2008; Bakkour, Darcos, Coumes, Li & 
Coudane, 2013; Chaiyasan, Srinivas & Tiyaboonchai, 2013; Hippalgaonkar, Adelli, 
Hippalgaonkar, Repka & Majumdar, 2013; Sinha, Bansal, Kaushik, Kumria & 
Trehan, 2004; Vandamme & Brobeck, 2005). Figure ‎1.7 illustrates a few types of 
the NDDS used in ocular drug delivery. The explanation of all the different NDDS 
systems is beyond the scope of this thesis but the reader is direct to read previous 
reviews (Diebold & Calonge, 2010; Lehner, Wang, Marsch & Hunziker, 2013). 
Special attention will be focused on polymeric self-assemblies (SA) as a 
consequence of their thermodynamic stability, ease of preparation and the 
possibility of eliminating organic solvents from the preparations method. 
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Figure ‎1.7: Types of nano-size delivery systems used in drug delivery. 
 
1.9 NDDS in Ocular Drug Delivery 
The use of nano-sized delivery systems is an emerging concept with 
promising potential to allow ophthalmic drugs to overcome the eye’s physiological 
barriers by enhancing penetration, prolonging drug residence time and allowing 
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the delivery of high drug concentrations to ocular tissues, with relatively fewer side 
effects such as toxicity in comparison to drug suspension and conventional 
formulations (Macha & Mitra, 2003; Mitra, 2003). NDDS are of special interest in 
ocular drug delivery due to their small size (typically 20-500 nm), which not only 
enables the foreign body sensation in the eye to be avoided but also inﬂuences 
their permeation through ocular barriers. For example the uptake of small PLGA 
nanospheres (100 nm) was found to be higher than larger particles (800 nm and 
10 µm) in primary cultured rabbit conjunctival epithelial cells (Qaddoumi et al., 
2004). Similarly, the size of the NDDS influenced their penetration into rabbit 
retinal tissue after intravitreal injection, wherein 200 and 50 nm nanospheres were 
observed in the retina unlike 2 µm spheres which were unable to penetrate the 
retina (Sakurai, Ozeki, Kunou & Ogura, 2001). 
NDDS have been reported to enhance drug bioavailability in the eye 
compared to drug alone solutions/suspensions. For example after topical 
instillation of an indomethacin chitosan nano-emulsion in rabbits the levels of 
indomethacin in the aqueous humour were found to be 30 times higher than 
topical administration of an indomethacin solution (Badawi, El-Laithy, Qidra, Mofty 
& Dally, 2008). Similarly, the levels of prednisolone in the aqueous humour of a 
rabbit eye following topical administration of polymeric micelles were similar to 
those found after administration of a tenfold dose of a commercial suspension of 
the drug (Qu et al., 2006). NDDS not only offer enhanced corneal permeation and 
high drug entrapment, but can also reduce drug related side effects. Poly-ε-
caprolactone nanocapsules with oily core containing metipranolo evaluated in 
rabbits eyes lowered the cardiovascular side effects in comparison to commercial 
drops (Torchilin, 2006).  
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Due to the high Brownian motion velocity and low settling velocity of NDDS 
in comparison to microparticles, NDDS can offer prolonged vitreal half-life. NDDS 
injected in the vitreous humour (static fluid) stays suspended for a prolonged 
period in comparison to microparticles before coming in contact with the 
surrounding tissue (retina) and hence limits contact of the drug with cells capable 
of engulfing and clearing the NDDS. Sakurai et al. reported decreased fluorescein 
vitreal half-life with an increase in size of polystyrene nanospheres containing 
fluorescein. The author reported fluorescein vitreal half-life of 5.4 ± 0.8, 8.6 ± 0.7 
and 10.1 ± 1.8 days for 2 µm, 200 nm and 50 nm particles, respectively (Sakurai, 
Ozeki, Kunou & Ogura, 2001).  
A plethora of reports demonstrated the capability of NDDS to sustain drug 
release in the posterior segment (Araujo, Nikolic, Egea, Souto & Garcia, 2011; 
Kompella & Edelhauser, 2011; Yang et al., 2013; Zhang, Li, Zhang, Wang & Song, 
2009) and to enhance corneal permeability, via transcellular, paracellular routes or 
by a combination of both (Baba et al., 2011; Contreras-Ruiz et al., 2011; De 
Campos, Diebold, Carvalho, Sanchez & Alonso, 2004; De la Fuente, Seijo & 
Alonso, 2008; Jain et al., 2011). 
1.9.1 Polymeric Self-Assemblies (SA) 
1.9.1.1 Polymer Architecture and SA Formation  
Self-assembly is a spontaneous process at which disordered amphiphiles 
(molecules consisting of hydrophobic and hydrophilic segments) organize into 
supramolecular aggregates (self-assemblies), typically in the nano size range 
(Chen, Cheng & Zhuo, 2011). The type and shape of these self-assemblies (SA) 
depends on the architecture of the amphiphiles (Letchford & Burt, 2007; 
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Thompson et al., 2008). Amphiphiles such as block co-polymers typically self-
assemble into polymeric micelles with dimension smaller than 100 nm (Kataoka, 
Harada & Nagasaki, 2012), whereas comb-shaped polymers (graft polymers) self-
assemble into polymeric micelles, vesicles or solid nanospheres as depicted in 
Figure ‎1.8 (Cheng et al., 2006; Hoskins, Lin & Cheng, 2012; Wang, Qu, Gray, 
Tetley & Uchegbu, 2004). At low concentrations amphiphiles remain as single 
molecules in solution, until reaching a critical concentration known as the critical 
aggregation concentration (CAC), at which molecules start to spontaneously 
assemble. The self-assembly process of the amphiphiles is driven by the entropy 
gain associated with the dehydration of the hydrophobic core. Freeing water 
molecules from the hydrophobic environment, facilitates the formation of hydrogen 
bonding between the unfettered water molecules and hence results in an increase 
in system entropy. 
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Figure ‎1.8: The self-assembly of amphiphiles into: polymeric micelles, polymeric vesicles and 
polymeric solid nanospheres. 
 
1.9.1.2 SA Drug Loading Methods  
SA may encapsulate drugs by chemical, physical or electrostatic means. A 
physical means is the most common; occurring via various drug loading methods 
such as oil in water emulsion, dialysis and sonication (Figure ‎1.9). The oil in water 
emulsion method involves preparing an aqueous solution of the amphiphilic 
polymer to which the solution of drug in water-miscible volatile organic solvent 
(e.g. chloroform) is added. An oil in water emulsion is formed by continuous 
magnetic stirring followed by evaporation of the volatile solvent. In this method it is 
almost impossible to completely eliminate the organic solvent which is potentially 
toxic, and hence this renders this method unsuitable for the preparation intended 
for ocular drug delivery (Pathak & Thassu, 2009).  
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In the dialysis method, both the polymer and drug are dissolved in an 
organic solvent; the polymer-drug solution is then dialysed against an aqueous 
based solvent. The passive diffusion of the organic solvent from the dialysis bag 
into the aqueous based solvent drives the formation of self-assemblies with the 
drug becoming encapsulated as a result of decrease in polymer/drug solubility with 
the decrease of concentration of the organic solvent. The organic solvent used in 
dissolving the drug and the polymer affects the morphology and particle size 
distribution of the nanoparticles (Rao & Geckeler, 2011). In order to ensure the 
removal of the organic solvent the dialysis has to be extended over several days, 
which is inconvenient from an industrial scale point of view. 
The direct dissolution method consists of equilibrating the drug and 
amphiphilic polymer in aqueous media. Despite this method being spontaneous, 
the aggregation of the molecules can be facilitated using sonication (Cheng et al., 
2006; Hoskins, 2010; Hoskins, Lin, Tetley & Cheng, 2012b). This method has the 
advantages over other methods of not using organic solvent and producing 
thermodynamically stable SA where the size and shape of these SA can be 
controlled by the polymer architecture (Thompson et al., 2008). 
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Figure ‎1.9: Methods of SA drug encapsulation. A) oil in water emulsion B) dialysis and C) 
sonication. 
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1.9.1.3 SA in Drug Delivery 
SA usually exhibit a much lower critical micelle concentration (CMC) or 
CAC compared to low molecular weight surfactants (Kedar, Phutane, Shidhaye & 
Kadam, 2010). The CAC of amphiphiles is typically in the order of 10−6 to 10−7 M, 
which is approximately a thousand times lower than the CMC of low molecular 
weight surfactants (10−3 to 10−4 M) (Douroumis & Fahr, 2012). Due to their low 
CMC/CAC, SA are relatively unaffected by dilution and remain stable at very low 
polymer concentrations (Nishiyama & Kataoka, 2006). The SA stability result in an 
enhanced circulation time compared to surfactant micelles especially when the 
formulation is applied intravenously (the ideal route for anticancer drugs and 
tumour targeting) (Cheng et al., 2010; Nishiyama & Kataoka, 2006; Oerlemans et 
al., 2010). The use of SA incorporating anticancer drugs avoids the use of 
adjuvants, such as ethanol or cremophor EL, which often have toxic side effects 
(Hamaguchi et al., 2007). SA have also been shown to be excellent solubilisers for 
poorly water-soluble drugs (Gu et al., 2011; Hoskins, Lin & Cheng, 2012) and this 
has resulted in great interest in their use in oral route (Hoskins, Lin, Tetley & 
Cheng, 2012b; Kedar, Phutane, Shidhaye & Kadam, 2010; Thompson, Tetley, 
Uchegbu & Cheng, 2009). 
1.9.1.4 SA in Ocular Delivery 
In recent years, a few reports have emerged wherein SA have been 
investigated for ocular drug delivery. Di Tommaso et al. prepared spherical 
polymeric micelles which enhanced the aqueous solubility of the very hydrophobic 
drug cyclosporin A (CsA) by approximately 400 times (Di Tommaso et al., 2012). 
The latter study also demonstrated the topical effectiveness and tolerability of the 
formulation in rat eyes as an alternative to the systemic treatment of CsA for the 
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prevention of corneal graft rejection. Another polymeric micelle system reported by 
Pepic et al. increased the bioavailability of dexamethasone (Dex) in rabbit eye by 
2.4 fold compared to commercial Dex eye drops despite the micellar system 
having a fourfold lower dose concentration (Pepic, Hafner, Lovric, Pirkic & 
Filipovic-Grcic, 2010). Qu et. al. have shown prednisolone polymeric micelles 
produced a 10-fold increase in aqueous humour prednisolone levels in rabbit eyes 
when compared to prednisolone suspension after topical ocular application (Qu et 
al., 2006). Other research groups also have demonstrated improved drug 
permeation and bioavailability in the eye by polymeric micelles (Civiale, Licciardi, 
Cavallaro, Giammona & Mazzone, 2009; Mitra, Velagaleti & Grau, 2010). There 
have been limited publications investigating SA made from comb-shaped 
amphiphilic polymers designed for ocular drug delivery (Qu et al., 2006; Yuan, Li & 
Yuan, 2006) despite the ease of preparation and the high hydrophobic drug 
encapsulation efficiency (Gu et al., 2011; Hoskins, Lin, Tetley & Cheng, 2012b). 
SA made from comb-shaped amphiphilic polymers have shown promising 
potential in protein delivery (Cheng et al., 2010) and intravenous hydrophobic drug 
delivery (Hoskins et al., 2010). They have also been shown to open tight junctions, 
facilitate transcellular transport in gut epithelial cell line and demonstrate an 
improved oral bioavailability in-vivo (Hoskins, Lin, Tetley & Cheng, 2012b; 
Thompson et al., 2011). Therefore in this work four SA spontaneously formed from 
comb-shaped amphiphilic polymers based on poly(allylamine) were synthesised 
and the effect on the different polymer architecture of these amphiphilic polymers 
in influencing their potential in ocular delivery was evaluated. 
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1.10  Aims and Objectives 
 The overall aim of this research project was to investigate drug delivery to 
the eye using novel polymeric nanoparticles as drug carriers. As such, the 
objectives of this work were: 
 To synthesise four amphiphilic polymers by attaching hydrophobic and 
hydrophilic moieties onto Poly(allylamine) (PAA) backbone. 
 To characterise the synthesised amphiphilic polymers. 
 To prepare and characterise polymeric SA formed by the amphiphilic 
polymers in aqueous media. 
 To prepare and optimize polymeric SA loaded with Triamcinolone 
Acetonide (TA) and to determine the TA content, and TA release from the 
SA.  
 To develop an in-vitro eye model. 
 To test and compare the permeability of the synthesised TA-SA using the 
developed in-vitro eye model.  
 To test the In-vitro toxicity of the synthesised amphiphilic polymers on a 
human cell culture line. 
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2.1 Introduction 
Amphiphilic polymers are composed of hydrophobic and hydrophilic 
moieties. The different arrangement of these moieties within the macromolecule 
produces various architectures such as block copolymers (Gaucher et al., 2005; 
Yao et al., 2011), comb-shaped polymers (Cheng et al., 2006)  and star-shaped 
polymers (Li et al., 2011). In aqueous media where the concentrations of 
amphiphilic polymers are lower than the critical aggregation concentration (CAC) 
they saturate the air/water interface in order to attain a state of minimal energy 
(Lee, 2008). Above the CAC threshold, the amphiphilic polymeric chains 
spontaneously self-assemble into a core-shell structure as a result of aggregation 
of the hydrophobic moieties, stabilised by the hydrophilic corona (Kedar, Phutane, 
Shidhaye & Kadam, 2010). Amphiphilic polymers are known to form different types 
of aggregates with nano-scale size such as polymeric micelles (Gu et al., 2007; 
Thompson et al., 2008), vesicles (Sarkar, El Khoury, Lopina & Hu, 2007; Wang, 
McConaghy, Tetley & Uchegbu, 2001; Zhu, Zhao, Qu & Yang, 2012) and 
nanoparticles (Cheng et al., 2006; Thompson, Tetley & Cheng, 2010). 
In recent years, there has been an increase in interest in the use of 
polymeric self-assemblies (SA) as a drug delivery vehicle (Gupta, Agrawal & Vyas, 
2013). The amphiphilic polymeric SA have several advantages over other vehicles 
(i.e. liposomes, niosomes and conventional formulations) such as 1) mild 
preparation conditions without the need of organic solvents or stabilisers which are 
potentially toxic 2) an inherent low CAC which is approximately a thousand times 
lower than the critical micelle concentration (CMC) of low molecular weight 
surfactant (Kedar, Phutane, Shidhaye & Kadam, 2010) 3) high hydrophobic drug 
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loading capacity (Xiong, Binkhathlan, Molavi & Lavasanifar, 2012) and 4) ease of 
surface functionalisation to achieve active targeting (Zhu et al., 2011). 
Effective ophthalmic drug delivery still remains a challenge due to clearance 
mechanisms of xenobiotics and the protecting nature of the ocular barriers 
(section 1.4). In recent years there has been an increased interest in the use of SA 
based drug delivery systems to overcome the challenges faced by the 
conventional ocular formulations (Gupta et al., 2010; Nagarwal, Kant, Singh, Maiti 
& Pandit, 2009). The permeability of positively charged molecules through the 
corneal epithelium cells is favoured owing to the transport of these molecules 
through active pump and carrier-mediated systems (Liaw, Rojanasakul & 
Robinson, 1992). Furthermore, positively charged molecules have a longer 
residence time on the surface of the eye as the corneal epithelial cells possess a 
negative charge at physiological pH (Rabinovich-Guilatt, Couvreur, Lambert & 
Dubernet, 2004). It has been demonstrated that the transcorneal permeation of 
cationic liposomes resulted in a higher permeation compared to anionic and 
neutral liposomes (Hathout, Mansour, Mortada & Guinedi, 2007; Schaeffer & 
Krohn, 1982). Similar behaviour is also predicted and observed for other drug 
vehicles such as cationic nanoparticles (De Campos et al., 2003; Fitzgerald, 
Hadgraft, Kreuter & Wilson, 1987) and cationic SA (Thompson et al., 2011). One 
example is a SA formed by hydrophobically modified Poly(allylamine) (PAA). PAA 
(Figure ‎2.4) is a cationic water soluble homo-polymer, which has primary amine 
groups. Previous reports have shown that hydrophobically  modified PAA-insulin 
nano-complexes were able to reversibly open tight junctions as well as increasing 
the gene transfer efficacy in comparison to commercial transfecting agents and the 
native polymer (Nimesh, Kumar & Chandra, 2006; Pathak et al., 2007; Thompson 
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et al., 2011). Furthermore, PAA hydrophobically  modified polymers offer stable 
aggregates at low modification percentages (2.5 and 5 %mole) in comparison to 
other polymers such as poly(ethylenimine) (Thompson et al., 2008).  However, to 
date SA formed by these hydrophobically modified PAA have not been explored in 
ocular drug delivery. 
Therefore, in this study four hydrophobically modified PAA polymers; 
containing 1) palmitoyl 2) cholesteryl 3) polyethylene glycol and 4) dansyl residues 
were synthesised. Palmitoyl groups have been shown to reduce the cytotoxicity of 
PAA by 2-3 fold and to form stable self-assemblies at low molar grafting 
percentages (Thompson, Tetley, Uchegbu & Cheng, 2009). Cholesterol is a 
naturally occurring sterol within the body and is a vital component of cell the 
membrane for regulating membrane fluidity. The introduction of a cholesteryl 
moiety to polymers has been reported to increase the biological compatibility of 
the polymer and to induce spontaneous formation of SA (Liu, Wang, Zhuang, 
Yang & Yang, 2012; Yu, Li, Qiu & Jin, 2008; Yusa, Kamachi & Morishima, 1998). 
A dansyl moiety has a bicyclic naphthalene ring which absorbs light in the UV-
visible range and undergoes fluorescence, these phenomena makes the dansyl 
modified polymer detectable by various analytical techniques. Additionally, 
previous work by Hoskins et al. has shown that  the SA of PAA modified with a 
dansyl group (10% mole modification) significantly improved the solubility of three 
hydrophobic drugs by at least 145 fold (Hoskins, Lin, Tetley & Cheng, 2012b). 
Although, positively charged SA are preferred for topical ocular drug delivery, they 
tend to aggregate in the vitreous humour due to electrostatic interaction with the 
negatively charged hyaluronic acid (Koo et al., 2012). The addition of a hydrophilic 
polyethylene glycol (PEG) moiety can significantly minimize protein adsorption 
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onto SA, consequently reducing the aggregation of SA (José Alonso, 2004; 
Peeters et al., 2005; Roberts, Bentley & Harris, 2002). Additionally, PEG coated 
nanocapsules have also been reported to migrate deeper across the corneal 
epithelium than chitosan coated nanocapsules (De Campos et al., 2003). 
Therefore, it was planned to synthesise PEG-palmitoyl PAA and compare to the 
cationic PAA.  
The analytical methods used in characterising the PAA and modified 
polymers were elemental analysis, nuclear magnetic resonance (NMR) and 
differential scanning calorimetry (DSC). 
2.1.1 Elemental Analysis 
Elemental analysis (EA) is a useful tool for determining the elemental 
composition of an unknown sample. The most common elements are carbon (C), 
hydrogen (H), nitrogen (N) and sulphur (S). The quantitative measurement of 
elements in the material under study enables the determination of the empirical 
formula of the material. The empirical formula is the smallest set of integer ratio of 
elements constituting the unknown compound.  
The C, H, N and S weight percentages are determined using an elemental 
analyser as shown in Figure ‎2.1. An accurate weighed sample is instantaneously 
oxidised at an elevated temperature (flash combustion), usually about 1000 °C, in 
the presence of excess oxygen and helium (gas carrier). A complete oxidation of 
the elements in the presence of a catalyst produces CO2, H2O, NO2 and SO2 
gases. The gaseous mixture is then passed over copper to reduce the nitrogen 
oxides to nitrogen and to remove excess oxygen. The gaseous mixture is then 
directed into a gas chromatography column where individual components are 
separated and eluted as N2, CO2, H2O and SO2. The eluted gases are detected by 
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a thermal conductivity detector producing a signal proportional to the concentration 
of the element. 
 
 
Figure ‎2.1: Schematic diagram of an elemental analyser. 
 
2.1.2 Nuclear Magnetic Resonance 
Nuclear magnetic resonance (NMR) is a powerful and useful analytical tool 
used in elucidating the structure and interactions of unknown compounds. The 
NMR phenomenon is based on the fact that some nuclei have magnetic spin 
properties. These nuclei resonate at a certain wavelength upon being placed in a 
magnetic field and excited by an electromagnetic radiation. The resonating 
wavelength corresponds to the radio frequency range in the electromagnetic 
radiation spectrum. The difference between the lower and higher energy levels in 
the resonating nuclei is proportional to the strength of the applied magnetic field. 
Different protons within a chemical structure resonate at slightly different 
frequencies, thereby producing a distinctive electromagnetic radiation (ER) signal. 
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The measured signal is recorded and processed to yield an NMR spectrum for the 
nucleus concerned. The chemical shift in the NMR spectrum is the frequency of 
the resonance expressed with reference to a standard compound, the chemical 
shift is expressed as parts per million (ppm, or δ).   
The different chemical environments surrounding the nuclei such as the 
presence of methyl/ethyl groups or electronegative atoms (e.g. O, Cl) give rise to 
different chemical shifts. The electronegative atoms have the ability to de-shield 
the nucleus by withdrawing the electron cloud thus influencing their nuclear 
resonance frequencies. De-shielded protons appear downfield in a NMR spectrum 
in comparison to shielded protons, as the de-shielded protons require less applied 
magnetic field to change their spin state. The spinning of nearby atoms can affect 
the magnetic field of the nucleus. This phenomenon is called spin-spin coupling 
and occurs as duplets, triplets or multiplets depending on the number of 
neighbouring magnetic nuclei. A schematic representation of an NMR 
spectrometer is shown in Figure ‎2.2. 
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Figure ‎2.2: The schematic diagram of NMR spectrometer. 
 
2.1.3 Differential Scanning Calorimetry 
Differential scanning calorimeter (DSC) is a highly sensitive analytical tool, 
used mainly in the investigation of thermal events associated with phase 
transitions such as the melting point and glass transition (Tg) of polymeric 
materials. The polymeric material is contained in an aluminium pan and an empty 
pan is used as a reference. Both pans are subjected to the same heat profile and 
the difference in the heat flow between the sample and the reference is recorded. 
At phase transition events more or less heat flows to the sample pan than the 
reference to maintain both pans at the same temperature. The recorded difference 
is plotted against temperature and this produces peaks in the thermogram 
corresponding to the thermal events. Figure ‎2.3 shows a schematic representation 
of the main components of a differential scanning calorimeter. 
 
Chapter 2: Polymer Synthesis and Characterisation 
60 
 
 
Figure ‎2.3: Schematic of a heat flux differential scanning calorimeter. 
 
2.1.4 Aim and Objectives 
The aim of the work in this chapter was to synthesise and characterise the 
hydrophobically and hydrophilically modified PAA. The objectives were: 
 To covalently attach palmitoyl, cholesteryl, dansyl and PEG moieties onto 
PAA backbone to form four different amphiphilic polymers. 
 To characterise the synthesised amphiphilic polymers using EA, NMR and 
DSC techniques. 
 To calculate the percentage mole modification of the attached moieties on 
the synthesised polymers.  
2.2 Materials and Methods 
Poly(allylamine hydrochloride) (PAA-HCl, average Mw = 15 kDa), palmitic 
acid N-hydroxysuccinimide ester (98%), cholesteryl chloroformate (97%), 
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methoxypolyethylene glycol p-nitrophenyl carbonate (average Mw = 5 kDa), dansyl 
chloride, triethylamine, tris (hydroxymethyl) aminomethane and deuterated 
solvents (D2O and CD3OD) were all purchased from Sigma Aldrich, United 
Kingdom. Sodium hydrogen carbonate, sodium hydroxide, sodium carbonate and 
all solvents (HPLC grade) were acquired from Fisher, United Kingdom. Dialysis 
tubing membranes (Mw cut-off = 7 and 12-14 kDa) were purchased from Medicell 
International Ltd, United Kingdom.  
2.2.1 Polymer Synthesis 
2.2.1.1 Conversion and Purification of PAA-HCl 
PAA-HCl was converted to PAA by dissolving PAA-HCl (10 g) in deionised 
water (100 mL) followed by the addition of sodium hydroxide pellets (8.5 g) under 
stirring until pH 13 was reached (pH meter 209, HANNA® Instruments, United 
Kingdom). The resulting solution was stirred for 1 h, and then dialysed in dialysis 
tube (Mw cut-off = 7 kDa) against deionised water (5 L) with six changes. The 
dialysate was then lyophilised for 24 h as described below to obtain PAA. 
Figure ‎2.4 illustrates the PAA structure based on the empirical formula of PAA 
monomer. 
 
Figure ‎2.4: The chemical structure of the free-base PAA monomer. 
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The lyophilisation process was performed as outlined below: 
The dialysate was cooled to -40 °C at a rate of 1° min-1 using a freeze dryer 
(LSB40 Freeze Dryer, MechaTech Systems Ltd, United Kingdom) and maintained 
for 60 min under normal atmospheric pressure. This was followed by heating the 
solution at a rate of 1° min-1 (LSB40 Freeze Dryer, MechaTech Systems Ltd, 
United Kingdom) and keeping the temperature at -30 °C for 180 min under low 
pressure (typically 5 x 10-1 mbar). Subsequently, the dialysate was further heated 
at a rate of 1° min-1 and maintained at -10 °C for 180 min under low pressure 
(typically 9 x 10-1 mbar). Finally, the lyophilised material was heated to 20 °C at a 
rate of 1° min-1 and maintained for 860 min under low pressure (typically 7.2 x 10-2 
mbar).  
The same lyophilisation protocol for PAA was used for all synthesised 
polymers reported in sections ‎2.2.1.1-‎2.2.1.5. 
Hydrophobic and hydrophilic pendant groups were attached on the PAA 
backbone using various initial feed molar ratios as described in sections  2.2.1.2 
to ‎2.2.1.5. The numerals in the polymer abbreviations indicate the initial feed mole 
percentage of the hydrophobic pendant groups as summarised in Table ‎2-1. The 
5% initial feed molar ratio was the highest that could be achieved with Ch5 and 
Pa5, attempts to modify the initial feed mole ratio of dansyl to 20% were not 
successful (due to the polymer being insoluble in water), so 10% was the highest 
that could be achieved. 
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Table ‎2-1: The synthesised polymer names and their corresponding abbreviations. 
Polymer Name Abbreviation 
Initial Percentage 
Feed Molar 
Palmitoyl Poly(allylamine) Pa5 5% 
Methoxypolyethylene glycol Palmitoyl 
Poly(allylamine) 
Pa5-MPEG 
5% Palmitoyl 
3.6% MPEG 
Cholesteryl Poly(allylamine) Ch5 5% 
Dansyl Poly(allylamine) Da10 10% 
 
2.2.1.2 Synthesis of Palmitoyl Poly(allylamine) (Pa5) 
The method for the synthesis of palmitoyl poly(allylamine) (Figure ‎2.5) was 
adapted from Thompson and colleagues (Thompson et al., 2008; Thompson, 
Tetley, Uchegbu & Cheng, 2009). Pa5 was synthesised by dissolving PAA (1 g) 
and NaHCO3 (1.18 g) in deionised water (100 mL) for 5 min at room temperature. 
Palmitic acid-N-hydroxysuccinimide ester (310 mg) was dissolved in ethanol (100 
mL). The latter solution was added to the PAA solution drop-wise over 1 h whilst 
stirring using magnetic flea and stirrer. The reaction was carried out for 72 h at 
room temperature. Solvents were evaporated using a rotary evaporator and the 
residue was washed with diethyl ether (3 x 50 mL). The residue was subsequently 
dissolved in deionised water (100 mL) and dialysed for two days using dialysis 
tubing (Mw cut-off = 12-14 kDa) with six changes of deionised water (5 L). The 
dialysate was lyophilised for 24 h and Pa5 was obtained as cotton like solid. 
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Figure ‎2.5: The preparation of palmitoyl poly(allylamine). 
 
2.2.1.3 Synthesis of Methoxypolyethylene Glycol Palmitoyl 
Poly(allylamine) (Pa5-MPEG) 
The synthesis method was adapted from Brown and colleges (Brown et al., 
2000). Pa5-MPEG was synthesised by dissolving Pa5 (300 mg) in Tris-HCl buffer 
(0.2 M, 100 mL). Methoxypolyethylene glycol p-nitrophenyl carbonate (600 mg) 
was then added to the polymer solution in 3 portions over 3 h intervals (200 mg 
every 1 h) while stirring using magmatic flea and stirrer. The mixture was stirred 
for a further 18-20 h at room temperature while protected from light. The solution 
was dialysed in dialysis tubing (Mw cut-off = 12-14 kDa) for four days against 
twelve changes of deionised water (5 L). Pa5-MPEG was obtained after 
lyophilising the dialysate for 24 h. Figure ‎2.6 illustrates the synthetic route of Pa5-
MPEG polymer. 
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Figure ‎2.6: The preparation of methoxypolyethylene glycol (MPEG) palmitoyl Poly(allylamine) 
(Pa5-MPEG). 
 
2.2.1.4 Synthesis of Cholesteryl Poly(allylamine) (Ch5) 
The method for the synthesis of cholesteryl poly(allylamine) was adapted 
from Thompson and colleagues (Thompson et al., 2008). Ch5 was synthesised by 
first dissolving PAA (2 g) in chloroform:methanol (1:1 (v/v), 100 mL). Triethylamine 
(2 mL) was then added to the solution and stirred for 0.5 h. Cholesteryl 
chloroformate (787 mg) was dissolved in chloroform:methanol (1:1 (v/v), 50 mL) 
and this solution was then added drop wise to the PAA solution over 2 h at 37 °C 
with continuous stirring using magnetic flea  and stirrer. The reaction was then left 
stirring for an additional 24 h at 37 °C. Solvents were evaporated using a rotary 
evaporator and the residue was washed with diethyl ether (3 x 50 mL). The 
residue was then dissolved in deionised water (100 mL) and dialysed in dialysis 
tube (Mw cut-off = 12 kDa) for two days against deionised water (5 L) with six 
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changes. Ch5 was obtained as a white solid after lyophilising the dialysate for 24 h. 
The synthesetic route of Ch5 is illustrated in Figure ‎2.7. 
 
 
Figure ‎2.7: The preparation of cholesterol Poly(allylamine) (Ch5). 
 
2.2.1.5 Synthesis of Dansyl Poly(allylamine) (Da10) 
The synthesis of Da10 was carried out as described by Hoskins et.al 
(Hoskins, Lin, Tetley & Cheng, 2012a) (Figure ‎2.8). Da10 was synthesised by 
dissolving PAA (2 g) in dioxane:water (1:1 (v/v)) (150 mL). Sodium carbonate (185 
mg) was then added to the solution and stirred until completely dissolved in the 
solution. Dansyl chloride (847 mg) was dissolved in dioxane (90 mL) and the 
solution was added drop-wise to the PAA solution over 2 h at 0 °C whilst stirring 
using magnetic flea and stirrer. The resulting solution was stirred continuously for 
4 h at 0 °C and followed by 14 h at room temperature. A solid was obtained after 
solvents were evaporated using a rotary evaporator. The residue was then 
washed with diethyl ether (3 x 50 mL) before dissolving in deionised water (100 
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mL) and dialysing in dialysis tubing (Mw cut-off = 12-14 kDa) for two days against 
deionised water (5 L, six changes). A yellow cotton like solid was obtained after 
lyophilising the dialysate for 24 h.  
 
 
Figure ‎2.8: The preparation of dansyl poly(allylamine) (Da10). 
 
2.2.2 Characterisation of Polymers 
2.2.2.1 Elemental Analysis 
The abundance of carbon (C), hydrogen (H), nitrogen (N) was determined 
in all modified polymers and PAA freebase. Additionally to C, H and N the 
abundance of sulphur (S) was determined for Da10. Samples (1 mg) were 
accurately weighed in a tin capsule and placed inside the auto-sampler drum. The 
determined weight percentage of C, H, N and S was performed using a FlashEA® 
1112 Elemental Analyzer based on the quantitative dynamic flash combustion 
method provided by Medac Ltd, United Kingdom. The instrument was calibrated 
with the analysis of standard compounds (i.e. Acetanilide, Aspartic acid, Benzoic 
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acid or Sulphanilimide) using the K factors calculation or linear regression method 
incorporated in the EAGER300™ software.  
2.2.2.2 Nuclear Magnetic Resonance (NMR) 
Approximately 7-15 mg of PAA and the modified polymers were probe 
sonicated (Hielscher UP200S, Germany) in CD3OD or D2O for 2 min at 100% 
amplitude on full cycle. The Pa5 and Ch5 suspensions were filtered into a NMR 
tube through cotton, to remove any insoluble particles. The 1H NMR spectra were 
obtained using a 600 MHz Ultrashield spectrometer (JEOL, Japan) at 25 °C. 
Samples were spanned at 16 Hz, locking and shimming was performed manually 
for each individual sample before acquiring 64 1H NMR scan. 
2.2.2.3 Differential Scanning Calorimetry (DSC) 
Thermal analysis of polymeric samples was performed using a DSC Q200 
(TA Instruments, UK) attached to a refrigerated cooling system (TA Instruments, 
UK). Indium standards were used to calibrate the DSC temperature and the 
enthalpy prior to use. Samples (3-10 mg) were weighed into standard aluminium 
pans (TA Instruments, UK). The pans were heated from -30 to 250 °C in a heat-
cool-heat cycle at a linear heating/cooling rate of 10 °C min-1. An inert atmosphere 
was maintained by purging nitrogen gas at a flow rate of 50 mL min-1. 
2.3 Results 
2.3.1 Physical Appearance and Reaction Yield Percentage 
The yield percentage of each polymer and modified PAA was calculated 
according to Equation ‎2.1 (Brown, 2006) and is shown along with a description of 
their physical appearance in Table ‎2-2. Different batches of each polymer were 
synthesised to ensure batch uniformity/repeatability. 
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Equation ‎2.1 
  
 
Table ‎2-2: Yield percentages and physical appearance of PAA and modified polymers.  
Polymer 
Yield Percentage  
(mean ± SD (n>3) or 
individual values (n=2)) 
Number of 
Batches 
Physical Appearance 
PAA 78.5 ± 5.8  5 
Transparent glassy 
viscous material 
Pa5 81.3 ± 4.6  4 White cotton like solid 
Pa5-MPEG 94.3 ± 3.5  4 White cotton like solid 
Ch5 (91.1, 93.5)  2 White powder 
Da10 89.1 ± 2.1  3 Yellow cotton like solid 
 
2.3.2 Elemental Analysis of PAA and Modified PAA 
2.3.2.1 PAA Calculations 
Elemental analysis was performed as an initial characterisation method to 
obtain the percentage mole modification of the PAA backbone. The empirical 
formula of the PAA free-base was calculated using Equation ‎2.2 & 2.3 and the 
result was tabulated in Table ‎2-3. 
 
                          
                                                                
                          
 
Equation ‎2.2 
 
 
                                   
                     
                        
 
Equation ‎2.3 
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Table ‎2-3: The calculations of the empirical formula of the PAA monomer. 
 
Elements in 
Unmodified PAA 
C H N 
Elements weight percentage obtained from 
elemental analysis 
59.0 12.0 24.0 
Element’s molar ratio (Equation  2.2) 4.9 12.0 1.7 
Element’s molar ratio relative to N  
(Equation  2.3) 
2.9 7.0 1.0 
 
The calculated molar ratios of C and H relative to the N atom based on the 
elemental analysis of PAA freebase was 2.9:7.0:1.0 (Table ‎2-3), which is in good 
agreement with the predicted structure of PAA monomer (3 C atoms: 7 H atoms: 1 
N atom (Figure ‎2.4)) (Thompson et al., 2008). 
2.3.2.2 Percentage Mole Modification of Modified Polymers 
 Calculation of Percentage Mole Modification of Pa5 & Ch5 2.3.2.2.1
The mole percentages of the cholesterol and palmitoyl groups attached to 
the PAA backbone were calculated using Equation ‎2.2 & 2.2 (‎2.3.2.1) followed by 
Equation ‎2.32.4 & 2.5. An example of the calculation of the percentage mole 
modification of palmitoyl groups is tabulated in Table ‎2-4. 
 
                                               
                                                                         
Equation ‎2.4 
 
                             
                                            
                                              
        
 
Equation ‎2.5 
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Table ‎2-4: The calculation of the percentage mole modification of palmitoyl in Pa5. 
 
Elements in Pa5 
C H N 
Element’s weight percentage obtained from elemental 
analysis 
56.3 10.6 14.9 
Element’s molar ratio (Equation  2.2) 4.7 10.6 1.1 
Element’s molar ratio relative to N (Equation  2.3) 4.4 10.0 1.0 
Moles of each element from attached moiety (Error! 
Reference source not found.) 
1.5 3.0 0.0 
Percentage mole modification (Equation ‎2.5) 9.7 9.6 - 
 
Elemental analysis of Pa5 revealed a carbon: hydrogen: nitrogen ratio of 
4.4: 10.0: 1, higher than the expected theoretical ratio of the empirical formula of 
Pa5 (3.8: 8.5: 1). On the contrary, the carbon: hydrogen: nitrogen ratio in the 
modified Ch5 was 4.6: 10.1: 1, concordant with the expected theoretical ratio of 
4.4: 9.2: 1. The percentage mole modification of Pa5 based on carbon (9.7%) was 
approximately double the initial feed molar ratio (5%). In contrast the percentage 
mole modification of Ch5 (6.1%) was close to the initial feed molar ratio (5%). 
 Calculation of Percentage Mole Modification of Pa5-MPEG 2.3.2.2.2
The mole percentage of the MPEG moiety attached to Pa5 was calculated 
using Equation ‎2.2 - Equation ‎2.5, with a modification in Error! Reference source 
not found. where the element molar ratio relative to N in PAA was replaced with 
the element molar ratio relative to N in Pa5, the reason being that Pa5 is the 
starting material. Table ‎2-5 shows an example of the calculation of the percentage 
mole modification of MPEG moiety onto Pa5. The carbon: hydrogen: nitrogen ratio 
in the modified Pa5-MPEG was 12.4: 26.7: 1, equating to 3.6% mole modification 
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of MPEG which correlates well with the expected theoretical modification ratio of 
3.5% (theoretical C: H: N is 11.6: 24: 1). 
 
Table ‎2-5: The calculation of the percentage mole modification of palmitoyl in Pa5-MPEG. 
 
Elements in 
Pa5-MPEG 
C H N 
Element’s weight percentage obtained from elemental 
analysis 
53.4 9.6 5.0 
Element’s molar ratio (Equation  2.2) 4.5 9.6 0.4 
Element’s molar ratio relative to N (Equation  2.3) 12.4 26.7 1.0 
Moles of each element from attached moiety (Error! 
Reference source not found.) 
8.0 16.7 0.0 
Percentage mole modification (Equation  2.5) 3.6 3.8 - 
 
 Calculation of Percentage Mole Modification of Da10 2.3.2.2.3
The mole percentage of the dansyl group in Da10 was determined using 
similar calculations as to those described in sections ‎2.3.2.1 and ‎2.3.2.2.1 
(Equation ‎2.2 - Equation ‎2.5), with the addition of an extra step (Equation 2.2A) 
between Equation ‎2.2 & Equation ‎2.3. This is due to the presence of a nitrogen 
atom in the dansyl moiety (Figure ‎2.8) which will contribute to the total nitrogen 
weight percentage of the PAA monomer. Since the molar ratio of N:S in the dansyl 
moiety is 1:1 (Figure ‎2.8), subtraction of the sulphur molar ratio from the total N 
molar ratio results in the corrected N molar ratio contributed by PAA monomer only 
(Equation 2.2A).  
 
                                                             
Equation 2.2A 
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The calculation of the mole percentage of dansyl moiety in Da10 is outlined in 
Table ‎2-6. The carbon: hydrogen: sulphur: nitrogen ratio in the modified Da10 was 
4.3: 8.2: 1: 0.1, this ratio is in agreement with the expected theoretical ratio of 
4.2: 8.2: 1: 0.1.  
 
Table ‎2-6: The calculation of the percentage mole modification of dansyl in Da10. 
 Elements in Da10 
C H N S 
Element’s weight percentage obtained from elemental 
analysis 
53.2 8.6 16.0 3.2 
Element’s molar ratio (Equation ‎2.2) 4.4 8.6 1.1 0.1 
Corrected N molar ratio (Equation 2.2A) 4.4 8.6 1.0 0.1 
Element’s molar ratio relative to N (Equation ‎2.3) 4.3 8.2 1 0.1 
Element molar ratio relative to N in PAA 2.9 7.0 1.0 - 
Moles of each element from attached moiety 
(Equation 2.4) 
1.4 1.2 - 0.1 
Percentage mole modification (Equation ‎2.5) 11.5 10.2 - 9.6 
 
Table ‎2-7 summarises the percentage mole modification for all modified 
polymers, and shows the small variation in percentage mole modification between 
batch to batch for each polymer. The calculated percentage mole modification of 
Pa5-MPEG, Ch5 and Da10 were close to the initial mole feed ratio, in contrast to 
Pa5 which had approximately double the initial mole feed ratio. 
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Table ‎2-7: Elemental analysis results for PAA and modified polymers, with their corresponding 
percentage mole modification. 
Polymer 
Element weight percentage obtained from 
elemental analysis 
Percentage 
mole 
modification   
Mean (n) 
(range)  
 
C 
Mean (n) 
(range) 
H 
Mean (n) 
(range) 
N 
Mean (n) 
(range) 
 
S  
Mean (n) 
(range) 
 
PAA 
57.8 (2) 
(59.0,56.6) 
12.2 (2)  
(12.0,12.3) 
23.6 (2)  
(24.0,23.2) 
- - 
Pa5 
53.9 (3) 
(52.1-56.3) 
10.3 (3)  
(10.0-10.6) 
14.6 (3)  
(14.2-14.9) 
- 
8.9 (3)  
(8.2-9.7) 
MPEG 
52.4 (3) 
(51.3-53.4) 
9.4 (3)  
(8.8-9.8) 
5.4 (3)  
(5.0-5.7) 
- 
3.4 (3)  
(3.2-3.6) 
Ch5 
62.8 (2) 
(65.1,60.5) 
11.6 (2)  
(12.1,11.1) 
15.8 (2)  
(16.3,15.3) 
- 
6.2 (2)  
(6.3,6.1) 
Da10 
53.2 (3) 
(52.0-54.3) 
8.7 (3)   
(8.6-8.9) 
15.6 (3)  
(15.1-16.0) 
3.1 (3) 
(3.0-3.2) 
9.6 (3)  
(9.2-10.0) 
 
2.3.3 NMR Spectra and Calculation of PAA and Modified PAA 
2.3.3.1 PAA 1H NMR Spectra and Calculation 
The peaks in the 1H NMR spectrum of PAA in CD3OD (Figure ‎2.9) were assigned 
to the CH2 (Figure ‎2.9, peak A), CH (Figure ‎2.9, peak B) and CH2-N (Figure ‎2.9, 
peak C) protons in the PAA monomer at δ1.15-1.35, δ1.54 and δ2.59-3.02, respectively 
(Thompson et al., 2008). The integration ratio of the peaks at δ1.15-1.35 = CH2 (A), 
δ1.54 = CH (B) and δ2.59-3.02 = CH2 (C) was 97:53:100 respectively. This ratio 
corresponds well to the theoretical 2:1:2 proton ratio in the PAA monomer 
structure. Similar results were obtained from the 1H NMR spectrum of PAA in D2O 
(Figure ‎2.10), the integration ratio of the peaks at δ1.06-1.22 = CH2 (A), δ1.44 = CH (B) 
and δ2.50-2.88 = CH2 (C) was 105:50:100 respectively. The two hydrogen atoms 
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attached to the nitrogen atom are invisible in the NMR spectra, due to the fast 
exchange with deuterium from the deuterated solvent (Kleckner & Foster, 2011). 
 
 
Figure ‎2.9: 
1
H NMR spectrum of PAA in CD3OD carried out using 600 MHz spectrometer at 25 °C. 
 
 
 
Figure ‎2.10: 
1
H NMR spectrum of PAA in D2O carried out using 600 MHz spectrometer at 25 °C. 
A 
B 
C 
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2.3.3.2 Modified polymers 1H NMR Spectra and Calculation 
The 1H NMR spectra of all modified polymers in CD3OD and D2O were 
presented in Figures 2.11-2.18. The extra peaks alongside the PAA peaks 
corresponding to the attached modified groups were assigned and labelled in the 
corresponding 1H NMR spectrum. The mole percentage of modified groups was 
calculated using Equation ‎2.6, where the CH2 PAA peak at approximately δ2.5 was 
used as reference peak of PAA backbone. This peak was chosen due to the fact it 
does not overlap with other peaks and can be easily and accurately integrated. A 
summary of the corresponding chemical shifts for each attached hydrophobic / 
hydrophilic groups and the percentage mole modification calculated using 
Equation ‎2.6 is tabulated in Table ‎2-8.  
 
                          
 
(
                               
                  
)
(
                                         
                             
)
        
 
Equation ‎2.6 
 
Table ‎2-8: Assignment of the corresponding chemical shifts in 1H NMR spectra of Pa5, Pa5-MPEG, 
Ch5 and Da10 amphiphilic polymers. 
Polymer 
D2O CD3OD 
Peak 
i (δ) 
No. of 
protons i 
Percentage 
Mole 
Modification 
Peak i 
(δ) 
No. of 
protons i 
Percentage 
Mole 
Modification 
Pa5 δ0.73 3 5.7% δ0.7 3 3.5% 
Pa5-
MPEG 
δ3.5 
δ3.2 
 
439 
3 
 
 
 
 
 
 
4.9% 
4.9% 
 
 
 
δ3.6 
δ3.3 
439 
3 
5.7% 
5.0% 
Ch5 δ0.63 3 1.2% δ0.70 3 6.2% 
Da10 δ6.9-8.4 6 5.5% δ7.1-8.5 6 8.8% 
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 Pa5 
1H NMR Spectra and Calculation 2.3.3.2.1
In CD3OD solvent all PAA peaks were still evident in Pa5 
1H NMR spectrum 
(Figure ‎2.11). In addition, a peak at δ0.75 was observed corresponding to the 
terminal CH3 from the attached palmitoyl group (peak D in Figure ‎2.11) (Jiang, 
Quan, Liao & Wang, 2006; Thompson et al., 2008). The peaks corresponding to 
the CH2 from the palmitoyl group were overlapping with the CH2 peak from PAA 
(peak E in Figure ‎2.11).  
The calculated percentage mole modification of palmitoyl moiety using the 
CH3 peak at δ0.75 was calculated using Equation ‎2.7. 
                           
 
                               
                        
 
 
                          
                            
 
        
[ 
    
 
  
    
  
  ⁄ ]         
 
 
Equation ‎2.7 
 
Similarly for the D2O solvent, the CH3 peak (δ0.73) (Figure ‎2.12) was used, the 
calculated percentage mole of palmitoyl modification was 5.7%. The increase in 
the mole percentage attachment in D2O compared to CD3OD is partially due to the 
overlapping of the CH3 peak from Pa5 with the PAA CH2. 
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Figure ‎2.11: 
1
H NMR spectrum of Pa5 in CD3OD carried out using 600 MHz spectrometer at 25 °C. 
 
 
Figure ‎2.12: 
1
H NMR spectrum of Pa5 in D2O carried out using 600 MHz spectrometer at 25 °C. 
 
 
 
 
Chapter 2: Polymer Synthesis and Characterisation 
79 
 
 Pa5-MPEG 
1H NMR Spectra and Calculation 2.3.3.2.2
The peaks at δ3.3 (F) and δ3.6 (E) in the Pa5-MPEG spectrum using CD3OD 
as a solvent (Figure ‎2.13), correspond to the terminal methoxy protons and MPEG 
OCH2, respectively (Chang et al., 2012; Sun, Du, Wang & Liu, 2011; Zhang, 
Jackson & Burt, 1996). The calculated percentage mole modification of MPEG 
moiety using δ3.6 and δ3.3 peaks (Figure ‎2.13) were 5.7 and 5.0%, respectively. The 
peak at δ3.28 in Figure ‎2.13 is due to an unsuppressed solvent peak. Conversely, 
the calculated percentage mole modification of MPEG in D2O (Figure ‎2.14) based 
on δ3.5 and δ3.2 peaks were both 4.9%.  
 
 
Figure ‎2.13: 
1
H NMR spectrum of Pa5-MPEG in CD3OD carried out using 600 MHz spectrometer 
at 25 °C. 
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Figure ‎2.14: 
1
H NMR spectrum of Pa5-MPEG in D2O carried out using 600 MHz spectrometer at 25 
°C. 
 
 Ch5 
1H NMR Spectra and Calculation 2.3.3.2.3
The 1H NMR spectrum of Ch5 in CD3OD (Figure ‎2.15) showed extra peaks 
at δ0.70, δ0.85, δ0.92, δ1.01, δ4.35, and δ5.36 in comparison to the PAA spectrum. These 
peaks were assigned to the CH3, CH-O and C=CH in the cholesterol moiety as 
shown in Figure ‎2.15 (Bagheri & Bigdeli, 2013; Chen et al., 2013; Kuang, Liu, Liu 
& Zhuo, 2012). The percentage mole modification of cholesterol attached onto 
PAA backbone was calculated using the CH3 peaks at δ0.70 and δ0.63 in the CD3OD 
and D2O spectra (Figures 2.15 and 2.16). The calculated percentage mole 
modification was very different depending on the solvent, as demonstrated by the 
6.2% and 1.2% obtained from the CD3O and D2O spectra, respectively.  
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Figure ‎2.15: 
1
H NMR spectrum of Ch5 in CD3OD carried out using 600 MHz spectrometer at 25 °C. 
 
 
Figure ‎2.16: 
1
H NMR spectrum of Ch5 in D2O carried out using 600 MHz spectrometer at 25 °C. 
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 Da10 
1H NMR Spectra and Calculation 2.3.3.2.4
The 1H NMR spectrum of Da10 in CD3OD (Figure ‎2.17) showed extra peaks 
at δ3.25 and at δ7.2-8.5 in comparison to the PAA spectrum. The δ3.25 peak 
corresponds to the six protons from CH3 groups attached to the nitrogen atom in 
the dansyl moiety (atom D in Figure ‎2.17) (Buruiana, Chibac & Buruiana, 2010; 
Hoskins, Lin, Tetley & Cheng, 2012a), whereas the δ7.1-8.5 peaks correspond to the 
protons of the naphthalene ring (atoms E-J in Figure ‎2.17) (Hoskins, Lin, Tetley & 
Cheng, 2012a). The percentage mole modification of dansyl attached to the PAA 
backbone was calculated using the peaks at δ7.2-8.5 (peaks E-J in Figure ‎2.17) 
resulting in 8.8% mole modification. Conversely, the calculated percentage mole 
modification of dansyl from the 1H NMR spectra in D2O (Figure ‎2.18) was 5.5%. 
The peaks at δ4.7 and δ4.6 in Figure ‎2.17 and Figure ‎2.18  respectively are due to 
absorbed H2O and a partially unsuppressed solvent peak.  
 
Figure ‎2.17: 
1
H NMR spectrum of Da10 in CD3OD carried out using 600 MHz spectrometer at 25 
°C. 
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Figure ‎2.18: 
1
H NMR spectrum of Da10 in D2O carried out using 600 MHz spectrometer at 25 °C. 
 
2.3.4 Differential Scanning Calorimetry (DSC) 
Figure ‎2.19 shows the enlarged sections of the DSC thermograms for PAA 
and the hydrophobically modified polymers. The thermogram shows the Tg of PAA 
at 26.1 °C. The modification of the palmitoyl moieties on the PAA backbone 
increased the Tg by two degrees from 26.1 to 28.2 °C. When a cholesteryl moiety 
was attached onto the PAA backbone the Tg further increased to 63.3 °C whereas 
dansyl moieties increased the Tg of PAA even more to 73.2 °C. Interestingly, the 
Tg of Pa5-MPEG polymer was absent, instead the polymer had melting 
temperature (Tm) at 56.8 °C as shown in Figure ‎2.20. The melting point at 56.8 °C 
in Pa5-MPEG polymer is due to the presence of the MPEG polymeric chains, this 
was confirmed by the DSC thermogram of the methoxypolyethylene glycol p-
nitrophenyl carbonate where the material had the same melting point (56.48 °C).  
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Figure ‎2.19: Differential scanning calorimetry thermogram of PAA, Pa5, Ch5 and Da10. Colour 
code: Blue line = PAA, Red line = Pa5, Green line = Ch5, Purple line = Da10. 
 
 
Figure ‎2.20: Differential scanning calorimetry thermogram of Pa5-MPEG (Red line) and 
Methoxypolyethylene glycol p-nitrophenyl carbonate (Blue line).  
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2.4 Discussion 
In this study, three hydrophobic (Pa, Ch and Da) and one hydrophilic 
(MPEG) pendant groups were successfully attached onto the PAA backbone, to 
form four different amphiphilic polymers.  
The modification of the PAA polymer with the four groups was successful. This 
was apparent from the differences in the physical appearance of all modified 
polymers (Pa5, Pa5-MPEG, Ch5 and Da10) in comparison to PAA (Table ‎2-2) and 
the confirmation obtained using data from EA, NMR and DSC. The yield 
percentage was high for all the modified polymers ranging from 81% (Pa5) to 94% 
(Pa5-MPEG). The percentage mole modification of attached groups was quantified 
using EA and NMR (Table ‎2-9). 
 
Table ‎2-9: The percentage mole modification of modified polymers obtained using EA and NMR. 
Polymer 
Percentage Mole 
Modification 
NMR 
EA 
D2O CD3OD 
Pa5 5.7 3.5 8.9  
Pa5-MPEG 
4.9 (δ3.5) 
4.9 (δ3.2) 
5.7 (δ3.6) 
5.0 (δ3.3) 
3.4   
Ch5 1.2 6.2 6.2 
Da10 5.5 8.8 9.6  
 
The successful attachment of palmitoyl group onto the PAA backbone was 
confirmed using elemental analysis. The calculations based on carbon abundance 
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of Pa5 revealed 8.9% mole modification of palmitoyl group onto PAA, which is 
higher than the initial molar feed ratio of 5%. This trend was reported by  
Thompson et al. where the author reported 4.2 ± 4.4% and 6.6 ± 7.8% mole 
percentage attachment for the 2.5 and 5% initial molar feed ratio (Pa2.5 and Pa5), 
respectively (Thompson et al., 2008; Thompson, Tetley, Uchegbu & Cheng, 2009). 
Wang et al. (Wang, Qu, Gray, Tetley & Uchegbu, 2004) proposed that the higher 
than expected percentage mole modification may be explained in terms of the coil 
expansion of the polymers. Polymeric chains with lower percentage mole 
modification are thought to escape from the dialysis tube due to the limited coil 
expansion in comparison to the higher percentage mole modified chains (Wang, 
Qu, Gray, Tetley & Uchegbu, 2004). 
In contrast to Pa5, elemental analysis results showed that the actual 
percentage mole attachment of MPEG onto Pa5 was 3.4 ± 0.2%, which is in good 
agreement with the initial molar feed ratio (3.5%). The approximate 110 repeating 
units in the MPEG group (polymeric chain), and the branching of the modified 
polymer chains (Pa5-MPEG) seem to prevent the loss of polymeric chains with 
lower attachment percentages from the dialysis tube, resulting in an accurate 
percentage mole modification results.  
The percentage mole modification of cholesteryl groups attached onto PAA 
was 6.2%. Whilst this value is higher than the expected 5%, it is in good 
agreement with previously published work by both Hoskins and Thompson co-
workers (Hoskins, Lin, Tetley & Cheng, 2012a; Thompson et al., 2008), where the 
authors reported 6 and 6.3% mole modification, respectively. For Da10 the 
elemental analysis calculation based on the sulphur abundance for Da10 resulted 
in 9.6 ± 0.4% as an actual percentage mole modification of dansyl group onto 
Chapter 2: Polymer Synthesis and Characterisation 
87 
 
PAA. This is in good agreement with the 9.3 ± 0.4% percentage mole modification 
of Da10 reported by Hoskins et al. (Hoskins, Lin, Tetley & Cheng, 2012a). 
The 1H NMR data in D2O for the hydrophobically modified polymers are 
indicative of the formation of hydrophobic interactions as a result of the 
amphiphiles aggregation in aqueous medium (Chen et al., 2004; Zhang, Jackson 
& Burt, 1996). The calculated percentage mole attachment of Pa5, Ch5 and Da10 in 
CD3OD and D2O were different (Table ‎2-9). The different percentage mole 
modification obtained in different solvents is not an unfamiliar phenomenon (Xu, Ji, 
Chen & Shen, 2005), as amphiphilic polymers form solvent dependent aggregates. 
These aggregates affect the mobility of a certain part of the amphiphile. Chen et 
al. reported a difference in the relaxation time (1H NMR longitudinal relaxation time 
(T1)) of the hydrophobic chain protons attached to an amphiphilic polyethylene 
glycol based polymer in D2O and CDCl3 (Chen et al., 2004). A decrease in 
relaxation time of the hydrophobic side chain protons in D2O was observed by the 
author, in contrast to no change in the relaxation time in CDCl3 (Chen et al., 2004). 
The relaxation time in D2O decreased with the increase in polymer concentration, 
followed by subtle decreases above the CMC. The subtle decrease of the 
relaxation above CMC occurred due to the aggregation of the hydrophobic groups 
in the core of nanospheres (Chen et al., 2004). The large size of the MPEG chain 
(109 unit) might enforce a partial motional restriction on the PAA backbone, 
resulting in lower intensities of the PAA peaks, and thus a higher calculated 
percentage mole modification of MPEG (approximately 5%) in both solvents (D2O 
and CD3OD) in comparison to theoretical 3.5% molar attachment of the MPEG. 
The 1H NMR spectrum of Ch5 in D2O revealed much broader peaks and 
lower integration values in comparison to the peaks in the CD3OD spectrum. 
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Furthermore, in the D2O spectrum two expected characteristic peaks of the 
cholesteryl moiety were not observed at around δ4.4 and δ5.4. Similarly, Xu et al. 
(Xu, Ji, Chen & Shen, 2005) showed all peaks corresponding to the cholesteryl 
group and phosphorylcholine group in CD3OD
 1H NMR spectrum of cholesteryl 
containing amphiphilic polyelectrolytes, whereas the peaks corresponding 
cholesteryl group either diminished or disappeared in the D2O 
1H NMR spectrum 
of the polymer. Likewise, Brown et al. (Brown et al., 2000) reported the absence of 
peaks corresponding to the amino acid polymer backbone in 1H NMR spectrum of 
the palmitoyl and PEG modified poly-L-lysine at normal temperature using CDCl3. 
However, it should be noted that Brown et al. observed the peaks at elevated 
temperature (48 °C). The author stated that the observed peaks at elevated 
temperatures were due to the increase in the mobility of the polymer backbone. 
The broadening effect observed in D2O spectrum and the low intensity of the 
previously mentioned peaks might be another reason for the absence of these two 
peaks. The broadening of the peaks in D2O is indicative of the restricted mobility of 
the cholesteryl groups as a result of the formation of tight self-assemblies. Similar 
findings were reported by Yusa et al. in a study which the authors investigated the 
1H NMR of cholesterol modified polyelectrolytes in D2O and deuterated dimethyl 
sulfoxide at room temperature (Yusa, Kamachi & Morishima, 1998). In D2O, the 
author observed a considerable peak broadening in contrast to corresponding 
peaks in deuterated dimethyl sulfoxide. The earlier study attributed the peak 
broadening in D2O to the highly restricted motion of cholesteryl moieties, as a 
direct result of the hydrophobic self-association of cholesteryl groups. The 
calculated percentage mole modification of cholesteryl from the 1H NMR spectrum 
in CD3OD was 6.2 %, this is in good agreement with the theoretical value and the 
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results obtained from the elemental analysis. This was in contrast to the low 1.2% 
mole modification of cholesteryl obtained from the D2O spectrum. 
Similar to Ch5, the 
1H NMR spectrum of Da10 showed broader peaks in D2O 
in comparison to the CD3OD spectrum. The calculated mole percentage 
attachment based on the CD3OD 
1H NMR spectrum was 8.8%, which correlates 
well with both EA and initial mole feed ratio. A lower mole percentage was 
calculated from the D2O 
1H NMR which was found to be 5.5%. This phenomenon 
is similar to the one observed in Ch5, in which the lower mole percentage 
attachment in Da10 is an outcome of restricted mobility of the dansyl groups as a 
result of the formation of tight self-assemblies in water. 
The modification of homo-polymer by pendant groups affects the thermal 
properties such as the melting point (Tm) and glass transition temperature (Tg).  
The absence of Tm and the presence of Tg in the DSC thermogram of PAA 
revealed the amorphous nature of the polymer. Given the structure of the modified 
polymers, the addition of the hydrophobic/hydrophilic pendant groups resulted in 
an acquired rigidity of the PAA backbone which ultimately restricts the motion of 
the PAA chains (Brydson, 1999; Gedde, 2001). The DSC thermograms revealed 
an increase in Tg of Pa5, Ch5 and Da10 in comparison to that of PAA. This increase 
in Tg seems to increase with the increasing moiety size and percentage mole 
modification of the attached group (dansyl > cholesteryl > palmitoyl). The trend is 
in agreement with the fact that Tg of hydrocarbon polymers (CH2-CH2) increases 
with the increasing size of the attached group (cholesteryl > palmitoyl) (Gedde, 
2001) and percentage mole modification  (Halary, Lauprêtre & Monnerie, 2011). 
No Tm was detected for Pa5, Ch5 and Da10, indicating the amorphous nature of 
these polymers. However, the Tg could not be determined for the Pa5-MPEG 
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polymer, instead the thermogram revealed a Tm at approximately 56.8 °C 
revealing the crystalline nature of the modified polymer. A similar finding has been 
reported by Huang et al. where the Tg of chitosan was suppressed in a chitosan 
based amphiphile modified with MPEG groups (Huang, Yu, Guo & Huang, 2010). 
2.5 Conclusion  
The hydrophobic (Pa, Ch and Da) and hydrophilic (MPEG) moieties were 
successfully attached on the PAA backbone. The presence of the attached 
moieties was confirmed and quantified using elemental analysis and NMR 
spectroscopy. The 1H NMR and elemental analysis results showed that the 
percentage mole modification of the attached moieties was close to the initial feed 
ratios. The NMR data of the hydrophobically modified polymers suggest the 
aggregation of these amphiphiles in aqueous environment. The presence of the 
attached moieties was further confirmed using DSC. The DSC thermograms 
demonstrated the attached moieties have an impact on the Tm and Tg of the 
modified polymers. 
The ability of the synthesised polymers to form spontaneous self-
assemblies (SA) and the capability of these SA to entrap hydrophobic drug is 
investigated in the next chapter. The SA size, surface charge, loading capacity 
and drug release time was also determined in order to study the effect of the 
aforementioned variables on ocular tissues permeation. 
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3.1 Introduction 
An ideal ophthalmic formulation should be able to 1) overcome the ocular 
barriers and deliver the drug to the target site 2) achieve the desired therapeutic 
levels at the site of action and 3) sustain the therapeutic level for the required 
duration of the treatment. Many novel nano-sized drug delivery systems (DDS) 
such as nanoparticles, liposomes and dendrimers have been explored in pursuit of 
these criteria (Gaudana, Ananthula, Parenky & Mitra, 2010; Liu, Wang, Zhuang, 
Yang & Yang, 2012; Nagarwal, Kumar & Pandit, 2012). These DDS have shown 
advantages compared with that attained using conventional formulations such as 
enhancement in the drug concentration reaching the targeted ocular tissue and 
prolonged action of the drug over conventional formulations. In recent years, some 
researchers have started to investigate the use of polymeric self-assemblies (SA) 
for ophthalmic drug delivery (Di Tommaso et al., 2012; Yuan, Li & Yuan, 2006). In 
the work described in this chapter, the SA have been investigated because of their 
high stability resulting from their low critical aggregation concentration (CAC), high 
entrapment efficiency of hydrophobic drugs,  nano-scale size which does not 
cause vision blurring and most importantly the absence of organic solvents or 
stabilisers, which  can cause undesirable effects in-vivo (i.e. toxicity), from the 
preparation method (Aksungur et al., 2011; Branco & Schneider, 2009; Hoskins, 
Lin & Cheng, 2012; Hoskins, Lin, Tetley & Cheng, 2012b).  
Self-assembly is an entropy driven physical process wherein disordered 
molecules establish themselves into regulated nano-scale structures (Gruen & 
Haydon, 1980). Amphiphilic polymers can self-assemble into either intramolecular 
or intermolecular structures. Intramolecular SA are formed from one amphiphilic 
molecule undergoing an intramolecular association resulting in small unimers 
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(Yusa, Hashidzume & Morishima, 1999). Intermolecular SA emanates from the 
ability of polymeric chains to form multipolymer aggregates (supramolecular) such 
as polymeric micelles or nanoparticles (Wu, Qiao, Yang & Wang, 2010). 
Depictions of the intramolecular and intermolecular SA’s are shown in Figure ‎3.1.   
 
 
Figure ‎3.1: Schematic diagram of intramolecular and intermolecular SA. 
 
The formation of SA in aqueous medium results in a decrease in the Gibbs 
free energy, due to the removal of hydrophobic groups from the aqueous 
environment and the formation of a SA hydrophobic core, which results in a 
increase in entropy. The creation of the SA is dependent on the concentration of 
the amphiphilic polymers in the aqueous solution, as SA are only formed above 
the CAC. The CAC of comb-shaped amphiphilic polymers is generally affected by 
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the type of the attached hydrophobic groups (Hoskins, Lin, Tetley & Cheng, 
2012a; Thompson et al., 2008) and decreases both with the increase in the chain 
length of the hydrophobic group ((Wu, Qiao, Yang & Wang, 2010) and  the level of 
the hydrophobic attachment (Thompson et al., 2008). The most frequent 
measurement techniques of the CAC are 1) surface tension (Hoskins, Lin, Tetley 
& Cheng, 2012a) 2) solvatochromic probes (Thompson et al., 2008) 3) NMR 
(Barhoum & Yethiraj, 2010) and 4) fluorescent probes (Wu, Qiao, Yang & Wang, 
2010). Each technique has it is own drawbacks, however in the literature the 
fluorescent probe techniques are the most commonly used, due to the ease of 
measurement, accuracy in determining the CAC and the advantage of providing 
more information about the hydrophobicity of the core. 
The comb-shaped amphiphilic polymers can form various types of SA with 
the most common being micelles and nanoparticles. Hydrophobic drugs can be 
physically entrapped within the hydrophobic core of a micelle or within the 
nanoparticle matrix mainly via hydrophobic interactions. A high drug loading 
capacity (LC) is preferred in DDS as it reduces the amount of polymer required for 
administration. The LC is dependent on many factors, one of which is the drug 
loading method used in the preparation of the SA. Generally, there are three major 
drug loading methods, namely solvent evaporation, dialysis and probe sonication.  
In the solvent evaporation method the polymer and hydrophobic drug are 
dissolved in an organic solvent (e.g. dichloromethane). The organic solvent is then 
evaporated and the drug-polymer SA is collected after centrifugation. The SA is 
then reconstituted in water (Danhier et al., 2012; Pignatello et al., 2002). 
In the dialysis method the polymer and drug are dissolved in water and a 
water miscible organic solvent. The solution is transferred into a dialysis 
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membrane and then exhaustively dialysed against water (Kim et al., 2012; Sinha, 
Bansal, Kaushik, Kumria & Trehan, 2004). The exchange of the organic solvent 
and water molecules through the dialysis membrane drives the formation of drug-
polymer SA. The dialysate is then filtered to remove any excess un-encapsulated 
drug. These two methods have a common disadvantage in that the use of organic 
solvent is essential. Some organic solvents can be toxic and hence any residual 
organic solvents entrapped within the drug-polymer SA may lead to undesirable 
effects in-vivo. 
Ultrasonic probe sonication has been used recently to entrap hydrophobic 
drugs within SA (Cheng et al., 2006; Hoskins, Lin, Tetley & Cheng, 2012a; 
Thompson et al., 2008; Thompson, Tetley & Cheng, 2010). In this method, both 
the drug and the amphiphilic polymer are dispersed in an aqueous solution and 
the solution is probe sonicated to encourage and accelerate the drug-polymer SA 
formation. The colloidal solution is then filtered to remove excess free drug. This 
method is safe, simple, cost effective and most importantly it does not require the 
use of organic solvents in the preparation method. 
The entrapped drug in the SA must be released at an appropriate rate in 
order to provide a prolonged therapeutic effect and controlled release. The drug 
release from the SA depends on the type of the SA. For example, drug released 
from the polymer matrix of nanoparticle SA occurs through diffusion, erosion or a 
combination of both (Zhang et al., 2012). Whereas drug released from micelle SA 
occurs through diffusion. The determination of the drug release profile is crucial as 
it provides information about release kinetics and the mechanism by which the 
drug is being released from the SA. Generally drug release profiles of SA can be 
described as a mono- or bi-phasic release pattern (Li, Zhuang, Wang, Sui & Pan, 
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2012; Suen & Chau, 2013). The biphasic pattern is usually characterized by an 
initial burst release of the drug followed by a slower continuous release. The initial 
burst is usually due to the release of un-entrapped drug adsorbed on the surface 
of the nanoparticles.  
The analytical methods used in characterising the SA were photon 
correlation spectroscopy (PCS), fluorescence spectroscopy and transmission 
electron microscopy (TEM). The drug content in the SA was determined using high 
performance liquid chromatography (HPLC). 
3.1.1 Photon Correlation Spectroscopy 
Photon correlation spectroscopy (PCS) or dynamic light scattering (DLS) is 
a technique that is used to determine the hydrodynamic size distribution of 
nano-sized colloidal particles (Figure ‎3.2). The size of dispersed particles is 
measured by passing a beam of monochromatic and coherent light (laser) through 
the colloidal dispersion. The incident light is scattered in all directions upon impact 
with the dispersed particle. As particles move randomly in solutions due to the 
Brownian motion the distance between the particles in solution is constantly 
changing with time. The scattering intensity varies dependent on time due to the 
distance variation of the particles. This time-dependent variation carries 
information about the diffusion coefficient of the particles (Collins, 2012). The 
hydrodynamic size of the particle can be determined using the Stokes-Einstein 
equation (Equation ‎3.1) (Collins, 2012):  
 
   
    
    
 
Equation ‎3.1 
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Where Dh is the hydrodynamic diameter, kB is Boltzmann’s constant, T is the 
temperature (Kelvin), η is the viscosity of solvent medium and D is the diffusion 
coefficient. 
 
 
Figure ‎3.2: Schematic diagram of photon correlation spectroscopy analyser. 
 
The observed time-dependent fluctuation at short time delays (usually 
nano-seconds intervals) is compared to an autocorrelation function. Smaller size 
particles have faster time-dependent fluctuation decay in comparison to the 
autocorrelation function of larger particles. The rate of change of light fluctuation is 
then used to determine the size distribution. The size distribution of a colloidal 
sample is presented by the polydispersity index (PDI) which can have any value 
between 0 and 1. A low PDI indicates a uniform particulate size (monodispersed) 
in the sample, whereas a high PDI indicates non-uniformity in particulate size 
(polydispersed). 
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3.1.2 Fluorescence Spectroscopy 
Fluorescence spectroscopy (Figure ‎3.3) is a technique used to measure the 
emission and excitation spectra of fluorophores (fluorescent compound). 
Fluorescence spectroscopy is based on exciting the ground level electrons, by 
electromagnetic waves (usually UV) to the excited state (Albani, 2007). Collisions 
between molecules and thermal loss cause the excited electrons to occupy a 
lower vibrational state in the excited electronic state than in the ground state. The 
excited electrons migrate to one of the various vibrational levels at the ground 
electronic state, emitting a photon in the process. The emitted photons will have 
different energies, usually lower than the incident exciting light (visible light), due 
to the migration to different vibrational states. 
  
 
Figure ‎3.3: Schematic diagram of fluorescence spectrophotometer. 
 
Fluorescence spectroscopy is a useful technique in studying the formation 
of an excimer, which can provide valuable information about the hydrophobicity of 
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the environment. An excimer is a short lived diatomic complex involving two atoms 
or molecules with at least one atom/molecule in their excited state (Birks, 1975). 
The formation of the excimer causes changes in the fluorescent emitted spectra of 
the fluorophore. Some fluorescent molecules i.e. pyrene (Figure ‎3.4) form 
excimers upon moving to the non-polar environment, this enables the use of these 
probes to investigate the polarity of the core and the CAC of the SA 
(Kalyanasundaram & Thomas, 1977). Pyrene is a commonly used fluorophore in 
determining the CAC of SA.  
 
 
Figure ‎3.4: The chemical structure of pyrene. 
 
The vibrational fine structure fluorescence peaks of a pyrene monomer and 
excimer are highly dependent on the polarity of the surrounding environment. The 
most apparent change in the fine structure pattern of pyrene occurs at the 373 and 
383 nm peaks (Figure ‎3.5). In non-polar surroundings, the 383 nm peak dominates 
the pyrene spectrum (excimer), whereas at a higher polarity environment, the 373 
nm peak is the most intense (monomer). Expressing the relative emission 
intensities at 383 and 373 nm as a ratio is a useful parameter to determine the 
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environment polarity of the hydrophobic domain (Matsui, Nakazawa & Morisaki, 
1991). 
 
 
Figure ‎3.5: The fluorescence vibronic peaks of pyrene in aqueous medium (polar environment). 
 
3.1.3 Transmission Electron Microscopy 
Transmission electron microscopy (TEM) is widely used in studying nano-
sized SA providing detailed information about the size, size distribution and the 
type of the SA (Bakkour, Darcos, Coumes, Li & Coudane, 2013). TEM in principle 
works in a similar way to a slide projector, however instead of using light, the TEM 
uses a beam of high energy electrons accelerated to nearly the speed of light 
(typically 60-120 kV). This beam of electrons is passed through a thin layer (nano-
scale) of the sample. The un-scattered electrons are collected on a fluorescent 
screen or CCD camera providing a shadow image (dark image) of the sample. The 
darker areas of the image represent the areas of the sample that had fewer 
electrons transmitted through it (thicker or denser areas). On the contrary, the 
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brighter areas of the image represent the sample areas that had more electrons 
transmitted through it (thinner or more penetrable areas) (Amelinckx, Gevers & 
Landuyt, 1978). The main component of TEM is illustrated in Figure ‎3.6. 
 
 
Figure ‎3.6: Schematic diagram of a transmission electron microscope. 
 
3.1.4 High Performance Liquid Chromatography 
High performance liquid chromatography (HPLC) is an analytical technique 
in which a mixture of compounds in a solution are separated for the purpose of  
quantifying and identifying individual compounds (Kazakevich & LoBrutto, 2007). 
The types of HPLC vary according to the principle of separation. The most 
common type is reversed phase HPLC. Reversed phase HPLC involves the use of 
a non-polar stationary phase such as silica, in which the surface has been 
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modified with alkyl groups such as C18H37, and a relatively polar mobile phase 
(Figure ‎3.7). The partitioning of the molecules between the mobile and stationary 
phase is the main principle responsible for the separation of compounds. The 
retention time is the time elapsed from the injection of the sample to the elution 
from the column, and dependent mainly on the hydrophobicity of the molecules 
and the polarity of the mobile phase. A shorter retention time means smaller polar 
molecules eluting faster due to preferential partition into the polar mobile phase, in 
contrast to the larger and less polar compounds. A HPLC chromatogram typically 
shows separated peaks against time, where the area under the peak is used to 
quantify the studied molecules. 
 
Figure ‎3.7: Schematic diagram of a HPLC. 
 
3.1.5 Model Hydrophobic Drug 
Triamcinolone acetonide (TA) was used as hydrophobic drug in the drug 
solubilisation studies for this project (Figure ‎3.8). TA is a corticosteroid anti-
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inflammatory drug, which has been used as an off-label drug to treat many 
posterior eye diseases such as diabetic macular oedema and AMD (Jonas, 
Kreissig & Degenring, 2002). TA has a Mw of 434.5, logP of 2.53 (Goundalkar & 
Mezei, 1984; Steckel, Thies & Müller, 1997) and 21 µg mL-1 aqueous solubility at 
28 °C (Block & Patel, 1973). 
. 
 
Figure ‎3.8: Triamcinolone acetonide structure (434.5 Mw, 21 µg mL-1 solubility in water at 28 °C, 
logp = 2.53). 
 
  Many commercial preparations of TA exist as an injectable suspension for 
ophthalmic use, such as Kenalog, Flutex and Kenacort-A. Kenalog-40 for 
example, is a 40 mg ml-1 TA suspension consistsing of sodium chloride for 
isotonicity, 0.99% (w/v) benzyl alcohol as a preservative and 0.75% v/v 
carboxymethylcellulose sodium and 0.04% w/v polysorbate 80 as stabilisers 
("KENALOG®-40 INJECTION," 2013). The suspension has a particle distribution 
size of 69.5% in the 1-5 µm range, 16% in the 5-10 µm range, 2.5% in the 10-20 
µm range and 7.6% greater than 20 µm (Jermak, Dellacroce, Heffez & Peyman, 
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2007). The main route of delivery of TA to the posterior segment of the eye is 
through an intravitreal injection (Danis, Ciulla, Pratt & Anliker, 2000).  
3.1.6 Aim and Objectives 
The aim of this study was to prepare and characterise the SA formed by the 
amphiphilic polymers synthesised in chapter 2 and to determine the TA content 
entrapped within these SA. The objectives were: 
 To prepare and characterise SA formed by four different amphiphilic 
polymers, namely: Pa5, Pa5-MPEG, Ch5 and Da10. 
 To determine the CAC of the SA  
 To prepare and characterise TA-SA formulations from four different 
amphiphilic polymers. 
 To study the in-vitro drug release profiles of the four TA-SA 
formulations  
3.2 Materials and Methods 
Pa5, Pa5-MPEG, Ch5, Da10 were synthesised as described in chapter two 
(sections 2.2.1.2 – 2.2.1.5). Acetonitrile, methanol and formic acid (HPLC grade) 
were all purchased from Fisher, United Kingdom. Syringe filters (0.45 µm GDX 
PVDF, Whatman, United Kingdom), nylon filter membranes (0.2 µm, Whatman, 
United Kingdom), cremophor® EL, tween® 80 and pyrene were obtained from 
Sigma-Aldrich, United Kingdom. Dialysis tubing membrane (Mw cut-off = 12-14 
kDa) was supplied by Medicell International Ltd, United Kingdom. Triamcinolone 
Acetonide micronized powder was aquired from Fagron, United Kingdom. Strata™ 
-X-C polymeric solid phase extraction (SPE) tubes were purchased from 
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Phenomenex®, United Kingdom. Highly purified water (deionised) were obtained 
using a Millli Q® integral water purification system. 
3.2.1 Preparation and Characterisation of SA 
3.2.1.1 Preparation of SA 
SA were formed by probe sonicating the modified polymer (50 mg) in 
deionised filtered water (10 mL, 0.2 µm, Whatman, United Kingdom) using an 
ultrasonic processor (Hielscher UP200S, Germany) for 15 min at 100% amplitude 
on full cycle. The colloidal solution was left to cool down for 15 min and then 
filtered using a syringe filter (0.45 µm filter). The filtrate was collected for further 
analysis.  
3.2.1.2 Characterisation of SA using PCS  
Hydrodynamic diameters, polydispersity indices (PDI) and zeta potentials of 
SA in aqueous medium (5 mg mL−1) were determined at 25 °C using photon 
correlation spectroscopy (Zetasizer Nano-ZS, Malvern Instruments, United 
Kingdom). Analysis was performed at a measurement angle of 173° and 
equilibration time of 120 s. The collected data were processed using multiple 
narrow modes (Zetasizer software v6.12). Analysis was performed in triplicate for 
each sample using a zeta potential cell for both size and zeta potential 
measurements. 
3.2.1.3 Characterisation of SA using TEM 
Samples were sent to the School of Pharmacy, at Keele University for TEM 
analysis. The method performed was as follows: A glass microscope slide was 
dipped into 5% formvar in chloroform solution and dried under a heating lamp. The 
edges of the film were liberated from the glass slide using a fresh razor blade. The 
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slide was gently lowered into a reservoir filled with deionised water. The film 
became dissociated from the slide and floated on top of the water. Copper grids 
were washed in chloroform and dried onto filter paper. The dry grids were placed 
gently with forceps onto the film surface dull side facing downwards. The film was 
‘scooped’ up by a clean glass slide and dried for 24 h under a heating lamp. The 
grids were dislodged from the main film using a razor blade and were placed on 
parafilm ready for use. SA were dried onto the formvar coated copper grids for 8 h 
under the heating lamp. The grids were imaged using a JEOL JEM-1230 
microscope (JEOl, Japan) using anaLYSIS software. 
3.2.1.4 Determination of SA CAC  
The CAC of SA in aqueous solution was determined using pyrene as a 
hydrophobic probe.  Pyrene stock solution was prepared by dissolving pyrene (40 
mg) in ethanol (100 mL), 100 µL of the solution was then transferred to a 
volumetric flask (100 mL) and the solvent was dried off under a stream of nitrogen 
gas. The pyrene was subsequently dissolved in 100 mL of deionised water to 
produce a 2 µM stock solution.  
SA (5 mg mL−1) were prepared in the pyrene stock solution (2 µM) and 
probe sonicated as described in section ‎3.2.1.1 but without the filtration step. 
Subsequently, a concentration range of 0.005 to 3 mg mL−1 polymer solutions 
were diluted using pyrene stock solution (2 µM) as the diluent. 
The pyrene fluorescence emission spectrum (350 - 500 nm) was measured 
using a fluorescence spectrophotometer (Perkin Elmer Precisely, LS 55, United 
State). The fluorescence emission spectrum was obtained by exciting the sample 
at 340 nm. The I3/I1 intensity values were calculated from the intensity of the third 
(383 nm) and first (375 nm) peaks in the pyrene emission spectra (Figure ‎3.5) and 
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plotted against polymer concentration and 2 µM pyrene stock solution to determine 
the CAC. The CAC was calculated as the intersection of the tangent to the curve 
of I3/I1 against polymer concentrations at the inﬂection with the horizontal line 
passing through the points at low polymer concentration (Figure ‎3.11). 
3.2.2 Preparation and Characterisation of TA-SA Formulations 
3.2.2.1 Preparation of TA-SA Formulations 
SA were prepared as described in section ‎3.2.1.1 without the filtration step. 
TA (100 mg) was added to the SA colloidal solution (4 mL, 5 mg mL-1) in 1:5 
polymer to TA weight ratio. The TA-polymer suspension was probe sonicated 
(Hielscher UP200S, Germany) for 5 min at 100% amplitude on full cycle. The TA-
polymer suspension was then left to cool to room temperature before 
centrifugation at 1008 G force (3000 rpm) for 5 min. The supernatant was 
transferred into eppendorf tubes and the centrifugation process was repeated two 
more times to remove any excess drug. Finally the colloidal solution was filtered 
with a 0.45 µm PVDF syringe filter (Whatman, United Kingdom) to ensure 
complete removal of any un-encapsulated TA above filter cut-off size. The first 5 
drops of the filtrate was discarded while the rest of the TA-SA formulation was 
collected for further analysis.  
3.2.2.2 Characterisation of TA-SA Formulations using PCS and TEM 
The characterisation of TA-SA formulations was carried out using PCS and 
TEM analysis as described in sections ‎3.2.1.2 and  3.2.1.3 respectively. 
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3.2.2.3 LC of TA-SA Formulations 
The LC of TA was calculated directly by determining the encapsulated TA 
within the SA using HPLC method (‎3.2.5) and applying Equation ‎3.2 (Araujo, 
Nikolic, Egea, Souto & Garcia, 2011). 
 
   
[  ]               
[       ] 
 
Equation ‎3.2 
3.2.3 TA Solubility 
The solubility of TA in water and in three conventional solubilising agents 
was performed by the addition of TA (4 mg) to 4 mL of either 1 ) water, 2)  0.1% 
tween® 80, 3) 0.2% cremophor® EL or 4) 30% ethanol (v/v). All TA suspensions 
were sealed in glass vials and left under constant agitation for 24 h (at room 
temperature approximately 22 °C) before filtering (0.45 µm GDX PVDF, Whatman, 
United Kingdom) and determining the amount of dissolved TA using the HPLC 
method (section ‎3.2.5). 
3.2.4 In-vitro TA Release from TA-SA Formulations 
Dialysis tubing with a 12-14 kDa MW cut-off were soaked and washed four 
times in deionised water. The TA-SA formulations (2 mL) prepared as described in 
section ‎3.2.2.1 and TA aqueous suspension (2 mL, 1 mg mL-1) were pipetted into 
the dialysis tubes. The dialysis tubes were tied and immersed in a receiver fluid 
(200 mL of deionised water) and incubated at 37 °C under magnetic stirring.  
The experimental work flow was as follows:  
During the first 3-8 h of the experiment, samples (1 mL) were taken at 
hourly intervals from the receiver fluid (t = 3-8 h), and replenished with 1 mL of 
receiver fluid at 37 °C. Following the eight hour sample, the receiver fluid was 
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completely removed and replenished with 37 °C deionised water (200 mL) in order 
to maintain sink conditions. Subsequent measurements and receiver fluid 
replacement (completer withdraw of receiver fluid) were taken at regular intervals, 
to yield samples at t = 23, 32, 47, 56, 71, 80, 97, 121 and 145 h. All withdrawn 
samples were analysed using the HPLC assay described in section ‎3.2.5 without 
the solid phase extraction step.  
3.2.5 HPLC Analysis Methods 
The amount of TA encapsulated within and released from the TA-SA 
formulations was determined using HPLC. Due to the relatively high entrapment of 
TA within the TA-SA formulation in comparison to the low amount of TA released 
from TA-SA formulations, two HPLC methods were required to ensure sensitivity 
and linearity across the wide concentration range required to this study. The HPLC 
system suitability was assessed in compliance with United States Food and Drug 
Administration (FDA) regulations (US Food and Drug Administration, 1994). The 
partial validation of the two methods was performed in accordance with the 
International Conference of Harmonisation (ICH) guidelines (International 
Conference of Harmonisation, 1995) for analytical methods as detailed below in 
section  3.2.5.6. The first method was used to determine the relatively high amount 
of TA entrapped within the TA-SA formulations, whereas the second method was 
used to determine the low amount of TA released from the TA-SA formulations. 
3.2.5.1 Solid Phase Extraction 
The polymers were found to interfere with the HPLC column, resulting in an 
increased pressure due to partial blockage of the column. This problem was 
eliminated by extracting TA from the TA-SA formulation using solid a phase 
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extraction (SPE) method. The extracted TA from the SA was quantified using the 
TA loading HPLC method (section  3.3.4). The SPE of TA work flow was as 
follows: 
SPE tubes (Strata™ -X-C, 6 mg sorbent, 3 mL) were conditioned by adding 
methanol (1 mL) to each tube before drying the tubes under low pressure (10-15 
inches Hg below ambient pressure) using a vacuum manifold. The tubes were 
then activated by adding HCl (1 mL, 0.1 M), followed by drying the tubes under low 
pressure. Prior to the loading step, TA-SA formulation samples were diluted 20 
fold in HCl (0.1 M) and mixed thoroughly, before the diluted sample (2 mL) was 
transferred onto the SPE tube. The samples were left to pass freely under ambient 
pressure through the SPE tube, followed by drying the tubes under low pressure. 
TA was eluted using 5% formic acid in methanol (2 ml, v/v) and analysed using the 
TA loading HPLC method.  
3.2.5.2 TA Extraction Recovery from TA-SA 
The percentage of TA recovered after extraction using SPE tubes was 
determined for standards at three concentrations, low (5 µg mL-1), medium (50 µg 
mL-1) and high (100 µg mL-1) and one TA-SA formulation (Da10). TA was extracted 
from four replicates of each standard concentration and TA-SA formulation. The 
results were reported as the mean recovery percentage of the four measurements 
at each concentration level. 
3.2.5.3 Chromatographic System 
Chromatographic measurements were performed using a Waters HPLC 
system consisting of Waters 2487 Dual λ Absorbance Detector, Waters In-Line 
Degasser AF, Waters 717Plus Autosampler, Waters™ 600S controller and 
Waters™ 616 Pump. 
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3.2.5.4 Chromatographic Conditions 
The mobile phase used was 40: 60 v/v acetonitrile: water. The injection 
volume and wavelength of detection were 20 µL and 240 nm, respectively. The 
analysis was carried out isocratically at room temperature on a Gemini 5 µm C18 
(250 mm x 4.6 mm x 5 µm) column (Phenomenex®, United Kingdom) and at a flow 
rate of 1 mL min-1. 
3.2.5.5 Calibration Standards 
TA (10 mg) was weighed and then transferred into volumetric flask (100 
mL) to which 40 mL of acetonitrile was added. Following complete dissolution of 
TA, the solution was made up to volume with deionised water, resulting in a stock 
concentration of 100 µg mL-1. Working standards were prepared by serial dilution 
using 40: 60 v/v acetonitrile: water solution as the diluent. The standard 
concentration range for the TA loading and TA in-vitro release HPLC methods 
were 0.5-100 µg mL-1 and 0.25-10 µg mL-1, respectively.  
3.2.5.6 Validation and Suitability of HPLC Methods 
The HPLC system suitability parameters such as theoretical plate number 
(N), capacity factor and tailing factor were assessed for the TA peak. Theoretical 
plate number is a measure of column efficiency; it is a dimensionless number fairly 
constant for each peak on a chromatogram. N was determined using Equation ‎3.3. 
 
        
  
  
   
Equation ‎3.3 
 
Where tr is the retention time of the peak and tw is the peak width at half peak 
height. 
Capacity factor (K) is a measure of the peak of interest position with respect to the 
void volume. K was calculated according to Equation ‎3.4. 
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Where t0 is the retention time of non-retained compounds. 
Tailing factor (T) is a dimensionless unit which determines when and where the 
peak of interest ends and therefore a lower T value results in more accurate 
calculation of the area under the peak. T was calculated according to 
Equation ‎3.5. 
 
 
Where wx is the width of the peak at x% from the baseline of the peak and f is the 
distance between the peak maximum and peak front at wx. 
The linearity, accuracy, precision, range, detection and quantitation limits 
were assessed to demonstrate the validity of the method (Shabir, 2003). A 
calibration curve was constructed by plotting the area of the TA peak in the 
integrated chromatogram versus corresponding concentration. The linearity of the 
methods was investigated at seven concentration levels in a range between 0.25 
and 10 μg mL-1 and 0.5 and 100 µg mL-1 for the TA loading and TA in-vitro release 
methods, respectively. Six replicates were prepared at each concentration. The 
accuracy of an analytical method expresses the closeness of the experimental 
value to the true (reference) concentration. The accuracy of the method was 
determined by analysing three different standard concentrations levels; low, 
medium and high for the in-vitro TA release (0.25, 5 and 10 µg mL-1) and for TA 
loading HPLC methods (0.5, 50 and 100 µg mL-1), and comparing the measured 
values to the true value using Equation ‎3.6. Four replicates were prepared at each 
concentration. The accuracy was presented as percentage recovery. 
 
    
     
  
  
Equation ‎3.4 
    
  
  
 
Equation ‎3.5 
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Equation ‎3.6 
 
Precision expresses the closeness of measured values between multiple 
sampling of the same sample under the same analytical conditions. Precision was 
considered at three levels: repeatability (intra-day), intermediate precision (inter-
day) and reproducibility. The repeatability of three standard concentrations (low, 
medium and high) was assessed by measuring six injections per sample. The 
inter-day precision was evaluated for three independently prepared standards 
(low, medium and high) on three different days (n = 4). The reproducibility was not 
assessed as all sample analysis was performed on the same HPLC system. The 
precision was expressed as relative standard deviation (RSD) percentage. The 
detection limit (DL) and quantitation limit (QL) were calculated based on the 
standard deviation of the response and the slope in accordance with Equations 3.7 
and 3.8, respectively. 
 
                  
 
 
       
Equation ‎3.7 
 
                        
 
 
      
Equation ‎3.8 
 
Where σ = the standard deviation of the response, S = the slope of the calibration 
curve. 
3.2.6 Statistical Evaluation 
Statistical analysis was performed using SPSS program version 19. The 
normality of the data was assessed using the Shapiro-Wilk test. Experimental 
difference between groups was compared with the control using the independent 
student’s t-test. Differences were regarded as significant, with P ≤ 0.05. 
Chapter 3: Triamcinolone Acetonide Loading into Self-Assemblies and Release 
from Triamcinolone Acetonide-Self-Assemblies 
114 
 
3.3 Results 
3.3.1 Photon Correlation Spectroscopy  
The hydrodynamic size of the SA ranged from 114 nm (Da10) to 314 nm (Pa5-
MPEG) as shown in Table ‎3-1. The Pa5, Ch5 and Pa5-MPEG SA all had a low 
polydispersity index (PDI) indicating a uniform single size population (Table ‎3-1). A 
representative size distribution of Pa5 SA is illustrated in Figure ‎3.9. On the other 
hand, Da10 had a high PDI and is attributed to the multi-size population distribution 
present in the sample. Figure ‎3.10 shows the bimodal size distribution for Da10, 
where a small peak appears at around 15-45 nm and a larger peak appears at 
around 100-400 nm. The Da10, Pa5 and Pa5-MPEG SA had similar zeta potential 
values, in contrast to the higher value associated with Ch5 SA (Table ‎3-1). 
 
Table ‎3-1: Average hydrodynamic size, PDI and zeta potential of the SA (Data represented as 
mean and standard deviation (S.D.), n = 5). 
SA ID 
Hydrodynamic 
Diameter (nm), 
mean ± S.D. 
Polydispersity 
Index (PDI), 
mean ± S.D. 
Zeta Potential 
(mV), mean ± 
S.D. 
Da10 114 ± 8 0.68 ± 0.03 +19.4 ± 0.5 
Pa5 184 ± 5 0.12 ± 0.01 +20.7 ± 0.9 
Ch5 232 ± 9 0.22 ± 0.01 +39.5 ± 2.1 
Pa5-MPEG 314 ± 7 0.12 ± 0.01 +23.6 ± 1.6 
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Figure ‎3.9: Photon correlation spectroscopy size correlation chart for Pa5 SA. 
Figure ‎3.10: Photon correlation spectroscopy size correlation chart for Da10 SA. 
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The hydrodynamic size of the TA-SA formulations ranged from 200 nm 
(Da10) to 334 nm (Pa5-MPEG) as shown in Table ‎3-2. All TA-SA formulations 
showed low PDI and single mode size distributions. Apart from Ch5 SA, the 
addition of TA did not affect the zeta potential of the SA where TA-SA formulations 
had similar zeta potentials to the unloaded SA. However, as a whole, addition of 
TA has an impact on the hydrodynamic size of TA-SA formulations. The 
hydrodynamic size of all TA-SA formulations was higher than the size of their 
counterpart SA. The Da10 TA-SA formulation had the highest increase in 
hydrodynamic size (t-test, p < 0.05) from 114 (Da10 SA) to 200 nm (approximately 
80 nm), whereas the rest of the TA-SA formulations had approximately 20 nm 
increase in hydrodynamic size (t-test, p < 0.05) in comparison to their counterpart 
SA. Interestingly, loaded TA-SA formulations resulted in a decrease in PDI in 
comparison to their unloaded counterparts, with Da10 having the most significant 
drop in PDI (from 0.68 to 0.1). This indicates that the addition of TA led to a mono-
dispersed size population. 
 
Table ‎3-2: Average hydrodynamic size, PDI and zeta potential of TA-SA formulations (Data 
represented as mean and standard deviation (S.D.), n = 5). 
TA-SA 
Formulation ID 
Hydrodynamic 
Diameter (nm), 
mean ± S.D. 
Polydispersity 
Index (PDI), 
mean ± S.D. 
Zeta Potential 
(mV), mean ± 
S.D. 
Da10 200 ± 1 0.10 ± 0.01 +20.5 ± 1.0 
Pa5 204 ± 3 0.09 ± 0.01 +21.3 ± 0.4 
Ch5 253 ± 4 0.13 ± 0.02 +45.7 ± 1.0 
Pa5-MPEG 334 ± 3 0.09 ± 0.01 +22.4 ± 0.5 
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3.3.2 Determination of SA CAC 
Figure ‎3.11, shows the CAC for the Pa5, Pa5-MPEG and Ch5 polymers, the 
CAC for the Da10 could not be obtained due to the interference between the dansyl 
absorptivity and the pyrene fluorescent signal. The dansyl group has high 
absorptivity between 300-450 nm, which masks the hydrophobic probe fluorescent 
signal (350-450 nm). The Ch5 polymer had CAC of 0.0052 mg mL
-1, the lowest 
CAC value in comparison to Pa5 (0.011 mg mL
-1) and Pa5-MPEG (0.027 mg mL
-1). 
The I3/I1 values for the Ch5 SA were higher than Pa5 and the latter had higher I3/I1 
values than Pa5-MPEG. This observation indicates that the core polarity is in the 
order of Pa5-MPEG > Pa5 > Ch5 (t-test, p < 0.05). 
 
 
Figure ‎3.11: The fluorescence vibronic peak ratio (I3/I1) of pyrene at various Pa5, Pa5-MPEG and 
Ch5 concentrations (Data represented as mean, error bars represent range, n = 3). 
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3.3.3 TEM of SA and TA-SA Formulations 
The TEM micrographs of SA in water are shown in Figures 3.12 to 3.15. 
The Pa5, Ch5 and Pa5-MPEG SA had an approximate size of 100, 100-200 and 
150 nm, respectively. The TEM images revealed an irregular shape for Pa5; 
spherical for Pa5-MPEG and Da10; and cuboid-like for Ch5 SA (Figures 3.12 to 
3.15). The Da10 SA TEM images (Figure 3.15) showed small spherical SA 
aggregated into larger clusters. The size of the individual small Da10 SA was 
approximately 40 nm and the larger clusters were approximately 200 nm. 
 
Figure ‎3.12: TEM micrographs of Pa5 SA (Scale bar A = 100 nm, B = 200 nm). 
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Figure ‎3.13: TEM micrographs of Pa5-MPEG SA (Scale bar A = 1 µm, B = 2 µm). 
 
 
Figure ‎3.14: TEM micrographs of Ch5 SA (Scale bar A = 200 nm, B = 1 µm). 
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Figure ‎3.15: TEM micrographs of Da10 SA (Scale bar A = 100 nm, B = 200 nm). 
 
The TEM micrographs of the TA-SA formulations (Figures 3.16 to 3.19) 
showed that for all formulations, addition of TA led to the formation of spherical 
particles. The size of the TA-SA formulations varied considerably with the smallest 
about 100 nm (Pa5) (Figure 3.16) and the largest around 400 nm (Pa5-MPEG) 
(Figure 3.17). The Ch5-TA and Da10-TA SA had an approximate size of 250 and 
200 nm, respectively (Figures 3.18 and 3.19). Interestingly, TA loaded Da10 
resulted in the disappearance of the large clusters of small aggregates 
(Figure ‎3.15) but instead consisted of discrete, individual spherical particles.  
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Figure ‎3.16: TEM micrographs of Pa5 TA-SA formulation (Scale bar A = 200 nm, B = 200 nm). 
 
Figure ‎3.17: TEM micrographs of Pa5-MPEG TA-SA formulation (Scale bar A = 500 nm, B = 500 
nm). 
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Figure ‎3.18: TEM micrographs of Ch5 TA-SA formulation (Scale bar A = 200 nm, B = 200 nm). 
 
Figure ‎3.19: TEM micrographs of Da10 TA-SA formulation (Scale bar A = 100 nm, B = 200 nm). 
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3.3.4 Partial Validation and Suitability of HPLC methods 
A well resolved TA peak at retention time (tr) of 10.8 min was obtained, as 
depicted in Figure ‎3.20. The constructed calibration curves based on the peak 
area gave excellent linearity (R2 > 0.999) in the range of 0.5-100 µg mL-1 for the 
TA loading method and 0.25-10 µg mL-1 for the in-vitro release method (Figures 
3.21 and 3.22). 
Figure ‎3.20: High performance liquid chromatogram of TA (50 µg mL-1) in 40: 60 v/v acetonitrile: 
water. 
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Figure ‎3.21: High performance liquid chromatography calibration curve for triamcinolone acetonide 
in 40: 60 v/v acetonitrile: water for drug loading studies (Data represented as mean, error bars 
represented as S.D., n = 6). 
Figure ‎3.22: High performance liquid chromatography calibration curve for triamcinolone acetonide 
in 40: 60 v/v acetonitrile: water for drug release studies (Data represented as mean, error bars 
represented as S.D., n = 6). 
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An optimized reversed-phase HPLC method for the assessment of TA 
entrapped within and released from the SA carriers was developed and found to 
be fit for purpose. All suitability and validation parameters of the two methods 
(Table ‎3-3) were within the limits proposed by the guidelines of ICH and US FDA, 
indicating that this method was precise and accurate with low detection and 
quantification limits. 
An optimized SPE method used to extract TA entrapped within the SA was 
developed. The TA percentage recovered from the SPE tubes for the low, medium 
and high standards were 98 ± 2%, 99 ± 1% and 100 ± 1%, respectively (n=4). The 
TA percentage recovered from the Da10 TA-SA was 98 ± 2% (n=4), indicating the 
suitability of this method.  
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Table ‎3-3: HPLC TA methods validation and suitability for the both TA loading and in-vitro release 
methods. 
Parameter 
HPLC Method 
Limits (ICH, 
US FDA) 
TA Loading 
TA 
In-vitro 
Release 
Capacity Factor K 4.2 4.2 > 2 
Tailing factor T 1.2 1.1 T ≤ 2 
Theoretical plate number 16452 14325 N > 2000 
Accuracy (low, med & high) (%) 99, 99 & 100 
99, 100 & 
100 
X = 100 ± 2% 
Intra-day precision (low, med & 
high conc) (R.S.D) 
0.26, 0.18 & 
0.03 
0.6, 0.3 & 
0.12 
R.S.D < 2% 
Inter-day precision (low, med & 
high conc) (R.S.D) 
0.54, 0.38 & 
0.34 
0.82, 0.61 & 
0.23 
R.S.D < 2% 
Limit of detection (µg mL-¹) 0.53 0.10 - 
Limit of quantitation (µg mL-¹) 1.69 0.30 - 
 
3.3.5 TA Entrapped and Solubility 
The amount of TA entrapped within SA and TA solubility in conventional 
solubilisers (tween 80, cremophor EL and ethanol) is shown in Figure ‎3.23. The 
solubility of TA in water, 0.1% tween 80, 0.2% cremophor EL and 30% ethanol 
were 13.58 ± 0.45, 18.52 ± 1.19, 29.93 ± 1.94 and 241.13 ± 12.26 µg mL-1 (n = 4), 
respectively. The TA entrapped within the TA-SA’s for Pa5, Ch5, Pa5-MPEG and 
Da10 were 453 ± 10, 729 ± 78, 910 ± 92 and 1282 ± 100 µg mL
-1 (n = 4), 
respectively. The Da10, Pa5-MPEG, Ch5 and Pa5 TA-SA enhanced the TA aqueous 
solubility by 92, 65, 52 and 32-fold, respectively. 
Chapter 3: Triamcinolone Acetonide Loading into Self-Assemblies and Release 
from Triamcinolone Acetonide-Self-Assemblies 
127 
 
 
Figure ‎3.23: Maximum TA concentration solubilised by TA-SA formulations at 1:5 initial TA: 
polymer loading ratio determined by HPLC, compared to the intrinsic solubility and other 
solubilising agents (Data represented as mean, error bars represent S.D., n = 5.All TA solubility 
and loading experiment were carried out at room temperature at approximately 22 °C). 
 
All TA-SA formulations exhibited higher TA entrapment than the 
conventional solubilisers as illustrated in Figure ‎3.23 and Table ‎3-4. The Da10 TA-
SA formulation had the highest LC (25.3%) and highest TA entrapment compared 
to the other TA-SA formulations, small molecular weight surfactants and 30% 
ethanol co-solventol (Table ‎3-4). The Da10 TA-SA formulation was able to 
encapsulate TA up to 66, 42 and 5-fold higher than the 0.1% w/v tween 80, 0.2% 
cremophor EL and 30% v/v ethanol, respectively (Table ‎3-4). In contrast, the Pa5 
TA-SA formulation had the lowest LC (9.1%) and lowest TA entrapment amongst 
the TA-SA formulations. The Pa5 TA-SA formulation was able to encapsulate TA 
up to 24, 15 and 2-fold higher than the 0.1% w/v tween 80, 0.2% cremophor EL 
and 30% v/v ethanol, respectively (t-test, p < 0.05) (Table ‎3-4). 
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Table ‎3-4: Loading capacity of TA-SA formulations and number of folds of TA entrapped within the 
TA-SA formulations in comparison to conventional solubilisers. 
TA-SA 
Formulation 
No. of fold 
increase in 
TA in 
comparison 
to 0.1% tween 
80  
No. of fold 
increase in 
TA in 
comparison 
to 0.2% 
cremophor EL 
No. of fold 
increase in 
TA in 
comparison 
to 30% 
ethanol 
LC% 
Da10 66 42 5 25.3 
Pa5-MPEG 48 30 4 18.2 
Ch5 39 25 3 14.8 
Pa5 24 15 2 9.1 
 
3.3.6 In-Vitro TA Release from TA-SA Formulation 
The in-vitro TA release profiles of the four TA-SA formulations and a TA 
control (TA suspension) are presented in Figure ‎3.24. A 100% drug release from 
the Pa5-MPEG, Pa5 and Ch5 TA-SA formulations were obtained in approximately 
two days (47 h). In contrast, the Da10 TA-SA formulation showed a prolonged 
release as it took approximately six days (145 h) for 100% release of the TA. In 
contrast to the Pa5, Pa5-MPEG and Ch5 TA-SA formulations, the Da10 TA-SA 
formulation showed a lower cumulative TA percentage release in comparison to 
the aforementioned formulations (Pa5-MPEG, Pa5 and Ch5 TA-SA). 
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Figure ‎3.24: Release profiles of TA from TA suspension (1000 µg mL
-1
), Da10 (1238 µg mL
-1
), Pa5-
MPEG (830 µg mL
-1
), Pa5 (468 µg mL
-1
), and Ch5 (762 µg mL
-1
) TA-SA formulations (Data 
represented as mean, error bars represent range, n = 4). 
 
Table ‎3-5 summarises the TA in-vitro release data fit to kinetic models. The 
kinetic models best fit for all TA-SA formulations and TA control were obtained 
using the Higuchi model (R2 >0.99). The zero order (R2 >0.95) and Hixon-Crowell 
(R2 <0.93) models had the second and third best fit, respectively. The first order 
model had the least best fit for all TA-SA formulations (R2 < 0.88). 
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Table ‎3-5: In-vitro release data fit to kinetic models.  
Kinetic 
Model 
Equation Parameter 
TA 
Suspension 
Ch5 Da10 Pa5 
Pa5-
MPEG 
Zero 
order 
Qt=k0t 
R² 0.95 0.99 0.96 0.95 0.98 
k0 17.4 30.6 16.6 21.0 38.1 
First 
order 
lnQt=-k1t 
R² 0.82 0.88 0.76 0.84 0.86 
K1 0.03 0.05 0.02 0.04 0.05 
Higuchi Qt=kHt
1/2 
R² 0.99 1.00 1.00 1.00 1.00 
KH 201.4 283.5 224.7 202.2 330.0 
Hixon-
Crowell 
Q0
1/3- 
Qt
1/3=kHCt 
R² 0.87 0.93 0.85 0.89 0.92 
kHC -0.07 -0.13 -0.06 -0.11 -0.15 
 
Qt is the cumulative amount of drug release at time t; Q0 is the initial amount of 
drug in the formulation; k0, k1, kH and kHC are the release rate constants for zero 
order, first order, Higuchi and Hixson-Crowell, respectively. 
3.4 Discussion 
The formation of SA in an aqueous environment, their CAC, TA solubilising 
capacity and in-vitro TA release were characterised and determined during the 
work described in this chapter.  
The formations of SA in aqueous medium were confirmed using TEM and 
PCS techniques. The PCS results showed the formation of mono-dispersed nano-
sized populations for Pa5, Pa5-MPEG and CH5 aqueous SA. In contrast to the 
mono-dispersed populations of the SA, Da10 SA had bimodal nano-sized 
populations. Different size populations (bimodal) phenomenon has been reported 
in the literature and was attributed to the existence of large loose assemblies in 
dynamic equilibrium with smaller more compact assemblies (Chiu, Chern, Lee & 
Chang, 1998; Wang, Tan, Huang, Che & Du, 2009). Others have attributed the 
bimodal distribution to the existences of unimers (typically few nm in size) 
coexisting with the multipolymer aggregates (Yusa, Hashidzume & Morishima, 
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1999). The size (approximately 40 nm) of the small aggregates in the Da10 TEM 
micrographs indicates the existence of small compact assemblies alongside large 
loose assemblies. The Da10 SA were found to have the lowest hydrodynamic size 
(114 nm) followed by Pa5 (184 nm), Ch5 (232 nm) and Pa5-MPEG (314 nm) SA. 
The lower mean hydrodynamic diameter of Da10 SA in comparison to the rest of 
the SA was due to the relatively high hydrophobically modification percentage of 
Da10 polymer and the presence of small compact assemblies. The higher 
modification percentage in Da10 (10%) results in greater hydrophobic interactions 
between the hydrophobic groups in the SA and it is these that are likely to have 
produced smaller compact SA (Yuan, Li & Yuan, 2006). Hoskins et.al reported 
smaller hydrodynamic sizes for three hydrophobically modified PAA (10%, dansyl, 
fluorenylmethoxy carbonyl and naphthalene) in comparison to their lower 
hydrophobically modified counterparts (5%) (Hoskins, Lin, Tetley & Cheng, 2012a, 
2012b). Likewise, Chen et al. has reported a decrease in the hydrodynamic size of 
SA of grafted cholesterol moiety onto poly(amidoamine) by increasing the 
modification percentage (Chen et al., 2013). The Pa5 SA had a lower 
hydrodynamic size than Ch5 SA despite having similar hydrophobic modification 
percentages.  The bigger size of the Ch5 SA was attributed to the steric hindrance 
of the cholesteryl moiety and the longer chain length of the cholesteryl moiety in 
comparison to the palmitoyl moiety (Thompson et al., 2008; Thompson, Tetley & 
Cheng, 2010). The addition of the hydrophilic moiety MPEG (3.5%) to the Pa5 
polymer altered the hydrophilic-lipophilic balance and resulted in larger 
hydrodynamic size SA. The increase in hydrodynamic size of nanoparticles due to 
the addition of polyethylene glycol (PEG) has been previously reported in the 
literature (Bagheri & Bigdeli, 2013). The size of nanoparticles increases with an 
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increase in the molecular weight of the PEG group and the relative content of the 
hydrophilic attached PEG groups (Bagheri & Bigdeli, 2013; Minimol, Paul & 
Sharma, 2013; Papadimitriou, Achilias & Bikiaris, 2012). 
The mean hydrodynamic diameters of the TA-SA formulations obtained via 
PCS were in the range of 200–334 nm and larger than their unloaded SA 
counterparts. Interestingly, the hydrodynamic diameters of Da10 SA increased by 
approximately 80 nm upon entrapping TA, whereas the Pa5-MPEG, CH5 and Pa5 
TA-SA formulation had increased by approximately 20 nm, in comparison to their 
counterpart SA. More interestingly, the Da10 TA-SA formulation transformed to a 
mono-disperse population with a low polydispersity index (0.1). The 
accommodation of TA molecules inside the core of the SA resulted in the 
expansion of the core and consequently an increase in the hydrodynamic size of 
the SA. This trend agrees with the findings reported elsewhere, in which loaded 
SA had bigger hydrodynamic size compared to unloaded SA (Hoskins, Lin, Tetley 
& Cheng, 2012b; Yang et al., 2012).   
The zeta potential of the Pa5, Pa5-MPEG and Da10 SA and their 
corresponding TA-SA formulations did not significantly change (t-test, p > 0.05). 
However, the zeta potential of the Ch5 SA and TA-SA formulations (approximately 
40 and 45 mV) was significantly (t-test, p < 0.05) higher than the rest of the SA 
and their corresponding TA-SA formulations (approximately 20 mV). Although 
precise stability thresholds of nanoparticles vary according to the particle type and 
composition, reports show the stability of colloidal dispersions with zeta potentials 
above (+/-) 30 mV (Mukherjee, Santra, Pattnaik & Ghosh, 2008; Yue et al., 2008). 
The stability of the colloids emanates from the highly repulsive surface charge 
which prevents aggregation. The colloids stability also affected by the ions and 
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their concentration in the solution; opposite ions charge of the amphiphilic polymer 
counter the surface charge of the colloid and hence reduce stability. Furthermore, 
divalent ions cross link two opposite charge polymer strands, resulting in polymer 
precipitation and increase in CAC, the divalent crosslinking explains the 
precipitation of amphiphilic polymer in PBS buffer in this work. The increase in the 
surface charge of the of Ch5 SA may be due to the amino groups on the PAA 
backbone being forced out from the hydrophobic domains of the SA to interact 
with solvent molecules (Thompson et al., 2008). This observation was supported 
by the pyrene results which indicated lower polarity of the Ch5 SA core in 
comparison to the Pa5 and PA5-MPEG SA (Figure ‎3.11).  
In contrast to the PCS technique, TEM analysis also provides additional 
information about the shape of SA. TEM micrographs of Da10 SA showed 
agglomeration of smaller spherical SA into larger agglomerates. The smaller SA 
had a size of approximately 40 nm, whereas the larger agglomeration had an 
approximate size of 150-200 nm. This finding is in agreement with the bimodal 
distribution obtained from the PCS result (Figure ‎3.10). The Pa5 TEM micrographs 
revealed an irregular shape SA with an approximate size of 100 nm, whereas Pa5-
MPEG had spherical SA with an approximate size between 100-150 nm. 
Interestingly, the Ch5 SA TEM micrographs revealed unusual cuboid-like shaped 
SA with a particle size of approximately 100-200 nm (Figure ‎3.18). Similar findings 
were reported by Liu et al. in which cubic and cuboid-like shaped SA formed from 
an amphiphilic polymer consists of approximately 6% mole modification of 
cholesteryl moieties onto poly(N-isopropylacrylamide-co-N-
hydroxylmethylacrylamide) (Liu, Pramoda, Yang, Chow & He, 2004). The author 
also reported changes in the shape of the SA from well-organized cubic and 
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cuboid-like to roughly spherical when the amphiphilic polymer concentration was 
increased from 0.1 to 0.6%. The formation of spherical shaped SA was attributed 
to the increasing hydrophobic–hydrophobic associations between the hydrophobic 
moieties. TEM micrographs revealed similar findings when the cuboid-like shape 
of the Ch5 SA transformed to spherical in the Ch5 TA-SA formulation. All TA-SA 
formulation TEM micrographs revealed a spherical shape with comparable sizes to 
the PCS data. The size of the SA and TA-SA formulation acquired using TEM was 
smaller than the size obtained from PCS. This is due to the fact that TEM reveals 
the size of SA in their dry state rather than the hydrodynamic diameter which have 
larger values because of the solvent effect (hydration double layer). 
The CAC values obtained in this work were comparable to the values 
quoted in the literature for comb shaped amphiphilic polymers (Yuan, Li & Yuan, 
2006). The CAC values for CH5, Pa5 and Pa5-MPEG were 0.0052, 0.011 and 
0.027 mg mL-1, respectively. The obtained CAC value for the Ch5 polymer was 
comparable to the CAC value (0.004 mg mL-1), obtained using a pyrene probe, for  
a similar cholesterol grafted comb shaped amphiphilic polymer (Liu, Pramoda, 
Yang, Chow & He, 2004). The lower CAC value of the Ch5 polymer compared to 
Pa5 is in agreement with the previously reported results of Thompson et al. 
(Thompson et al., 2008). The author reported CAC values of 0.02 and 0.08 mg 
mL-1, using a methyl orange probe, for Ch5 and Pa5 polymers, respectively. The 
higher CAC values reported by Thompson et al. are thought to be due to different 
techniques used in measuring the CAC. Lin et al. reported CAC values of 0.05 and 
0.002 mg mL-1 for amphiphilic siloxane graft copolymer using methyl orange and 
pyrene, respectively (Lin & Alexandridis, 2002). The lower CAC value of Ch5 in 
comparison to Pa5 was due to the higher hydrophobicity of the cholesteryl group. 
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A decrease in the CAC was reported with an increase in the hydrophobicity of the 
modified group (Wu, Qiao, Yang & Wang, 2010). Unlike the palmitoyl group the 
cholesteryl moiety is a bulky group with a near planar conformation (Liu, Pramoda, 
Yang, Chow & He, 2004), which upon self-assembly had restricted mobility. They 
restricted mobility observation was supported by the NMR results (Chapter two, 
section 2.3.3.2.3) and by the lower core microviscosity (rigidity) of the Ch5 SA in 
comparison to Pa5 SA as reported by Thompson et al. (Thompson et al., 2008). 
The core rigidity of the Ch5 SA limits the entry of the flexible PAA backbone into 
the core of the SA. This explains the lower core polarity (Figure ‎3.11) and the 
higher zeta potential (Table ‎3-1) of Ch5 SA in comparison to Pa5 SA. The addition 
of a hydrophilic MPEG groups to the Pa5 polymer increases the overall 
hydrophilicity of the polymer (Lin, Zhang, Kumar & Mark, 2009). This alteration in 
the hydrophilic-lipophilic balance results in an increased size, CAC and core 
polarity of the SA (Figure ‎3.11). 
The four SA described in this work possessed the ability to encapsulate TA 
at high concentrations within their hydrophobic cores. The LC of TA within the SA 
ranged from 9% for Pa5 to 25% for Da10. The values are similar to the reported LC 
of amphiphilic polymers which normally range between 5 and 30% (Bagheri & 
Bigdeli, 2013; Bagheri & Motirasoul, 2013; Chang et al., 2012; Gaucher, 
Satturwar, Jones, Furtos & Leroux, 2010; Gu et al., 2011).  
The SA had superior solubilizing capacity of TA in comparison to 
conventional solubilisers such as surfactants and co-solvents (Figure ‎3.23). The 
Da10 had the highest TA entrapment followed by Pa5-MPEG, Ch5 and Pa5 TA-SA 
formulations. The higher LC of Da10 is mainly due to the higher modification 
percentage and better TA-hydrophobic moiety compatibility. Higher 
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hydrophobically modified polymers have been shown to exhibit higher LC than 
their lower modified counterparts (Chang et al., 2012; Hoskins, Lin, Tetley & 
Cheng, 2012b). Moreover, polymers modified with drug-like hydrophobic moieties 
have been shown to have higher LC as a result of improved compatibility between 
the drug and the hydrophobic moiety (Gu et al., 2011; Mahmud, Xiong & 
Lavasanifar, 2008). The higher TA LC by Ch5 SA compared to Pa5 was due to a 
better TA-cholesteryl compatibility in comparison to palmitoyl, as the cholesteryl 
moiety has a steroid like structure whereas palmitoyl has a hydrocarbon chain. 
Similar results were reported by Gu et al. were poly-L-lysine (PLL) modified by the 
cholate moiety encapsulated significantly higher levels of sterol drugs 
(prednisolone and estradiol) than palmitoyl modified PLL (Gu et al., 2011). The 
addition of the hydrophilic moiety MPEG to Pa5 resulted in increased TA LC, the 
reason for this increase is not well understood and could be due simply to the 
bigger size of the Pa5-MPEG SA as a result of altering the hydrophilic-lipophilic 
balance of the Pa5 SA. 
The TA release profile from the TA-SA formulations (Figure 3.24) showed 
Ch5, Pa5 and Pa5-MPEG TA-SA formulation were able to achieve sustained TA 
release over 47 h, whilst the Da10 TA-SA formulation achieved sustained release 
over 145 h. Interestingly, the Da10 TA-SA formulation had a lower cumulative 
percentage released in comparison to the Ch5, Pa5 and Pa5-MPEG TA-SA at any 
time point. This was can be explained by high drug affinity to the hydrophobic 
domain (dansyl group). Similar findings have been reported by Chang et al. in 
which he found introducing hydroxyl groups to the core of nanoparticles resulted in 
higher doxorubicin LC and a lower cumulative release percentage (Chang et al., 
2012). The author related the higher LC and lower release to the formation of 
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hydrogen bonding between the doxorubicin and hydroxyl group. TA can potentially 
form hydrogen bonds through two hydroxyl groups (Figure ‎3.8) with either the 
sulfonyl group or with the nitrogen atom on the dansyl moiety. In contrast, TA can 
form hydrogen bonds with the cholesterol or palmitoyl moieties only through the 
single carbonyl group which is sterically hindered. The predicted hydrogen 
bonding between TA and the dansyl group may explain both the slower TA release 
and the higher LC for Da10 TA-SA in comparison to other TA-SA’s. Although π (a 
type of non-covalent interaction that involves π systems) binding between the 
aromatic naphthalene ring (dansyl) with TA might be another explanation for the 
higher LC and lower TA release. 
The best mathematical fit for the in-vitro release of TA from TA-SA 
formulations was obtained using Higuchi (R2 > 0.95) and zero order (R2 > 0.99) 
models. The two mathematical models tell a great deal about the way TA is 
released from the TA-SA formulation. The Higuchi mathematical model describes 
drug release from a matrix or porous system. This model is only valid for systems 
in which erosion or swelling of the matrix does not significantly contribute to drug 
release. A good fit to the zero order model indicates that the TA release rate is 
independent of the initial TA concentration within the TA-SA formulation. The 
deduced information from both models (Higuchi and zero order) leads to the 
conclusion that TA diffuses away from the matrix of the SA without a significant 
change in volume (no erosion or swelling) and at constant rate (Brophy & Deasy, 
1987). The previous assumptions (TA diffusion from SA matrix at a constant rate) 
were supported with the low mathematical fit of the first order model (R2 < 0.88) 
and the Hixon-Crowell model (R2 < 0.93). Hixson and Crowell recognized that 
particle area is proportional to the cube root of its volume (Dash, Murthy, Nath & 
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Chowdhury, 2010); accordingly the model describes the release from particles 
where there is a change in surface area and diameter.  
3.5 Conclusion 
This study showed that a poorly water soluble drug (TA) can be loaded into 
SA in a higher concentration than aqueous solubility of the drug. The study also 
showed that the type of pendant group grafted on the polymer has a significant 
impact on the SA size, surface charge, TA LC and drug release profile. The control 
of the previously mentioned parameters has significant importance in developing 
ocular formulations. The solubilisation of TA within the described SA in this work 
resulted in particles having a diameter of 200-334 nm and positive surface charge 
(21-46 mV). The positive charge should increase the residence time in the eye 
through mucoadhesion with the negatively charged cornea, whereas the nano-size 
should minimise potential vision blurring.  
In chapter four the TA-SA formulations prepared in this chapter were tested 
using an in-vitro eye model to assess if the size, surface charge and TA LC and 
release time influence TA permeation through ocular tissues. 
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4.1 Introduction 
Novel delivery systems such as nanoparticles (Nair, Vidyanand, James & 
Kumar, 2012), liposomes (Li, Zhuang, Wang, Sui & Pan, 2012), dendrimers 
(Vandamme & Brobeck, 2005) and  polymeric micelles (Di Tommaso et al., 2012) 
have been explored to enhance the delivery of therapeutic agents to the anterior 
and posterior eye segments. These delivery systems have in general been 
assessed using in-vivo animal models, despite ethical concerns for animal 
wellbeing and criticism of the validity and the precision of the animal models (Kirk, 
2001). This chapter explores the possibility of developing an in-vitro eye model to 
reduce, refine and replace the number of animals used when developing and 
testing ocular formulations.  
4.1.1 Existing In-Vitro Eye Models 
For many years the in-vivo Draize eye test has been the standard method 
for evaluating the safety of materials which might be in contact with the eye (Kirk, 
2001). In recent years, the ethical concerns of animal wellbeing and criticism of the 
validity and the precision of the test have led many researchers and governments 
to look for an alternative (Kirk, 2001; Vinardell & Mitjans, 2008). The alternative 
approaches can be categorised in four groups; in-vitro artery perfused eye model, 
organotypic animal models cell (i.e. isolated animal cornea), culture models and 
Franz type eye model. 
The artery perfused eye model is the closest to the in-vivo situation, as the 
perfusate provides oxygen and vital nutrients necessary to maintain cell viability ex 
vivo (Wilson, Shahidullah & Millar, 1993). Furthermore, the perfusate circulation 
mimics the blood circulation in the choroidal tissue and hence acts as a dynamic 
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barrier for the periocular drug delivery route mimicking the in-vivo conditions. This 
model also provides the benefit of instilling the material under study via any of the 
four drug delivery routes (topical, systemic, periocular and intravitreal). However, 
this model suffers many draw backs. The perfusion process of the artery/arteries is 
a technical challenge due to the difficulty in keeping the cannula secured inside 
the artery (De Coo, Zonnenberg & Trap, 1993). A further problem is monitoring the 
viability of the cells and the barrier integrity parameters. Additionally, this model 
also suffers the possibility of having fluctuated arterial perfusion pressure (APP) 
due to blood vessel occlusions (strokes), air bubbles and collapse of the structural 
integrity of the blood vessels. This fluctuation in APP affects the secretion of 
aqueous humour which ultimately affects the intra ocular pressure (IOP) (De Coo, 
Zonnenberg & Trap, 1993; Koeberle, Hughes, Skellern & Wilson, 2006; Niemeyer, 
2001; Wilson, Shahidullah & Millar, 1993). Elevated IOP can result from 
deterioration or damage to the trabecular meshwork (Koeberle, Hughes, Skellern 
& Wilson, 2006), affecting inversely the permeability of the drug under study 
(Cruysberg et al., 2005; Rudnick, Noonan, Geroski, Prausnitz & Edelhauser, 
1999).  
The organotypic animal tissue models are mainly used as an in-vitro 
toxicological test assessing potential irritants and corrosives (Vinardell & Mitjans, 
2008). The most common organotypic animal models are, the isolated rabbit eye 
(IRE), the isolated chicken eye (ICE), the bovine corneal opacity and permeability 
(BCOP) and the hen’s egg test-chorioallanoic membrane (HET-CAM) (Barile, 
2010; Hammer, Richter, Kobuch, Mata & Schweitzer, 2008; Kobuch et al., 2008). 
The four previously mentioned methods are not considered to be replacements for 
the Draize eye test. However, they are considered to be screens for the 
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identification of potential ocular corrosives and irritants in a tiered testing 
approach. These methods have the disadvantage of maintaining the normal 
physiological conditions of the cornea in an isolated system for a short time. Also 
the results from these models typically suffers from an over prediction of human 
response (Barile, 2010), due to the absence of reflux mechanism and the high 
dose of test material used. On the other hand, organotypic tissue models are easy 
to setup, cost effective and avoid unnecessary sacrifice of animals, 
Cell culture models are a promising alternative for drug permeability studies 
and irritancy tests. Despite the difficulties in obtaining natural environmental 
conditions, many cell culture models of the ocular barriers have been established. 
In recent years a promising three dimension (3D) cell culture of the whole cornea 
was constructed (Reichl, Döhring, Bednarz & Müller-Goymann, 2005). The 
constructed multilayered corneal tissue was built step by step with fibroblast cells 
embedded in a matrix of collagen cultivated on an underlying layer of endothelial 
cells covered by corneal epithelial (Reichl, Döhring, Bednarz & Müller-Goymann, 
2005). Reichl et al. (Reichl, Döhring, Bednarz & Müller-Goymann, 2005) studied 
the permeability of six drugs in both the human donor cornea and the human 
cornea construct model. Their results showed similar permeation behaviour in both 
for all six drugs (Reichl, Döhring, Bednarz & Müller-Goymann, 2005). A 3D human 
corneal epithelium construct (3D HCEC) model has been studied as an alternative 
irritancy test by Jung et al. (Jung et al., 2011). The latter workers studied 25 
reference chemicals with known eye irritancy potential on the 3D HCEC model. 
The results obtained from the 3D HCEC model had 88% accuracy when compared 
with the chemical classification for the studied references obtained from the 
globally harmonised system (GHS). Despite the accuracy this model offers, it has 
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a few drawbacks. The process of assembling the 3D structure requires time and 
expertise, it is relatively expensive and it requires certain laboratory settings (i.e. 
sterility). 
An in vitro eye model utilising excised tissue in a Franz type diffusion cell 
provides a simple method, which enables researchers to investigate the 
permeability of drugs through ocular tissues. This type of in-vitro eye model (Franz 
cells) has been used to test the permeability of many compounds (hydrophilic and 
hydrophobic) utilising both anterior (cornea) and posterior ocular tissues (mainly 
sclera) (Araujo, Garcia, Mallandrich, Souto & Calpena, 2012; Mora et al., 2005; 
Ostacolo et al., 2013; Pescina et al., 2010; Reichl, Döhring, Bednarz & Müller-
Goymann, 2005). The Franz type model has the advantages of being well 
established, cost effective and relatively quick to set up. The model also can be 
used to study either mono-tissue layer or multi-tissue layers.  
4.1.2 Human, Porcine and Rabbit Ocular Tissues 
Porcine ocular tissues are the closest to humans after primate; this is due to 
the absence of the tapetum layer in porcine eyes, which is present in many other 
animals such as cows, sheep and rabbits (Prince, 1960). Other similarities are that 
both human and porcine eyes have a similar retinal pigment epithelium, 
photoreceptors cells and comparable scleral thickness and water content (Nicoli et 
al., 2009; Olsen, Aaberg, Geroski & Edelhauser, 1998; Olsen, Sanderson, Feng & 
Hubbard, 2002). Human, porcine and rabbit scleral tissue vary in thickness. For 
both human and porcine the sclera tends to have maximum thickness at the 
posterior pole region decreasing to minimum near the equator and then increasing 
again towards the limbus, whereas rabbit has maximum thickness at the limbus 
region decreasing to a minimum thickness near the optic nerve. The reported 
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mean human sclera thickness was found to be 0.53 ± 0.14 mm at the limbus, 0.39 
± 0.17 mm near the equator and 0.9-1.0 mm near the optic nerve (Olsen, Aaberg, 
Geroski & Edelhauser, 1998). The reported mean porcine sclera thickness were 
found to be dependent on the size of the animal, the thickness of large sized pigs 
were 1.12 ± 0.23 mm at the limbus, 0.43 ± 0.16 mm at its thinnest (6 mm posterior 
to the limbus), 0.86 ± 0.18 at the equator and approximately 0.9 mm near the optic 
nerve (Olsen, Sanderson, Feng & Hubbard, 2002). The reported average rabbit 
sclera thickness at the limbus has been found to be 0.5 mm and 0.2 mm near the 
optic nerve (Prince, 1960; Tsonis, 2008). Nicoli et al. (Nicoli et al., 2009) reported 
similarity in histology and scanning electron microscope (SEM) images of porcine 
and human scleral tissues. The rabbit scleral tissue also has a similar extracellular 
matrix composition to human scleral tissues (Boubriak, Urban, Akhtar, Meek & 
Bron, 2000; Young, 1985). The water content of human, porcine and rabbit scleral 
tissues is approximately 70% (Boubriak, Urban, Akhtar, Meek & Bron, 2000; Nicoli 
et al., 2009).  
Human, porcine and rabbit scleral tissues are vascular, opaque tissues 
consisting of interwoven dense collagen fibre bundles (lamellae) with scattered 
elastic fibres present between the collagen bundles (Nicoli et al., 2009; Watson & 
Young, 2004; Young, 1985). Conversely, the cornea is an avascular transparent 
tissue comprising five layers, where the epithelium and the stoma are the main 
barrier for drug delivery (section 1.2.1.2).  
The horizontal and vertical diameters of adult human, porcine and rabbit 
corneas are approximately 11.5 and 10.5 mm, 14.9 and 12.4 mm, 13.4 and 13.0 
mm, respectively (Bozkir, Bozkir, Dogan, Aycan & Guler, 1997; Faber, Scherfig, 
Prause & Sorensen, 2008; Willoughby et al., 2010). The corneal thickness of adult 
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human, porcine and rabbit cornea are approximately 535 µm, 666 µm and 407 µm, 
respectively (Chan, Payor & Holden, 1983; Doughty & Zaman, 2000; Faber, 
Scherfig, Prause & Sorensen, 2008). 
The analytical methods used in this chapter were HPLC, fluorescence 
spectroscopy and liquid scintillation counting (fluorescence spectroscopy and 
HPLC are explained in chapter three sections 3.1.2 and 3.1.4, respectively). 
4.1.3 Liquid Scintillation Counting 
Liquid scintillation counting (LSC) is a widely used method in the biological 
sciences for measuring β-emitting radioactive isotopes such as tritium and carbon-
14. In the LSC procedure the radioactive sample is mixed with compounds in 
solution (liquid scintillation cocktails), these compounds (phosphors or scintillators) 
are capable of absorbing the emitted energy from the β-emitting radioactive and 
re-emitting the energy as light. The re-emitted light is then detected by a 
photomultiplier tube, which converts the photons to an electrical signal. The 
intensity of the re-emitted light corresponds to the emission energy of β-emitting 
isotope and the number of re-emitted light photons per second corresponds to the 
number of radioactive emissions (disintegrations per minute (DPM)) (Glick, 2009). 
The SI unit for radiation is Becquerel (Bq), which corresponds to 60 DPM.  
4.2 Aims and Objectives 
In this study, the aims were to develop, and partially validate an in-vitro 
porcine eye model in order to test the permeability of hydrophobic and hydrophilic 
pentrants from solutions, suspensions or polymeric formulations (TA-SA’s) across 
ocular tissues using the developed model. As such the objectives were: 
 To develop an in-vitro porcine eye model 
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 To partially validate the developed eye model 
 To evaluate and compare  tissue barrier integrity of fresh and stored 
porcine ocular tissues using tritiated water as a rapid and 
inexpensive method, in order to use stored tissues as an alternative 
practical and more convenient option to using fresh tissues 
 To compare the permeability of four markers across porcine corneal 
and scleral tissues with permeability across human counterpart 
tissue 
 To study and compare the permeability of human, porcine and rabbit 
corneal tissues, in order to evaluate differences or similarities in 
corneal permeation between the three species 
 To assess TA permeation through posterior porcine ocular tissues 
(sclera, choroid and retina) and human scleral tissue from the TA 
self-assemblies (TA-SA) developed in chapter three and  a TA 
suspension  
 To study the effect of potential permeation enhancers on marker 
permeation across human and porcine corneal and scleral tissues  
4.3 Materials and Methods 
4.3.1 Materials 
Fluorescein sodium salt (MW 376.27), fluorescein isothiocyanate–Dextran 
(FITC-Dextran) average MW 3-5 kDa, FITC-Dextran average MW 10 kDa, FITC-
Dextran average MW 20 kDa, tris(hydroxymethyl)aminomethane, tween 80, L-
glutamic acid, chitosan (low MW), poly(vinylpyrrolidone)–iodine complex, minimum 
essential medium eagle (Earle′s salts, 25 mM HEPES and sodium bicarbonate, 
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without L-glutamine, Sigma M7278), antibiotic antimycotic solution (10,000 units 
penicillin, 10 mg streptomycin and 25 μg amphotericin B per mL, Sigma A5955), 
fetal bovine serum (Sigma F0804), penicillin-streptomycin (10,000 units penicillin 
and 10 mg streptomycin per mL in 0.9% NaCl, Sigma P0781) and dextran from 
leuconostoc spp average Mw 500 kDa were all purchased from Sigma Aldrich, 
United Kingdom. Phosphate buffer saline (PBS) tablets, soluene, scintillation 
cocktail high performance (ScintiSafe 2), sodium chloride,  potassium chloride, 
sodium phosphate dibasic, sodium dihydrogen phosphate monohydrate, calciulm 
chloride, magnesium sulphate, glucose, ethanol, acetonitrile, acetic acid and all 
solvents (HPLC grade) were acquired from Fisher, United Kingdom. Triamcinolone 
Acetonide micronized powder (TA) was purchased from Fagron, United Kingdom. 
Tritiated water (3H2O) was purchased from GE Healthcare, United Kingdom at a 
specific activity of 37 MBq mL-1. 
4.3.2 Franz Cells Setup 
Ocular tissue (human, porcine and rabbit cornea; human and porcine 
sclera; posterior porcine ocular tissues) was positioned between the two 
compartments of a Franz cell with the corneal epithelium or the episclera (the 
outer layer of the sclera) facing the donor compartment as shown in Figure ‎4.1. 
The two compartments were wrapped with parafilm® and clamped together. A 
small magnetic stirrer was inserted into the receptor compartment of the Franz cell 
which was then filled with an appropriate receiver fluid (RF, section ‎4.4.3.1) 
suitable for the experiment (i.e. PBS). The Franz cells were then placed in a water 
bath maintained at either 37 °C (to mimic the in-vivo temperature of the eye) or at 
45 °C (to study the effect of elevated temperature on permeation) for 15 min to 
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equilibrate. The donor solution (1 mL of TA suspension/marker solution or 0.1 mL 
3H2O) was added into the donor compartment before sealing with parafilm
®.  
At pre-determined time points, the receiver fluid was mixed, manually three 
times using a sampling syringe, prior to the withdrawal of sample aliquots (0.3 mL 
for permeation and enhancer studies or 0.1 mL for 3H2O study). Instantly after 
sampling, the receiver fluid was replenished with pre-warmed receiver fluid. 
Samples were analysed using HPLC (Triamcinolone Acetonide), a fluorescence 
microplate reader (fluorescein sodium salt, 4, 10 and 20 kDa FITC-Dextran) or 
liquid scintillation counting (3H2O).  
 
 
 Figure ‎4.1: Schematic representation of Franz cell set-up.  
4.3.2.1 Franz Cell Size  
The limited availability of human and rabbit ocular tissues required 
performing experiments on as little tissue as possible, especially corneas. The 
different areas of the tissue exposed to the donor solutions were investigated 
using large, medium and small Franz cells having an approximate aperture area of 
0.9, 0.6 and 0.1 cm-2, respectively. The receptor compartment volume of the large, 
medium and small size cells were approximately 3, 2.6 and 1 mL, respectively. 
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The large and medium Franz cells were used in studying the posterior ocular 
tissues, whereas the medium and small cells were used in studying the corneal 
tissue. Each Franz cell were individually calibrated for volume and diameter in 
triplicate. 
4.3.3 Ocular Tissues Preparation and Storage 
4.3.3.1 Porcine Tissue Preparation 
Scoped out porcine eyes were freshly collected from a local farm (Evans 
and Sons, Bedfordshire). The eye globes were immersed in a 0.9% saline solution 
within 2 h of slaughter and upon arrival at the laboratory, all extraocular tissues 
attached to the sclera were removed using surgical scissors and tweezers.  The 
cornea was excised from the globe by carving a small incision using a scalpel 
approximately 1-3 mm away from the pars plana (the sclera-cornea intersection); a 
circumferentially cut separated the cornea from the eye globe. This was followed 
by complete separation of the cornea from the pars plana using a 7 mm radius 
cork borer. The separated corneas were transferred into PBS buffer (10 mM) after 
which they were either used immediately or stored as described in section ‎4.3.3.2. 
The lens capsule and vitreous humour were gently separated from the 
retinal tissue. A straight cut through the equator of the globe was made towards 
the optic nerve, cutting the eye globe in half. A maximal area where the three 
posterior tissues remain intact (sclera, choroid and retina) were excised 
approximately 1-3 mm from the optic nerve. To obtain bare sclera, the intraocular 
tissues were removed, including retina and choroid tissues. The prepared tissues 
were kept moist by placing in PBS buffer (10 mM) awaiting mounting onto Franz 
cells or stored as described in follow section ‎4.3.3.2. 
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4.3.3.2 Porcine Tissue Storage 
 The scleral cuts were gently dried using tissue paper and wrapped in 
aluminium foil before storing in a freezer at - 20 °C for two weeks. 
The storage and de-swelling of the fresh porcine corneas was performed in 
accordance with the Moorfields Eye Hospital standard operating procedure – 
organ culture storage of corneas (Appendix B). The porcine corneal buttons 
(dissected corneas) were transferred from the PBS solution immediately after 
tissue preparation (Section ‎4.3.3.1) into 5% poly(vinylpyrrolidone) iodine complex 
solution (w/v) and left to soak for 5 min. The corneas were then transferred into a 
sterile saline 0.9% solution and immersed for 5 min, before submerging into 0.5% 
penicillin-streptomycin solution for 5 min. The corneal storage medium was 
prepared by adding 0.5% (v/v) antibiotic antimycotic solution and 5% (v/v) fetal 
bovine serum to minimum essential medium eagle. The sterilised corneas were 
stored in 50 mL corneal storage medium (two corneas per 50 mL) at 31 °C in an 
oven for either 4 or 11 d. The corneal storage medium was changed every 2-3 d 
for the duration of the storage. Nevertheless such corneal storage for between 4 or 
11 d resulted in an increase in the thickness of the cornea (swelling). As such a 
corneal de-swelling medium was made by the addition of 5% 500 kDa dextran 
(w/v) to the corneal storage medium. The 4 and 11 d stored corneas were then 
transferred into 50 mL of the de-swelling medium (two corneas per 50 mL) before 
storing in the dark at room temperature for further 3 d. As the 4 and 11 d stored 
corneas were de-swelled for 3 d they are referred to as one and two weeks stored 
corneas, respectively. 
An alternative method of porcine corneal storage was also investigated, in 
which sterilised corneas were stored in sterile PBS buffer at - 80 °C for one month. 
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4.3.3.3 Human Corneal Tissue Preparation 
The human cadaver corneal-scleral tissues were obtained from Moorfields 
eye hospital and Manchester royal eye hospital; the tissue was transferred and 
stored in CorneaJet® de-swelling medium at room temperature. The human 
corneal-scleral tissues were removed from the de-swelling medium and placed on 
a Petri dish, with the corneal epithelium layer facing upward. Visual inspection of 
the tissue integrity was performed before aligning a 7 mm radius cork borer at the 
circumference of the cornea. Continuous pressure and twisting movement was 
applied until the corneal tissue was separated from the pars plana region. The 
dissected corneas were immediately immersed in PBS buffer whilst waiting to be 
mounted onto Franz cells.  
4.3.3.4 Human Scleral Tissue Preparation 
The human cadaver globes were obtained from Moorfields eye hospital and 
Manchester royal eye hospital; the tissue was transferred and stored in 70% 
ethanol at room temperature. The human globes were then removed from the 
preserving medium to a Petri dish. Visual inspection of the outer sclera was 
performed followed by removal of the detached choroidal-retinal tissues using 
forceps. A 7 mm radius cork borer was inserted inside the eye globe through the 
corneal aperture. A continuous pressure and twisting movement were applied to 
obtain four scleral punches; three punches were taken  from a semi consecutive 
arc  1-2 mm away from the optic nerve, and a forth punch was taken as close as 
possible to the formed arc. 
4.3.3.5 Human and Rabbit Corneal Tissue Preparation 
The human and rabbit corneal tissues were a gift from MedPharm, United 
Kingdom. The corneal tissue was transferred in Optisol GS de-swelling medium 
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and stored at 4 °C in a fridge. Both tissues were prepared similar to human cornea 
as described in section ‎4.3.3.3. The dissected corneas were divided into four 
quarters and immediately immersed in PBS buffer whilst waiting to be mounted 
onto small Franz cells.  
4.3.4 Thickness Measurement of Posterior Porcine Ocular 
Tissues  
The thickness of the posterior porcine ocular tissue was measured using a 
micrometre (MITUTOYO, Japan). The middle of the measured tissue was placed 
on top of the bottom micrometre plate (anvil) before carefully lowering the spindle 
of the micrometre; the readings were recorded at the first sign of resistance 
observed in the ratchet knob. The reported thickness was an average of triplicate 
measurements around the middle of the tissue.  
4.3.5 Development of Suitable Receiver Fluids  
Although it is desirable to have a receiver fluid which mimic the 
physiological condition of the eye, it is also crucial to ensure that the chosen 
receiver fluid has no effect on the stability of the drug over the duration of the 
experiment, the tissue barrier integrity or the actual amount of drug permeating 
through the tissue during the experiment. Due to the very low solubility of TA in 
modified Dulbecco’s buffer solution (13.7 ± 0.5 µg mL-1 at room temperature 
approximately 22 °C), receiver fluids with 0, 5, 10 and 30% (v/v) ethanol were 
investigated, in order to maintain sink conditions (drug concentration in the 
receiver compartment of Franz cell not to exceed 10% of the drug solubility in the 
receiver fluid (Aulton & Cooper, 1988)) over the duration of the experiment. The 
modified Dulbecco’s buffer solution consisted of MgSO4 (89 mg L
-1) and glucose 
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(9008 mg L-1) added to Dulbecco’s buffer solution ((NaCl (8000 mg L-1), KCl (200 
mg L-1), Na2HPO4 (1150 mg L
-1), NaH2PO4 (200 mg L
-1), CaCl2 (111 mg L
-1)). 
The considerable swelling of the corneal tissues over the period of 24 h in 
PBS buffer solution required the use of a de-swelling medium for performing 
longer duration experiments. Both PBS buffer solution and 5% 500 kDa dextran 
(w/v) in PBS were used as receiver fluid for testing the permeation through porcine 
corneal tissues. 
4.3.6 TA and Marker Stability in Receiver Fluids 
The stability of TA in 30% ethanol receiver fluid was studied by incubating 
three concentrations (10, 30 and 50 µg mL-1) at 4 °C and room temperature for two 
weeks and at 45 °C for two days. The stability of the fluorescein sodium salt (FSS) 
and FITC-dextran in PBS solution and 5% (w/v) 500 kDa dextran was evaluated 
for three standards concentrations (low, medium and high) at -20 °C, 4 °C and at 
room temperature (in the dark) for two weeks. Similarly, the stability of the FSS 
and FITC-dextran in PBS and 5% 500 kDa dextran was evaluated at 45 °C (in the 
dark) for two days. 
The stabilities of the analytes were determined by comparing the measured 
concentration after incubation to the original control concentration and expressed 
as recovery percentage of the initial concentration. All measurements were 
performed in quadruplicate. 
4.3.7 Tritiated Water Studies 
The 3H2O studies were investigated as a measure of tissue barrier integrity 
and as a potential way of normalising the drug permeation data as an alternative 
to using tissue thickness. 
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Ocular tissue was mounted on to Franz diffusion cells as previously 
described in section ‎4.3.2. The receptor compartment was filled with de-ionised 
water, whereas the donor chamber was dosed with 100 µL of 3H2O (14.8 kBq).  
The Franz cells were then placed in a water bath maintained at 37 °C. Sample 
aliquots (0.1 mL 3H2O) were withdrawn at pre-determined time after the receiver 
fluid was mixed. Instantly after sampling, the receiver fluid was replenished with 
pre-warmed de-ionised water. The surface of the ocular tissues and both the 
donor and receptor compartments of the Franz cells were washed five times with 
de-ionised water after the 3H2O diffusion experiment and prior to the start of TA or 
FSS permeation studies. 
4.3.8 Tritiated Water Correlation with TA and FSS  
The permeation of TA and FSS were conducted as described in 
sections ‎4.3.10.1 and ‎4.3.9 after the completion of the 3H2O study as described in 
the previous section (section ‎4.3.7). The percentage of the permeated 3H2O at 15 
min (% applied dose) was plotted against the flux rate of the permeated TA or FSS 
and the correlation was expressed using Pearson correlation coefficient (r). 
4.3.9 Marker Permeation Studies 
The donor solutions of the four markers used in the corneal and scleral 
(human and porcine) marker permeation studies were composed of 5 mg of FSS, 
50 mg of 4 kDa FITC-dextran, 100 mg of 10 kDa FITC-dextran and 200 mg of 20 
kDa FITC-dextran in 1 ml of PBS buffer (10 mM, pH 7.4). PBS buffer (10 mM, pH 
7.4) was used as the receiver fluid. The donor solution used in the FSS porcine 
scleral permeation correlated to the 3H2O permeation at 15 min was composed of 
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1 mg of FSS in 1 mL of PBS buffer (10 mM, pH 7.4). All marker permeation 
studies were performed at 37 °C.  
4.3.10 TA Permeation Studies 
4.3.10.1 TA Permeation Study across Posterior Porcine Ocular Tissues 
The permeation of TA from a range of donor vehicles (shown in Table ‎4-1) 
was determined in order to investigate the effect of ethanol and polymeric SA on 
TA permeation across posterior porcine ocular tissues. The TA permeation study 
was performed at 37 °C using 0, 5, 10 and 30% ethanol receiver fluids. 
 
Table ‎4-1: The TA donor vehicles used in permeation studies. 
TA Vehicle TA Concentration (µg mL-1) 
Solution/Suspension 
Composition 
TA 
Solution 
500 ethanol: water mixture (50: 50 v/v) 
TA 
Suspensio
n 
500 water 
Pa5 450 Water (5 mg mL-1 polymer) 
Pa5-
MPEG 
450 Water (5 mg mL-1polymer) 
Ch5  450 Water (5 mg mL-1polymer) 
Da10 450 Water (5 mg mL-1polymer) 
 
4.3.10.2 TA Permeation Study through Human Scleral Tissue 
The donor solution for the TA permeation study using human scleral tissue 
was composed of Da10 polymeric self-assembled formulation (1 mg L
-1 TA) and 
aqueous TA suspension (1 mg mL-1). Tris buffer (10 mM) was used as a receiver 
fluid in this experiment as Da10 precipitate in PBS buffer. The TA permeation study 
was performed at 37 °C. 
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4.3.11 Permeation Enhancer Studies 
The donor solution for the potential permeation enhancer studies were 
composed of 10 kDa FITC-Dextran (100 mg) or FSS (5 mg) dissolved in one of the 
following solutions: 
1) 0.1% L-glutamic acid in 1 mL PBS buffer solution (10 mM) 
2) 0.001% tween 80 in 1 mL PBS buffer solution (10 mM) 
3) 0.01% tween 80 in 1 mL PBS buffer solution (10 mM)  
4) 5% w/v Pa5 polymer in 1 mL tris buffer solution (10 mM, pH 7.4) 
5) 1 mL acetate buffer (0.1 M. pH 5)  
6) 0.5% (w/v) chitosan in 1 mL acetate buffer solution (0.1 M, pH 5) 
The donor solutions of the controls consisted of 10 kDa FITC-Dextran (100 
mg) or FSS (5 mg) in 1 mL PBS buffer solution (10 mM, pH 7.4). All the chemical 
permeation enhancer studies were performed at 37 °C. The effect of elevated 
temperature (45 °C) was studied as a potential permeation enhancer by replicating 
the donor and receiver fluids of the controls in a second experiment conducted at 
45 °C. The receiver fluid for all Franz cells in the this study consisted of 10 mM 
PBS buffer, except the Pa5 experiment in which the receiver fluid consisted of 10 
mM tris buffer (Pa5 precipitate in PBS buffer). 
4.3.12 Analytical Methods  
The analytical methods used in assessing the ocular tissue permeability 
and integrity were HPLC, fluorescence microplate reader and liquid scintillation 
counting. 
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4.3.12.1 HPLC Analytical Method  
The TA content in the receiver fluids was determined using a fit for purpose 
validated in-vitro TA release HPLC method (Chapter three, section 3.3.4). None of 
the biological matrices or chemical materials used in this study interfered with the 
HPLC assay. 
4.3.12.2 Fluorescence Analysis Method  
Samples containing FSS and FITC-dextrans were diluted accordingly with 
PBS to fit within the range of the corresponding calibration curve. The range of the 
calibration curves of the four markers are shown in Table ‎4-2 (Section ‎4.4.1). 
Diluted samples were analysed using a fluorescence microplate reader (BMG 
LABTECH, United Kingdom). The excitation and emission wavelengths were 485 
and 520 nm, respectively. Calibration graphs were constructed from known 
standard concentrations of each marker, and the linearity, limit of detection and 
limit of quantification were determined as previously explained in chapter three 
(section 3.2.5.6). Corneal and scleral tissues were incubated with PBS to examine 
the fluorescence of the tissues at 485 nm and to check for interference with the 
markers. None of the biological matrices or chemical materials used in this study 
interfered with the fluorescence assay. 
4.3.12.3 Liquid Scintillation Counter Method 
Receiver fluid samples (0.1 mL) from the 3H2O experiments were 
transferred to scintillation vials to which 4 mL of liquid scintillation cocktail 
(ScintiSafe 2) was added. The scintillation vials were sealed and the contents 
mixed by vortexing before analysis using an LS 6500 multipurpose liquid 
scintillation counter (Beckman CoulterTM, Buckinghamshire, United Kingdom). 
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4.3.13 Permeation Parameters 
The cumulative amount of TA or marker compounds (Qt) permeated 
through the scleral and corneal tissues per unit area was calculated, at each time 
point, from the TA and marker concentrations in the receiver fluids. The flux (J, 
µg.cm−2.h−1) across the ocular tissues was calculated by plotting the cumulative 
amount per cm2 of TA or markers that permeated through the tissue against time 
and determining the slope of the regression line at steady state. The permeability 
coefficient (kp, cm.h
−1, Equation‎4.1) at steady state was calculated by dividing the 
flux (J) by the initial concentration (C0) in the donor solution: 
 
                         (  )  
        
  
 
Equation‎4.1 
 
4.3.14 Statistical Evaluation 
All statistical analysis was performed using SPSS program version 20. The 
normality and the homogeneity of variances of the data were assessed using 
Shapiro-Wilk and Levene’s tests, respectively. Experimental differences between 
groups were compared with each other or with controls using the independent 
student’s t-test or analysis of variance (one way ANOVA). Differences were 
regarded as significant, with p ≤ 0.05. The correlation between tritiated water 
percentage permeation at 15 min and TA, FSS flux and porcine posterior ocular 
tissue thickness were calculated using the Pearson test, a correlation was 
regarded as significant, with p < 0.01. 
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4.4 Results 
4.4.1 Analytical Methods 
The TA solubility in the 0, 5, 10 and 30% (v/v) ethanol receiver fluids were 
13.7 ± 0.5, 23.5 ± 1.2, 29.9 ± 1.9 and 243.3 ± 14.6 µg mL-1 (n = 5, measurements 
were performed at room temperature at approximately 22 °C), respectively. The 
summary of the validation values for the markers analytical fluorescence assays 
are show in Table ‎4-2. All analytical methods were partially validated similar to 
section 3.2.5.6 (data not shown) and was found to be fit for purpose to determine 
the concentration of markers understudy. 
 
Table ‎4-2: Parameters of FSS and FITC-dextran calibration graphs. 
Parameter 
Fluorescein 
Sodium Salt 
4 kDa FITC-
dextran 
10 kDa FITC-
dextran 
20 kDa FITC-
dextran 
Range (µg mL-1) 
0.0047 -  0.37 0.5 - 32 0.31 - 12.5 0.16 - 10.0 
Linearity (R2) 0.99 0.99 0.99 0.99 
L.D (µg mL-¹) 0.05 2.20 1.27 0.86 
L.Q (µg mL-¹) 0.14 6.68 3.85 2.59 
 
4.4.2 Porcine Ocular Tissue Thickness 
The thickness of fresh corneal tissues increased significantly (t-test, p < 
0.05) after 24 h in PBS buffer from 0.60 ± 0.04 mm (n = 6) at t = 0 h to 1.35 ± 0.21 
mm at t = 24 h (37 °C). Following de-swelling treatment the corneas then had a 
mean thickness of 0.76 ± 0.09 mm (n = 8) which was significantly different (t-test, 
p < 0.05) from the thickness of fresh corneal tissue (t = 0 h). On the other hand, 
the thickness of scleral, choroidal and retinal tissues (will be referred to as 
posterior tissues) did not change significantly (t-test, p > 0.05) after 28 h in 0% 
ethanol receiver fluid. The average thickness of the fresh posterior tissues was 0.8 
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± 0.13 mm (n = 11), whereas the average thickness after 28 h was 0.9 mm ± 0.18 
mm (n = 11). 
4.4.3 In-Vitro Porcine Eye Model Development  
4.4.3.1 Development of Suitable Receiver Fluids  
Receiver fluids with 0, 5, 10 and 30% ethanol in modified Dulbecco’s buffer 
solution were investigated, with a view to maintaining sink conditions over the 
duration of the experiment. The cumulative permeation profiles of TA across 
porcine posterior tissues from an aqueous TA suspension (500 µg mL-1) using four 
receiver fluids are shown in Figure ‎4.2. The flux for TA was significantly higher (2.1 
µg. cm-2.h-1)   when using 30% v/v ethanol as the receiver fluid compared to all the 
others investigated (0.5 and 10% v/v ethanol; 0.7 µg. cm-2.h-1).   
The enhancing effect of ethanol on the TA permeation was confirmed using 
TA solution (ethanol: water (50: 50), 500 µg mL-1) in the donor compartment 
(Figure ‎4.3) which produced a TA flux statistically comparable (one way ANOVA, p 
> 0.05) to the TA flux of the TA suspension using 30% (v/v) ethanol as R.F 
(Figure ‎4.2) despite having lower ethanol percentages in the receiver fluids (0, 5 
and10%). 
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Figure ‎4.2: TA permeation profiles from TA suspension (donor solution, 500 µg mL
-1
) across 
posterior porcine ocular tissues using 0, 5, 10 and 30 v/v % ethanol receiver fluids (Data 
represented as mean, error bars represented as S.D., n = 6). 
 
Figure ‎4.3: TA permeation profiles from TA solution (ethanol: water (50: 50), 500 µg mL
-1
) across 
posterior porcine ocular tissues using 0, 5, 10 and 30% ethanol receiver fluids (Data represented 
as mean, error bars represented as S.D., n = 6). 
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The suitability of two receiver fluids (PBS and 5% 500 kDa dextran in PBS) 
for marker permeation across corneal tissues were investigated using fluorescein 
sodium salt as shown in Figure ‎4.4. The flux rates of fluorescent sodium salt in 
either receiver fluid were not significantly different (t-test, p > 0.05). 
 
 
Figure ‎4.4: Fluorescein sodium salt (5 mg mL
-1
) permeation profiles through one week stored 
porcine corneal tissues using PBS and 5% 500 kDa Dextran in PBS as receiver fluids. (Data 
represented as mean, error bars represent range, n = 4) 
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4.4.4 Partial Validation of the In-Vitro Porcine Eye Model 
4.4.4.1 Franz Cell Size Effect 
Due to the limited availability of the corneal tissue and the continual 
variation in the scleral tissue thickness (Olsen, Aaberg, Geroski & Edelhauser, 
1998; Olsen, Sanderson, Feng & Hubbard, 2002), different size Franz cells were 
used in investigating the permeability of ocular tissues. The flux of FSS through 
two week stored corneas using medium and small cells (Figure ‎4.5) resulted in no 
significant difference (t-test, p > 0.05) in the values obtained between the two cells. 
Similarly, there was no significant difference (t-test, p > 0.05) between the flux of 
the TA from the TA suspension using large and medium cells (Figure ‎4.6).  
 
 
Figure ‎4.5: Fluorescein sodium salt (5 mg mL
-1
) permeation profiles through two week stored 
porcine corneal tissues using 5% (w/v) 500 kDa Dextran as receiver fluids. (Data represented as 
mean, error bars represent range, n = 4). 
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Figure ‎4.6: TA suspension (500 µg mL
-1
) permeation profiles through posterior porcine ocular 
tissues using 5% (v/v) ethanol as receiver fluids (Data represented as mean, error bars represent 
range, n = 4). 
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Figure ‎4.7: 
3
H2O permeation profiles across porcine posterior tissues (n=14) and corneal tissue 
(n=9) (Data represented as mean, error bars represent S.D.). 
 
The percentage of the applied 3H2O permeating across porcine corneal and 
posterior tissues after 15 minutes was compared for fresh and stored (- 20 °C, two 
weeks) tissues and no significant difference (t-test, p > 0.05) was found (Table ‎4-3 
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Table ‎4-3: 
3
H2O% permeating at 15 minutes through fresh and frozen posterior porcine ocular 
tissues. 
Fresh posterior 
Tissue 
Frozen posterior 
Tissue 
Tissue ID 3H2O% (15 min) 
Tissue1 5.0 7.7 
Tissue2 12.9 12.1 
Tissue3 15.4 6.7 
Tissue4 14.8 9.2 
Tissue5 7.5 12.7 
Tissue6 21.5 16.5 
Tissue7 19.3 17.0 
Tissue8 5.9 12.0 
Tissue9 11.5 13.6 
Tissue10 22.8 11.1 
Tissue11 15.0 9.1 
Tissue12 8.6 7.2 
Mean ± S.D. 13.4 ± 5.9 11.2 ± 3.4 
 
Table ‎4-4: 
3
H2O% permeating at 15 minutes through fresh and one week stored porcine corneal 
tissues. 
Fresh Cornea Stored Cornea 
Tissue ID 3H2O% (15 min) 
 
Tissue1 1.3 1.1 
Tissue2 1.9 0.8 
Tissue3 1.6 1.0 
Tissue4 2.1 1.7 
Tissue5 2.8 1.8 
Tissue6 1.7 0.7 
Tissue7 2.1 3.2 
Tissue8 1.8 2.2 
Tissue9 3.0 2.0 
Mean ± S.D. 2.0 ± 0.6 1.6 ± 0.8 
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 TA and FSS Permeation across Fresh and Stored Tissues 4.4.4.2.2
The barrier integrity in both fresh and frozen (- 20 °C, two weeks) posterior 
porcine ocular tissues was compared, the TA fluxes are shown in Table ‎4-5. The 
TA flux did not change significantly (t-test, p > 0.05) between the two tissues. On 
the other hand the FSS flux rates through fresh and stored corneas increased 
significantly (t-test, p < 0.05) and were dependent on the storage time and 
conditions as illustrated by Figure ‎4.8.  
 
Table ‎4-5: TA flux through fresh and frozen posterior porcine ocular tissues. 
Fresh Posterior 
Tissue 
Frozen Posterior 
Tissue 
Tissue ID TA Flux (µg.cm
-2.h-1) 
Tissue1 2.8 3.3 
Tissue2 2.6 2.6 
Tissue3 2.9 1.7 
Tissue4 2.4 2.9 
Tissue5 2.8 3.0 
Tissue6 2.7 1.8 
Tissue7 2.8 1.9 
Tissue8 2.9 2.2 
Tissue9 3.3 2.0 
Tissue10 2.2 2.0 
Tissue11 2.7  
Mean ± S.D. 2.7 ± 0.3 2.3 ± 0.6 
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Figure ‎4.8: FSS (5% w/v) permeation profiles across fresh porcine corneal tissue, stored corneal 
tissues for one and two weeks and at -80 °C (Data represented as mean, error bars represent 
range., n = 4). 
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with the 3H2O percentage permeation at 15 min. No correlation could be calculated 
between the FSS flux rates and the 3H2O percentage permeation at 15 min (or at 
any other time points) through corneal tissues (data not shown).  
 
Figure ‎4.9: Correlation between TA flux and 
3
H2O percentage permeation (15 min) across 
posterior porcine ocular tissues. 
 
Figure ‎4.10: Correlation between FSS (1 mg mL
-1
) flux and 
3
H2O percentage permeation (15 min) 
across posterior porcine ocular tissues. 
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4.4.4.4 Tritiated Water Permeation and Posterior Porcine Ocular Tissue 
Thickness 
The 3H2O percentage permeation at 15 min was correlated to the posterior 
porcine ocular tissue thickness (Figure ‎4.11). The correlation between the 3H2O 
percentage permeation at 15 min and porcine posterior ocular tissue thickness 
were significant (Pearson test, p < 0.01), with a correlation coefficient of r = 0.81. 
The 3H2O percentage permeation at 15 min was inversely related to the tissue 
thickness. 
 
 
Figure ‎4.11: Correlation between posterior porcine ocular tissues thickness and 
3
H2O percentage 
permeation (15 min) across the tissues. 
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tissues. For the purpose of comparing the permeability of the markers, the figures 
have been presented with the permeability coefficient rather than the flux, as the 
four markers were applied in different concentration in the donor solutions and the 
saturated solubilities were not determined. Figures 4.12 and 4.13 show the 
permeability coefficient of the four markers for scleral and corneal human and 
porcine tissues, respectively. Both figures show a similar trend, in which the 
permeability decreases with an increase in molecular weight of the marker. The 
permeability coefficients of FSS and 4 kDa FITC-Dextran permeating across 
porcine scleral and corneal tissues were lower than there counterpart in the 
human tissue (t-test, p > 0.05), whereas the permeability coefficients of 10 and 20 
kDa FITC-Dextran permeating across porcine scleral and corneal tissues were 
similar to their counterpart human tissue (t-test, p < 0.05). The fluxes of the 
permeation and enhancer studies are tabulated in the appendix A. 
 
Figure ‎4.12: The permeability coefficients of FSS, 4, 10 and 20 kDa FITC-Dextran across human 
corneal and scleral tissues (Data represented as mean, error bars represent range, n= 4). 
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Figure ‎4.13: The permeability coefficients of fluorescein sodium salt, 4, 10 and 20 kDa FITC-
Dextran across porcine scleral and corneal tissues (Data represented as mean, error bars 
represent range, n= 4). 
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Figure ‎4.14: Comparative permeation profiles of FSS (5% w/v) across human, porcine and rabbit 
corneal tissues (Data represented as mean, error bars represent S.D., n = 6). 
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Figure ‎4.15: TA suspension (1000 µg mL
-1
) and Da10 TA-SA permeation profiles through human 
scleral tissue (Data represented as mean, error bars represent range. n = 4). 
 
Figure ‎4.16: TA suspension (500 µg mL
-1
) and TA-SA permeation profiles through posterior 
porcine ocular tissues (Data represented as mean, error bars represent range, n = 4). 
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4.4.6 Enhancer Permeation Studies 
As the permeability of the markers decreased considerably with the 
increasing molecular weight and the polymeric SA did not significantly increase TA 
flux through human or porcine scleral tissues, it was appropriate to investigate the 
use of enhancers with a view to increasing the permeability of the penetrant and to 
possibly lower potential formulations applied dosage. It was not possible to 
determine the permeability of TA across corneal tissue due to the corneal swelling 
and long lag time, hence the enhancer permeation studies were carried out on two 
markers (FSS and 10 kDa FITC-Dextran) instead. Four potential chemical 
enhancers and one thermal approach (elevated temperature 45 °C) were 
investigated using porcine and human tissues. None of the potential enhancers 
produced a significant difference (t-test, p > 0.05) in the permeation of the 10 kDa 
FITC-Dextran across porcine or human scleral and corneal tissues (Figures 4.17 
and 4.18). The enhancing effect of the aforementioned promoters was also 
explored using a smaller marker (FSS) more representative of the molecular 
weight of more commonly used drugs. The FSS enhancer permeation study was 
performed on porcine scleral tissues as human scleral tissues were unavailable 
(Figure ‎4.19). There was no significant difference in the flux between the control 
and the 0.1% (w/v) glutamic acid, 0.01 and 0.001% (w/v) tween 80, 45 °C and Pa5 
polymer (t-test, p > 0.05). However there was a considerable reduction (t-test, p < 
0.05) in the FSS flux when using the acetate buffer and the 0.5% (w/v) chitosan. 
This reduction was due to the precipitation of the FSS in the former solution and 
the formation of a gel in the latter solution.  
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Figure ‎4.17: The flux of 10 kDa FITC-Dextran added to various enhancers and at elevated 
temperature through human corneal and scleral tissues (Data represented as mean, error bars 
represent range, n = 4). All percentages in the figure are w/v. 
 
 
Figure ‎4.18: The flux of 10 kDa FITC-Dextran added to various enhancers and at elevated 
temperature across porcine scleral tissues (Data represented as mean, error bars represent range, 
n = 4). All percentages in the figure are w/v. 
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Figure ‎4.19: The flux of fluorescein sodium salt added to various enhancers and at elevated 
temperature across porcine scleral tissues (Data represented as mean, error bars represent range, 
n = 4). All percentages in the figure are w/v. 
 
4.5 Discussion 
In chapter three, the simplicity of preparing different self-assembled 
nanoparticles as a drug carrier was demonstrated. However, testing the release 
profiles of these formulations in conditions similar to those in-vivo is very difficult. 
An eye model which correlates well with that of the human clinical setting is 
necessary to investigate the delivery properties of potential formulations destined 
for human use. This chapter focused on developing a porcine in-vitro eye model 
where potential formulations could be evaluated without the huge financial burden 
of in-vivo studies or the use of sacrificed animals. The model developed also offers 
instant availability within almost any laboratory and correlates well to results 
obtained from human tissues. 
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The similarities between porcine and human eyes in terms of anatomy and 
scleral thickness were studied by Olsen et al. (Olsen, Aaberg, Geroski & 
Edelhauser, 1998; Olsen, Sanderson, Feng & Hubbard, 2002). These similarities 
are absent in other animal models, in particular rabbits, the animal most used in 
testing ophthalmic formulations. Furthermore, porcine eye globes are easily 
obtained from slaughterhouses in large numbers and can efficiently substitute for 
rabbit. In this work, the porcine posterior ocular tissues and corneal tissue were 
investigated as an alternative to human tissue. The posterior tissue model is of 
interest to ocular drug delivery to the posterior segment of the eye, whereas the 
corneal model is of interest to topical drug delivery to the anterior chamber of the 
eye. The lipophilicity and permeability of different molecular size penetrants across 
scleral and corneal tissues (mainly rabbit and bovine, occasionally human and 
porcine) has been investigated by many researchers, in which they found optimal 
corneal permeability (rabbit) in the range of 1-3 log partition coefficient of the 
penetrant and scleral tissue (human) allowing large penetrant (up to 120 kDa) to 
transverse across (Lee, 1990; Mitra, 2003; Mosher & Mikkelson, 1979; Myung et 
al., 2006; Nicoli et al., 2009; Pescina et al., 2012; Qi et al., 2013). However, little 
has been done to directly compare the permeability of human and porcine ocular 
tissues and to develop and validate an in-vitro eye model fit for the purpose of 
permeation studies (Kadam, Cheruvu, Edelhauser & Kompella, 2011; Nicoli et al., 
2009). In this work, a human alternative porcine in-vitro eye model was developed 
and partially validated, in order to investigate the TA-SA formulations developed in 
chapter three. 
TA is a hydrophobic corticosteroid drug widely used in ophthalmology as 
off-label treatment of many posterior ocular diseases such macular oedema 
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(Jonas, Kreissig & Degenring, 2002). In recent years, many TA formulations were 
formulated aiming to deliver the drug to the posterior tissues for a prolonged 
period of time in comparison to the previously marketed TA suspensions (Araujo, 
Nikolic, Egea, Souto & Garcia, 2011; Kim, Lim, Kim, Kim & Shin, 2008). The 
permeation of hydrophobic drugs from a suspension or potential ophthalmic 
formulations is typically tested in-vitro across scleral or sclera-choroida-RPE 
tissues using buffer solutions as receiver fluids in a diffusion cell (i.e. Ussing 
chambers or Franz cells) (Araujo, Garcia, Mallandrich, Souto & Calpena, 2012; 
Kadam, Cheruvu, Edelhauser & Kompella, 2011; Loch et al., 2012; Mora et al., 
2005; Olsen, Edelhauser, Lim & Geroski, 1995; Thakur, Kadam & Kompella, 
2011). Araújo et al. reported that sink conditions for TA in HEPES buffer could not 
be obtained after 12 h (Araujo, Garcia, Mallandrich, Souto & Calpena, 2012).  
In this work, TA permeation studies across porcine posterior tissues were 
carried out using modified Dulbecco’s buffer solution with different levels of 
ethanol (0, 5, 10 and 30%). The TA permeation through porcine corneal tissues 
were not studied due to the severe swelling of the corneal tissues over a 
prolonged period of time and the high lag time of TA.  TA permeation across 
posterior porcine ocular tissues showed that the TA flux in the presence of 30% 
ethanol, or more, in either the donor or receiver solution is approximately 3 fold 
higher than the TA flux from TA suspension where no or low ethanol (<30%) is 
present in the receiver fluid (Figure ‎4.2). There are two suggested mechanisms in 
the literature which might explain the increase of TA permeability. The first is, 
which has been interpreted from skin diffusion studies, ethanol is known to extract 
lipids and hence lower the skin barrier function and render the membrane more 
permeable (Lachenmeier, 2008; Van der Merwe & Riviere, 2005). This mechanism 
Chapter 4: The Development of a Porcine In-Vitro Eye Model for Investigating 
Potential Ophthalmic Formulations 
180 
 
of action is irrelevant to the ocular tissues in particular the sclera as it lacks the 
presence of lipids, hence no ethanol extraction occurs and no corresponding 
increase in tissue permeability should occur. The second mechanism is due to the 
permeation of the ethanol through the membrane which increases the co-
permeation of the drug by the effect of solvent drag without affecting the barrier 
integrity. The solvent drag effect was reported by Ungphaiboon & Maitani 
(Ungphaiboon & Maitani, 2001) in which a significant increase in the cumulative 
amount of TA penetrating a synthetic membrane to the receiving ﬂuid was 
observed with increasing ethanol content in the donor solution (10, 20 and 30%). 
In the current study, the difference in the thickness of porcine posterior 
tissues before and after TA permeation studies was found to be insignificant. 
Reports have shown scleral thickness is affected by the hydration level of the 
scleral tissue (Boubriak, Urban, Akhtar, Meek & Bron, 2000; Lee, Geroski, 
Prausnitz & Edelhauser, 2004). A study by Olsen et al. found no significant 
difference between the hydration of human scleral tissue stored in balance salt 
solution for 3 h and scleral tissue stored in moist chamber for two days (Olsen, 
Edelhauser, Lim & Geroski, 1995). Ambati et al. also have reported no significant 
difference between scleral hydration of fresh rabbit scleral tissues and tissues 
exposed to Hanks’ balanced salt solution for 4 h (Ambati et al., 2000). The 
unchanged thickness of the porcine posterior tissue indicates the unaffected 
hydration level of the tissue, and hence no alteration in scleral permeability over 
the duration of the experiment.  
Furthermore, to compare the barrier function of freshly excised and frozen 
porcine posterior tissues (- 20 °C, two weeks), TA and 3H2O permeation studies 
were performed. These studies have shown that there is no significant difference 
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in permeability of TA or 3H2O percentage permeating through fresh and frozen 
posterior porcine ocular tissues demonstrating that freezing the porcine posterior 
tissue does not alter the barrier properties (Table ‎4-3 & Table ‎4-5). This outcome 
is in agreement with the reported literature, in which cryotherapy had no effect on 
permeability of human and porcine sclera was observed (Nicoli et al., 2009; Oh et 
al., 2009; Olsen, Edelhauser, Lim & Geroski, 1995). 
Commonly the barrier integrity of tissues used in in-vitro models are 
assessed by monitoring the permeation of a marker compound, either 
concurrently, before or after the permeation of the drug. The limitations of this 
technique are that it is time consuming, costly and might alter the permeation 
profile of the drug. Tritiated water has previously been used in monitoring the 
barrier integrity of tissues, in particular human skin (Lawrence, 1997). In most skin 
studies 3H2O permeation is measured over a 2 to 6 h period, in order to determine 
barrier integrity prior to lengthy drug studies or to normalise permeation data 
(Chilcott, Dalton, Emmanuel, Allen & Bradley, 2002; Dugard, Walker, Mawdsley & 
Scott, 1984). The skin is a semi-impermeable natural barrier which has a structure 
akin to a bricks and mortar model (Brown, Martin, Jones & Akomeah, 2006; 
Williams, 2003) whereas the sclera tissues have collagen and elastic fibres with a 
few cells imbedded in-between. Due to the difference in structure between the two 
tissues, the permeability of water through porcine scleral tissue (51.1 ± 11.9% 
after 1 h) was found to be much higher in comparison to the skin (less than 10% of 
the applied dose of 3H2O permeated within 2 h through full-thickness human 
abdominal skin (n =42, kps were lower than 20 x 10-4 cm.h) (Lawrence, 1997)). 
The 3H2O permeation at 15 min could be potentially exploited as a rapid screening 
test to determine ocular tissue integrity prior to commencing the time consuming 
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drug permeation studies. As the tritiated water studies have shown that 
approximately no more than 25% of the applied dose of 3H2O can permeate 
through posterior tissues in 15 min (Table ‎4-3), this value has been considered as 
a cut-off limit for integrity check of the porcine posterior tissues (the 25% value is 
an arbitrary value approximately two standard deviations above the mean value 
percentage of 3H2O permeating through fresh posterior porcine ocular tissue at 15 
min). This methodology has previously been used in other tissue types, for 
example Brown et al. rejected human nails which allowed the permeation of 20% 
and 40% higher than the average mean nails that had undergone the same 
treatment at 1 and 20 h, respectively (Brown et al., 2009). A similar approach was 
reported by Lawrence who used an upper cut off limit of approximately 3 x SEM 
above the mean kp value of 
3H2O for human skin (Lawrence, 1997). The 
3H2O 
percentage permeating at 15 min of the porcine corneal tissues was much lower in 
comparison to the posterior tissues 3H2O percentage permeating at 15 min. This is 
expected due to the presence of tight junctions between corneal epithelial cell 
layers which hinders the transport of hydrophilic molecules via the paracellular 
pathway (section 1.5.1). An arbitrary cut-off limit of 3H2O percentage permeating at 
15 min was set at 3.5% of the applied dose. 
Additionally, the 3H2O percentage permeating at 15 min provided a valuable 
method to normalise penetrant flux, as porcine posterior tissue thickness inversely 
related to 3H2O percentage permeating at 15 min (Figure ‎4.11). This confers an 
advantage as the exact thickness of the scleral tissue is hard to measure, due to 
the sclera not having a uniform thickness across the entire eye and this therefore 
makes it impractical to cut a uniform section. The TA and FSS fluxes correlated 
well with 3H2O percentage permeating at 15 min through frozen porcine posterior 
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tissues (Figures 4.9 & 4.10). As the 3H2O percentage permeating at 15 min 
increased the permeability of TA and FSS increased as well, suggesting that the 
two molecules (the hydrophobic TA and the hydrophilic FSS) may traverse through 
the tissue using the same route as water. This can be largely explained by the 
structure of the scleral tissue where the penetrant molecules diffuse through the 
spaces between the collagen bundles (fibre matrix pores) (Edwards & Prausnitz, 
1998; Haghjou, Abdekhodaie & Cheng, 2013; Maza, Tauber & Foster, 2012) and 
therefore the penetrant permeation is affected by the collagen architecture. The 
collagen fibres are loose interwoven in the posterior sclera in comparison to the 
anterior scleral tissue (Curtin, 1969), this difference in the scleral architecture 
results in higher penetrant permeation through the posterior scleral tissue 
(Boubriak, Urban & Bron, 2003). 
Little has been done to evaluate the effect of storage time and conditions on 
the permeability of the corneal tissues. Gratieri et al. recently showed the structure 
integrity and barrier function of porcine epithelial corneal tissue was maintained 
throughout the duration of the experiment (6 h), without the need of gassing CO2 
into the receiver solution (HEPES buffer) (Gratieri, Gelfuso, Thomazini & Lopez, 
2010). Similarly, Majumdar et al. assessed rabbit cornea permeability after storing 
overnight in phosphate-buffered saline (PBS) or Hanks balanced salt solution 
(HBSS) in wet ice. They found no difference in transcellular and paracellular 
passive diffusion between the fresh and the overnight stored corneas (Majumdar, 
Hingorani & Srirangam, 2010). 
The data presented in this thesis shows significant swelling of the porcine 
corneas after storage in PBS buffer at 37 °C for 24 h. This does significantly 
affects the permeability of penetrants, in particular hydrophobic drugs as the 
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corneal stroma is the main limiting barrier. The swelling is due to the presence of 
four-fold higher glycosaminoglycans (GAG, water binding molecules) 
concentration in the cornea (4-4.5% GAG) than the sclera (Akhtar et al., 2002; 
Huang & Meek, 1999; Watson, Hazleman, McCluskey & Pavesio, 2012). 
Interestingly, the FSS corneal permeability increased with time and was 
dependent on storage conditions (Figure ‎4.8). The increase in corneal permeability 
is mainly due to the change of tight junctions between the epithelial cell layers or 
the death of the tightly packed epithelium cell, especially in the superficial layer. 
The change in tight junctions can be confirmed using transepithelial electrical 
resistance (technique before and after storage. The increase in FSS permeability 
with the increasing storage time is an important finding indicating the gradual 
decline in barrier function of the epithelium layers, and to the best knowledge of 
the author this has not been reported before. Nevertheless FSS permeability in 
rabbit and two weeks stored porcine corneal tissues (Figure ‎4.14) were not 
significantly different from human (one way ANOVA, p > 0.05). The porcine in-vivo 
eye results may relate more accurately to human in-vivo than the in-vivo rabbit 
results, due to rabbits having a higher corneal area, lower tear turnover and lower 
blinking rate than humans (Edelhauser & Maren, 1988; Rathbone, Hadgraft & 
Roberts, 2003). Therefore, a porcine in-vitro eye model is more appropriate than 
rabbit in-vitro model to screen potential formulations.  
The in-vitro permeability of human and porcine tissues was compared with 
a series of hydrophilic markers with increasing molecular weights. FSS was 
selected to represent the molecular weights of more commonly used drugs, 
whereas the larger FITC-dextran polymers have similar molecular weights as 
larger molecules, such as peptides, growth factors and ribonucleic acid (RNA). 
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The data obtained revealed an inverse relationship between the permeability 
through scleral and corneal tissues of both species (human and porcine) and the 
molecular weight of the markers. The inverse relationship and the abrupt decline in 
the permeability of various compounds and their molecular weights has been 
reported using bovine scleral tissue by Maurice and Polgar (Maurice & Polgar, 
1977) and human sclera tissue by Olsen et al. (Olsen, Edelhauser, Lim & Geroski, 
1995). The latter authors suggested the permeability data from the human scleral 
tissue can be compared to the bovine if the thickness of the bovine sclera is 
considered (bovine sclera thickness is approximately 0.92  mm at the limbus, 0.65 
mm at the equator and more than 1 mm at the optic nerve region (Cheruvu & 
Kompella, 2006)). Loch et al. also found the permeability of three drugs 
(ciprofloxacin hydrochloride, lidocaine hydrochloride, timolol maleate) were higher 
in rabbit posterior tissues, followed by porcine and then bovine (Loch et al., 2012). 
Similarly Kadam et al. found the cumulative percentage of eight beta-blockers 
transported through posterior ocular tissues followed the trend rabbit > human > 
porcine > bovine. The workers also found upon normalization to scleral thickness 
the species differences in scleral transport were abolished (Kadam, Cheruvu, 
Edelhauser & Kompella, 2011). A similar trend to the one observed by Kadam et 
al. in which human scleral tissue was more permeable than porcine was observed 
in the findings of this work (Figures 4.12 & 4.13). The kp values of FSS and 4 kDa 
FITC-dextran were nearly two fold higher in human scleral tissue in comparison to 
porcine and this is probably due to the thicker porcine scleral tissue. Interestingly if 
the tissue thickness at the equator of both species (porcine and human scleral 
thickness at the equator are approximately 0.86 and 0.39 mm, respectively) were 
to be considered the difference in the permeability between the two species 
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diminishes (the kp values of FSS normalised by the equator thickness of human 
and porcine scleral tissue were 1.47 and 1.63 x 10-5 cm.h-1, respectively, whereas 
the normalised kp values for the 4 kDa FITC-dextran were 0.58 and 0.61 x 10
-5 
cm.h-1).  
 The permeability of the corneal tissues had the same inverse relationship 
and abrupt decline in permeability with increasing molecular weight observed in 
the human and porcine sclera (Figures 4.12 & 4.13). Interestingly, there was a 
large difference (t-test, p > 0.05) in the permeation of FSS and 4 kDa FITC-dextran 
between human corneal tissues and one week stored porcine corneal tissues. The 
porcine corneal tissue was less permeable than human tissue (5 and 7 folds lower 
for FSS and 4 kDa FITC-dextran, respectively). The lower permeability of the 
porcine corneal tissue in comparison to human tissue is likely to be due to the 
difference in thickness (human cornea thickness 535 µm, porcine cornea thickness 
666 µm) and to the undamaged corneal epithelium and endothelium cells in the 
porcine corneal tissues which were stored for a shorter period of time in 
comparison to the human corneal tissues (no more than 4 weeks). The percentage 
of damaged corneal endothelial cells in organ culture medium and dextran 
containing medium increases with storage time and is affected by the storage and 
transport media (Borderie, Baudrimont, Lopez, Carvajal & Laroche, 1997; Pels, 
Beele & Claerhout, 2008). The presence of 500 kDa dextran (macromolecule de-
swelling agent) has been shown to cause 8.4% loss in the number of endothelia 
cells after two days and severe epithelial injuries and lysis of keratinocytes after 
four days (Borderie, Baudrimont, Lopez, Carvajal & Laroche, 1997). The increase 
in corneal permeability due to the more damaged epithelial cells can also be 
deduced from the reported literature, in which de-epithelialized human cornea had 
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the same kp as the sclera (Edelhauser & Maren, 1988), and from the finding of this 
work in which the permeability of the porcine corneal tissues increased with 
increased duration of storage (Figure ‎4.8). The fresh porcine corneal tissue were 
impermeable (below limit of quantification, data not shown) to the 4 kDa marker, 
whereas the 20 kDa marker did permeate through stored porcine corneal tissue 
(one week) indicating an alteration in the corneal epithelium layers. A molecular 
weight cut-off for the permeability of fresh and stored corneal tissues has not 
previously been reported, further marker permeation studies with various 
molecular weights are necessary to determine the highest molecular weight which 
can permeate through the cornea.  
The calculated TA permeability coefficient (kp of TA suspension) through 
human sclera was 1.23 x 10-5 cm.s-1 and is in good agreement with a previously 
reported value (1.47 x 10-5 cm.s-1) (Mora et al., 2005). The TA Kp value (1.32 x 10
-5 
cm.s-1) in porcine posterior tissues was similar to that obtained in human tissue, 
demonstrating the similarity in permeability between the two tissues and hence the 
suitability of porcine posterior tissues as an alternative model to human posterior 
tissues. The TA-SA (TA polymeric nanoparticles), did not significantly increase (t-
test, p > 0.05) TA flux through human or porcine scleral tissues (Figures 4.15 & 
4.16). This suggested the SA did not pass through the scleral tissue, and only TA 
molecules released from the SA traversed across the tissue. This finding is 
supported by the in-vitro permeability of 20 and 200 nm nanoparticles across 
bovine sclera and posterior tissues over 24 h (Amrite, Edelhauser, Singh & 
Kompella, 2008). The latter workers reported no quantifiable permeation of the 
200 nm nanoparticles across either tissue, whereas only 0.46% ± 0.06% of the 20 
nm nanoparticles crossed through the sclera. The observed and reported results in 
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which large nanoparticles could not penetrate the scleral tissue might be explained 
by scleral structure and the passive diffusion of penetrants through the scleral 
aqueous pathways in between the free spaces of the collagen bundles (Ambati et 
al., 2000; Edwards & Prausnitz, 1998; Komai & Ushiki, 1991a; Thakur, Kadam & 
Kompella, 2011). As a result the porosity of the collagen fibre matrix is the main 
determinant of the rate and size of the penetrants traversing across the sclera. 
Increasing the permeability of ocular tissue is highly desirable, as the 
applied dosage encounters many static and dynamic barriers before reaching the 
targeted tissue in very low concentrations. The potential permeation enhancer 
studies showed there were no significant difference in kp values of the FSS and 10 
kDa FITC-Dextran in the presence of penetration enhancers compared to standard 
solutions through both human and porcine tissues (Figures 4.17, 4.18 & 4.19). The 
corneal chemical enhancers assist drug delivery via two mechanisms; the first is 
through the alteration of the tight junction of the epithelium cells (paracellular) 
whereas the second is via the transcellular route. The chemical enhancers did not 
have any significant difference on the 10 kDa marker permeating through human 
cornea (Figure ‎4.17), due to the loosened tight junctions between the corneal 
epithelial cells as a result of the storage conditions. In addition, the 10 kDa FITC-
dextran traverses paracellular route and acts as a paracellular marker (Kikuchi, 
Suzuki, Kusai, Iseki & Sasaki, 2005; Krug et al., 2013).  
Chemical enhancers might not be sufficient to enhance permeation through 
the scleral and corneal stroma, due to limited viable cells and lipids in the structure 
of these tissues. This might necessitate the use of active permeation techniques, 
such as iontophoresis, electroporation and sonophoresis (Cheung et al., 2010; 
Hao, Li, Liu & Kao, 2009). Despite the hypocellular nature of the scleral tissue, 
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thermopertubation is unlikely to be used in the eye as the scleral tissue is rich in 
nerves. Other aggressive forms of active permeation techniques such as the use 
of needleless injections might possibly enable delivering drugs to the posterior 
segment of the eye. Despite recent reports showing heat facilitated drug transport 
through human skin by reversible lipid fluidisation at 37 - 45 °C (Akomeah, Nazir, 
Martin & Brown, 2004; Brown, Martin, Jones & Akomeah, 2006; Wood, Brown & 
Jones, 2012), the elevated temperatures (45 °C) have did not improve the 
permeation of the 10 kDa marker through the sclera, which can be explained by 
the absence of lipids in the scleral tissue.  
4.6 Conclusion 
A porcine in-vitro eye model was developed; the results showed that a 
percentage of ethanol up to 10% v/v in modified Dulbecco’s buffer solution can be 
used as a receiver fluid without significantly altering the permeability of the tissue. 
The integrity of porcine ocular tissue was checked by monitoring the permeation of 
tritiated water, this study has shown that it is possible to ensure the membrane is 
intact after 15 min. This technique may also be used as a method to normalise 
drug flux to reduce the inherent variability between tissue samples thus increasing 
the accuracy of the in-vitro eye model. Furthermore, the results of this work have 
shown the validity of using frozen posterior tissues as an alternative practical and 
more convenient option to using fresh tissues.  
In-vitro permeation studies were performed with four markers having 
different molecular weights. The results showed the permeation of the markers 
reduced with increasing molecular weight in both corneal and scleral tissues in 
both human and porcine tissue. The four markers had similar permeability in both 
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human and porcine tissues strengthening the suitability of the porcine eye model 
as an alternative to human tissue. 
Enhancer permeation studies showed for a range of chemical enhancers 
and the use of nano-self assemblies no enhancement was found in the delivery of 
marker compounds to the eye. However, the corneal permeability from tissues 
stored for one or two week revealed an important finding, where fresh corneas 
might be susceptible to permeation enhancement in comparison to stored corneas 
due to the undamaged epithelium layers in fresh corneas. Ultimately this finding 
can lead to the development of an in-vitro corneal model mimicking the in-vivo 
response at a fraction of the cost of in-vivo studies and in conventional laboratory 
settings. 
In conclusion, a porcine in-vitro eye model was developed to assess 
hydrophobic and hydrophilic drug permeation through anterior and posterior ocular 
tissues. The porcine in-vitro eye model shows good correlation with the human in-
vitro model providing strong evidence that the porcine in-vitro eye model can be 
used to screen potential formulations before testing in-vivo using the porcine 
model which ultimately might correlate well with the in-vivo human responses. The 
development of an in-vitro eye model for permeation studies is crucial for 
screening of potential formulations. However, this type of models can provide only 
limited information about the effect of the formulation components on the ocular 
tissue, hence in the next chapter two methods were investigated to determine the 
toxicity of formulations components. 
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5.1 Introduction 
Today, a plethora of emerging novel drug delivery systems such as 
nanoparticles and polymeric implants have been developed to deliver drugs to the 
anterior and posterior ocular tissues (Bourges et al., 2006; Yang et al., 2013). 
These systems might offer many advantages over marketed formulations such as 
prolonged drug release and less frequent dose application (Bhatta et al., 2012; 
Kompella & Edelhauser, 2011). However, it is essential to evaluate the in-vitro 
biocompatibility of these formulations to determine whether these formulations can 
progress further to in-vivo testing and ultimately be introduced to the market as a 
commercial product. 
In-vitro cell culture studies allow the screening of potential formulations 
before performing expensive in-vivo experiments. Some of the most common used 
in-vitro ocular cell culture models are listed in Table ‎5-1. 
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Table ‎5-1: Most common in-vitro ocular cell culture models 
In-vitro 
Model 
Cell Type Applications 
Advantages / 
Disadvantages 
Reference 
EpiOcular TM 
Human 
derived 
epidermal 
keratinocytes 
Ocular irritation 
determination 
Cornea like 3D tissue 
structure. Excellent 
correlation in-vivo to in-
vitro test Results. 
Unsurpassed long term 
tissue reproducibility 
Lot to lot, year to year 
(Kolle, 
Kandárová, 
Wareing, van 
Ravenzwaay & 
Landsiedel, 
2011; 
Pfannenbecker 
et al., 2013) 
TMC 
Primary 
human 
trabecular 
meshwork 
cells 
Toxicity and 
permeability 
studies 
 
culture time 3-4 weeks 
(Kernt et al., 
2009) 
HCE 
Primary 
human corneal 
epithelial cells 
Toxicity and 
ocular irritation 
determination 
culture time 3-4 weeks 
(Geerling, 
Daniels, Dart, 
Cree & Khaw, 
2001; Hornof, 
Toropainen & 
Urtti, 2005) 
HCE-T 
Transfected 
immortalised 
human corneal 
epithelial cells 
Toxicity, 
permeability 
studies and 
prediction of 
ocular 
pharmacokinetics 
HCE-T cells form a 
stratified culture when 
grown at the air-liquid 
interface on a collagen 
membrane in serum free 
medium. Similar barrier 
properties to isolated 
corneal tissue. Higher 
TEER values in 
comparison to other HCE 
cell lines 
(Hornof, 
Toropainen & 
Urtti, 2005; 
Kruszewski, 
Walker & 
DiPasquale, 
1997) 
HCE-S 
Spontaneously 
immortalised 
human corneal 
epithelial cells 
Cell biology and 
gene regulation 
studies 
HCE-S can be cultured in 
a simple DMEM and only 
serum-based media. 
expression of 
characteristic 
markers similar to primary 
cells such as cytokeratin 
3, PAX 6, integrins β1 
and γ9 
(Notara & 
Daniels, 2010) 
H1RPE7 
Transfected 
immortalised 
human retinal 
pigment 
epithelial cells 
Toxicity, 
permeability 
studies and 
transplantation 
studies 
Expression of cytokeratins, 
and displaying junctional 
distribution of ZO-1, p100-
p120 and beta-catenin. 
Exhibit a strong growth 
potential 
(Kanuga et al., 
2002) 
ARPE-19 
Spontaneously 
immortalised 
human retinal 
pigment 
epithelial cells 
Toxicity and 
permeability 
studies 
Time course of tight-
junction formation 
reached a maximum of 
50-100 omega cm
2
 after 4 
weeks 
(Dunn, Aotaki-
Keen, Putkey & 
Hjelmeland, 
1996) 
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Although in-vitro analysis is able to provide basic information about the 
interaction between the cell and the delivery system, it might not be a true 
representation of the in-vivo results. Unlike in-vivo studies, in-vitro cell culture 
studies have typically homogenous cells and a controlled physiochemical 
environment. For example, corneal epithelia cells grown in-vitro lack the 
morphological diversity of those observed in-vivo. The latter consists of five to 
seven layers of superficial, wing and basal cells with tight junctions (Hao, Li, Kao & 
Liu, 2010). The superficial cells are flat cells with surface microvilli, whereas wing 
and basal cells have no surface microvilli and adapt wing-like and cuboidal 
shapes, respectively (Holland, Mannis & Lee, 2013). The tight junction complexes 
also differ between the superficial, wing and basal cells. The controlled in-vitro 
physiological environment is also lacking of the complex physiological conditions 
present in-vivo. One example is the tear film covering the corneal epithelial cells 
(Ohashi, Dogru & Tsubota, 2006) which is not recreated in any current in-vitro 
model. 
In-vitro biocompatibility tests have been developed to predict biological 
reactions to materials/excipients when they are in contact with cells in the body. 
The determination of the toxicity and biocompatibility of new emerging 
formulations can be examined using a number of in-vitro biocompatibility tests. 
The most common in-vitro biocompatibility tests are the haemolysis assay, 
histological examination and cytotoxicity assays. The haemolysis assay is 
irrelevant to ocular formulations as the majority of formulations are applied 
topically or through intravitreal injections (no direct contact between the 
formulation and blood cells). Histological examination of ocular tissues has 
previously been used to determine the toxic effect of materials or formulations 
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(Bourges et al., 2003; Huhtala et al., 2009; Prow, 2010). However this approach is 
limited by the complex tissue preparation methods which might alter the structure 
of the tissue under study or introduce artifacts such as uneven shrinkage, wrinkles 
and folds and dye precipitates (Cormack, 2001; Dartt, Dana, D'Amore & 
Niederkorn, 2011). The most common methods of assessing the toxicity of 
materials or formulations are cytotoxicity assays such as trypan blue, lactate 
dehydrogenase (LDH) and methylthiazole tetrazolium (MTT) based assays 
(Chang, Wu, Tseng, Kuo & Tseng, 2007; Huhtala et al., 2009; Spitzer et al., 2006). 
In the trypan blue method, dead cells which are unable to maintain an intact cell 
membrane are stained with trypan blue. In contrast, viable cells with an intact cell 
membrane are able to prevent trypan blue uptake and therefore appear clear 
under light microscopy. The unstained cells reflect the total number of viable cells, 
whereas the stained cells reflect the total number of dead cells. Trypan blue 
strongly binds to proteins which results in a high false value of viability, and thus, 
there should not be proteins in the medium when analysing cell viability (Picot, 
2004). Also this method suffers from the subjective manual counting of cells, and 
therefore it requires the use of flow cytometry which is not available in all 
laboratory settings (Katsares et al., 2009; Stone, Johnston & Schins, 2009). LDH 
is a soluble enzyme that is normally found within the cell cytoplasm, it serves as 
an indicator of cell death as it is released into the extracellular medium subsequent 
to cellular membrane damage. The LDH assay is a less sensitive method than the 
MTT and in some cases it can produce false positive result (Fotakis & Timbrell, 
2006; Hillegass et al., 2010). The MTT assay is based on reduction of MTT into 
formazan in active mitochondria within viable cells by mainly mitochondrial 
succinate dehydrogenase or similar reducing molecules (i.e. NADH) that transfer 
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electrons to MTT (Marshall, Goodwin & Holt, 1995). The reduced water insoluble 
formazan is subsequently solubilized by dimethyl sulfoxide (DMSO) and quantified 
using a visible light spectrophotometer. The absorbance value is representative of 
both cell number and the metabolic activity of cells. It is worth mentioning that the 
metabolic activity of cells may vary by different conditions or chemical treatments 
(the chemical nature of the supplements) which might cause significant variation in 
results obtained from this assay (Riss et al., 2004; Wang, Henning & Heber, 
2010). The MTT assay has been used in investigating proliferation as well as 
material toxicity (Berridge, Herst & Tan, 2005; Organisation for Economic Co-
operation and Development, 2009). 
The selection of the assays to be used will depend on many factors such as 
the desired endpoint (i.e. material toxicity, cell viability, cell proliferation or damage 
to the cell membrane), the cost, simplicity, reproducibility and the time required to 
perform the assay. Despite the limitations of the MTT assay, such as the multi-
step protocol (i.e. removal of culture medium) and the use of organic solvent 
(DMSO), MTT is still one of the most commonly used cytotoxicity assays in 
biological sciences (Riss et al., 2004). Da Costa et al. compared MTT to the 
aforementioned assays (trypan blue and LDH) in human cultured epithelial cells 
and found MTT was the most sensitive assay alongside other advantages such as 
speed and simplicity (Da Costa, de Assis, de Andrade Marques & Plotkowski, 
1999).  
In recent years, many cytotoxicity assays have been investigated with the 
aim of establishing a rapid and robust assay without the limitations associated with 
the MTT assay. AlmarBlue is resazurin based assay used in measuring cell 
viability. Similar to MTT, the non-fluorescent resazurin dye penetrates cells where 
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it is converted by the intracellular enzymes into a fluorescent dye (resorufin). 
AlmarBlue is easy to use and has been shown to be more sensitive than the MTT 
assay (Hamid, Rotshteyn, Rabadi, Parikh & Bullock, 2004). Furthermore, this 
assay was shown to have better linearity with cell number, its activity was not cell 
line dependent, non-destructive, easy to handle, and less time consuming in 
comparison to MTT assay (Bopp & Lettieri, 2008; Patel, Zaveri, Zaveri, Shah & 
Solanki, 2013). PrestoBlue® is a new dye reagent based on the resazurin dye 
introduced by Invitrogen; the new reagent enables a more rapid cellular uptake of 
the dye (Hamalainen-Laanaya & Orloff, 2012; "Invitrogen," 2013). PrestoBlue® is 
quickly reduced by metabolically active cells, providing a quantitative measure of 
viability and cytotoxicity in a time frame of only 10 min. The manufacturer of this 
reagent listed PrestoBlue® as the most sensitive viability assay from a panel 
consisting of MTT, XTT, AlmarBlue and Resazurin ("Invitrogen," 2013). The 
sensitivity of this reagent is 12 cells per well compared to 1000 cell per well for 
MTT assay ("Invitrogen," 2013). This reagent has not yet been reported as being 
used as a viability test for ocular subcultures, and hence PrestoBlue® was used to 
determine the viability of corneal epithelium cell line as a proof of concept in this 
work.  
Due to the unique structure of the eye, the in-vitro biocompatibility of 
materials used in ocular drug delivery can mainly be performed on two types of 
cells, namely corneal epithelial cells; representing the anterior segment of the eye, 
and retinal pigment epithelial (RPE) cells; representing the posterior segment of 
the eye. In this work, two cytotoxicity assays namely MTT and PrestoBlue® have 
been used to assess the toxicity of the modified polymers in eye cell cultures 
(H1RPE7 and HCE-S). 
Chapter 5: In-Vitro Cytotoxicity of Modified Amphiphilic Polymers 
198 
 
 
5.1.1 Human Retinal Pigment Epithelial Cell line 
The H1RPE7 cell line is an immortalized RPE cell line derived from primary 
human retinal pigment epithelial cells acquired from a 50-year-old female 
Caucasian donor (Lund et al., 2001). This is an adherent cell line and the 
morphology of the cells are polygonal (Figure ‎5.1). The H1RPE7 cell line was 
obtained by genetically modifying the primary cells (cells taken directly from living 
tissue) with a construct encoding SV40 large T antigen to extend the cell line in-
vitro lifespan (Lund et al., 2001). This cell line retains many of the morphologic and 
biochemical characteristics of primary cells and expresses cytokeratins and 
junctional protein zonula occludens-1 (ZO-1). Therefore, it is similar to RPE cells 
in-vivo and other RPE cell lines such as ARPE-19 (Kanuga et al., 2002). This cell 
line has the advantage of a short culture time (typically 3 d) and is easy to 
maintain compared to primary RPE cells. Additionally, it has an extended lifespan 
and maintains unaltered characteristics with high number of passages (Hahne & 
Reichl, 2011). The P-glycoprotein efflux pump has recently been identified in the 
apical and basolateral cell membranes of human RPE and in pig RPE (Constable, 
Lawrenson, Dolman, Arden & Abbott, 2006; Pitkänen, Ranta, Moilanen & Urtti, 
2005). The H1RPE7 cell line has the advantage of having P-Glycoprotein (P-gp) 
efflux pump unlike the ARPE-19, making this cell line more suitable for in-vitro 
drug transport studies (Constable, Lawrenson, Dolman, Arden & Abbott, 2006). 
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Figure ‎5.1: Phase contrast image of H1RPE7 cells grown in culture medium at day three. 
 
5.1.2 Human Corneal Epithelial Cell Line 
The HCE-S cell line is a new immortalized adherent corneal epithelial cell 
line which was passaged spontaneously until reaching over 100 cell duplications 
(Notara & Daniels, 2010). The cell line was derived from primary human corneal 
epithelial (HCE) cells and it has similar morphology (hexagonal cells, Figure ‎5.2) to 
the primary corneal epithelial cells (Notara & Daniels, 2010). The HCE-S cell line 
expresses cytokeratin and has tightly packed cells mimicking the tight junctions in 
the corneal epithelium layer (Notara & Daniels, 2010). The cell line has 
advantages over other HCE cell lines, including the fact that they can be cultured 
in a simple Dulbecco's Modified Eagle Medium (DMEM) without the need for 
supplements such as insulin. Additionally, it can also be cultured without 
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extracellular matrix (ECM) coating on tissue culture plastic (Notara & Daniels, 
2010). HCE cell lines have been used in corneal epithelial wound healing and as 
an eye irritation test to toxicologically assess chemicals (Cho et al., 2012; Li et al., 
2013). 
 
 
Figure ‎5.2: Image of HCE-S cells grown in culture medium at day two. 
 
5.1.3 MTT Assay 
The MTT assay is a modified method adapted from Mosmann et al. 
(Mosmann, 1983). The assay is based on the reduction of the water soluble yellow 
tetrazolium salt (MTT) by mitochondrial dehydrogenase into a blue water insoluble 
formazan dye (Vega-Avila & Pugsley, 2011). The formazan crystals are soluble in 
dimethyl sulfoxide (DMSO) so can be recovered at the end of the assay and 
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formazan concentration quantified measuring absorbance at 550 nm. The 
measured values are directly proportional to the number of living cells (Gerlier & 
Thomasset, 1986; Mosmann, 1983). The IC50 value (the polymer concentration at 
which 50% of the cells is viable) can be calculated by plotting the determined cell 
viability (as a percentage of the total cells) versus polymer concentration.  
5.1.4 PrestoBlue® Assay 
PrestoBlue® is a non-fluorescent blue dye reagent based on resazurin (7-
Hydroxy-3H-phenoxazin-3-one-10-oxide). The PrestoBlue® reagent is a cell 
permeant dye, upon entering the cytosol of active cells it is converted from 
resazurin form to resorufin which exhibit fluorescence property and it is red in 
colour (O'Brien & Pognan, 2001). The assay can be quantified by measuring either 
the absorbance at 570 or 600 nm or by fluorescence, measuring the excitation and 
emission wavelengths at 560 and 590 nm, respectively. The rate at which 
PrestoBlue® is reduced is proportional to the number of viable cells. 
5.1.5 Aims and Objectives 
The aim of the work described in this chapter was to assess the in-vitro 
cytotoxicity of PAA and hydrophobically modified PAA polymers described in 
chapter two on RPE and corneal epithelial cell lines. The objectives were: 
 To compare the cytotoxicity of the Pa5, Pa5-MPEG, Ch5 and Da10 polymers 
to the unmodified PAA   
 To establish the IC50 for the aforementioned polymers in the RPE cell lines 
 To assess the viability of corneal epithelium cell line using new assay 
(PrestoBlue®) as a proof of concept.  
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5.2 Materials and Methods 
5.2.1 Materials 
Nutrient mixture F-10 ham (with sodium bicarbonate, without L-glutamine), 
heat inactivated fetal bovine serum, L-glutamine solution (200 mM), 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (thiazolyl blue tetrazolium 
blue (MTT), glycine, sodium chloride, tween® 80, L-glutamic acid, penicillin-
streptomycin (10,000 units penicillin and 10 mg streptomycin per mL in 0.9% w/v 
NaCl) and trypsin-EDTA solution 10X (0.5% v/v) were all purchased from Sigma 
Aldrich, United Kingdom. Phosphate buffer saline (PBS) tablets, dimethyl 
sulfoxide, triton X (10x) and all solvents (HPLC grade) were supplied by Fisher, 
United Kingdom. PrestoBlue® cell viability reagent, Dulbecco's modified eagle 
medium (Gibco® DMEM), adult bovine serum (Gibco®) and penicillin/streptomycin 
(Gibco®) were acquired from Invitrogen, United Kingdom. Triamcinolone 
Acetonide micronized powder (TA) was obtained from Fagron, United Kingdom. 
Human retinal pigment epithelial cell line (H1RPE7) was purchased from the 
health protection agency (HPA, United Kingdom). The HCE-S cells used in this 
work were courtesy of Dr. Moore, University of Ulster. 
5.2.2 Cell Resuscitation and Freezing 
The frozen cell stock was heated in a water bath for 1-2 min at 37 °C until 
fully thawed. The ampoule was cleaned by tissue soaked with 70% (v/v) alcohol 
prior to opening. The whole content of the ampoule was pipetted in 25 cm2 flask 
containing 10 ml of pre warmed culture medium. Cells were grown for three days 
at 37 °C in a humidified atmosphere containing 5% v/v CO2. The grown cells were 
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sub-cultured in three 75 cm2 flask (15 ml of culture medium) as described in 
section ‎5.2.4.1. 
The establishment of a cell line bank were made as follows. Cells from 75 
cm2 flask were trypsinized as described in section ‎5.2.4.1. The detached cells 
were thoroughly dispersed in 15 mL of culture medium and counted before 
transferred to centrifuge tube (15 ml sterile centrifuge tube). The tube was span at 
5004 G force (1500 rpm) for 5 min. The supernatant was decanted using pipette, 
the cells pellet was then re-suspend in freezing medium (10% (v/v) DMSO in cell 
culture medium) before transferring into cryovials. The cryovials were transferred 
immediately to -80 °C overnight before permanent storage in liquid nitrogen. 
5.2.3 Heat-inactivation of Fetal Bovine Serum 
The fetal bovine serum was thawed in a water bath for 1-2 h at 37 °C and 
gently mixed. The serum was then immersed in 56 °C water bath and incubated 
for 1 h. The heat inactivated serum were then transferred into 50 mL sterile 
centrifuge tube and stored at 4 °C in a fridge. 
5.2.4 H1RPE7 Cell Growth Medium 
The H1RPE7 culture medium was prepared under aseptic conditions. The 
culture medium consisted of nutrient mixture F-10 ham (500 mL) supplemented 
with 20% v/v heat-inactivated fetal bovine serum (125 mL), 2 mM L-Glutamine 
solution (6.4 mL) and 100 U mL-1 penicillin, 100 µg mL-1 streptomycin (6.4 mL). 
5.2.4.1 H1RPE7 Cell Growth and Sub-culture 
The H1RPE7 cells were grown in 15 mL of the culture medium for three 
days in 75 cm2 cell culture flasks at 37 °C in a humidified atmosphere containing 
5% v/v CO2. The culture medium was aspirated after two days and replaced with 
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fresh medium. On the third day post-seeding, the cells were sub-cultured when 
approximately 90% confluent. This was achieved by washing the cells three times 
with sterilised PBS pH 7.4 buffer (5 mL, 10 mM) followed by one wash with trypsin-
EDTA (3 mL, 0.05% w/v) to dislodge the cells attached to the surface of the flask. 
The detached cells were thoroughly dispersed in 15 mL of culture medium and 
sub-divided into three 75 cm2 cell culture flasks before adding 10 mL of culture 
medium to each flask. Cells between passages 15 and 18 were used for cell 
viability test experiments. 
5.2.5 MTT and Glycine Buffer Preparation 
MTT (50 mg) was dissolved in 10 mL of sterile PBS buffer, the solution was 
then filtered and stored immediately in the fridge for further use. Glycine (3.75 g) 
and 2.93 g of NaCl was dissolved in 450 mL of sterile water; the pH of the solution 
was then adjusted by the addition of sodium hydroxide solution (1 M) until pH 10.5 
(pH meter 209, HANNA® Instruments, United Kingdom) was reached, before 
topping the solution volume to 500 mL. 
5.2.6 L-glutamic acid and tween 80 Solution Preparation 
L-glutamic acid (20 mg) was dissolved in 10 mL of H1RPE7 culture 
medium. From this stock solution, five concentrations (0.06 - 1 mg mL-1) were 
prepared by serial dilution using H1RPE7 culture medium as the diluent. Tween 80 
(40 mg) was dissolved in 40 mL H1RPE7 culture medium. From this stock solution 
seven concentrations (0.01 - 0.5 mg mL-1) were prepared by serial dilution using 
H1RPE7 culture medium as the diluent. 
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5.2.7 H1RPE7 Cell Viability Test 
PAA and hydrophobically modified polymers, namely Pa5, Pa5-MPEG, Ch5 
and Da10 were dissolved separately in sterile water (4 mg mL
-1) and sonicated for 
5 min. The polymeric colloidal solutions (0.5 mL) were then diluted in culture 
media (4.5 mL) to form a 0.4 mg mL-1 solution. From the stock solutions, ten 
concentrations (0.2-3.9 x 10-4 mg mL-1) were prepared by serial dilution using 
culture medium as a diluent. The H1RPE7 cells were seeded in exponential 
growth phases in 96-well plates at 1x104 cells per well in 200 µL of culture 
medium. The 96-well plate was then incubated for two days at 37 °C in 5% v/v 
CO2 humidified atmosphere. 
On the second day, the culture medium was aspirated and replaced with 
one of the polymers at a concentration as prepared above (200 µL, 3.9 x 10-4 - 0.4 
mg mL-1). Untreated cells cultured in medium were the negative control whereas 
cells treated with triton X (1:5 PBS) were the positive control. The 96-well plate 
was incubated for a further 24 h. The following day MTT (50 μL, 5 mg mL-1) was 
added to the 96-well plate before incubation in the dark for 4 h (37 °C with 5% 
CO2). The medium in the wells were carefully aspirated before dissolving any 
purple formazan complexes in DMSO (200 μL) and adding glycine buffer (25 µL, 
pH 10.5) to enhance the sensitivity of the MTT (Plumb, Milroy & Kaye, 1989). The 
96-well plates were shaken gently for 10 min to ensure the dissolution of formazan 
before the absorbance was measured using an ELISA reader (Ascend Lab-
Systems, United Kingdom) at 570 nm. The cell percentage viability was calculated 
relative to the positive controls. 
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5.2.8 HCE-S Cell Growth Medium 
The HCE-S culture medium was prepared under aseptic conditions. The 
culture medium consisted of Dulbecco's modified eagle medium (DMEM) (500 mL) 
supplemented with 10% v/v fetal bovine serum (55 mL) and 1% v/v 
penicillin/streptomycin (5.5 mL). 
5.2.8.1 HCE-S Cell Growth and Cell Viability Test 
The HCE-S cells were grown in 5 mL of the culture medium in 25 cm2 cell 
culture flasks for six days, the cells were maintained at 37 °C in a humidified 
atmosphere containing 5% v/v CO2. Hydrophobiclly modified polymers (50 mg) 
were dissolved in sterile water (10 mL) and sonicated for 5 min. The polymeric 
colloidal solutions (0.5 mL) were then diluted in culture media (4.5 mL) to form 0.5 
mg mL-1 solution. From the stock solutions, five concentrations (0.25 - 1.25 x 10-2 
mg mL-1) were prepared by serial dilution using culture medium as a diluent. The 
HCE-S cells were seeded in 96-well plates at 6x103 cells per well in 100 µL of 
medium. The 96-well plate was then incubated for 24 h at 37 °C in a 5% v/v CO2 
humidified atmosphere. The medium was then aspirated and replaced with one of 
the polymers at a concentration as prepared above (100 µL, 0.5 - 1.25x10-2 mg 
mL-1) and incubated for a further 24 h. Untreated cells cultured in medium were the 
negative control whereas cells treated with triton X (1:5 PBS) were the positive 
control. PrestoBlue® reagent (15 µL) was then added to each well before 
incubating for 30 min in a 5% v/v CO2 humidified atmosphere at 37 °C. The 
fluorescence of the PrestoBlue® was measured using a fluorescence microplate 
reader (BMG LABTECH). The excitation and emission wavelengths were 560 and 
590 nm, respectively. 
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5.2.9 Statistical Evaluation 
Statistical analysis was performed using SPSS program version 19. The 
normality of the data was assessed using the Shapiro-Wilk test. Experimental 
difference between groups was compared with the control using the independent 
student’s t-test. Differences were regarded as significant, with p ≤ 0.05. 
5.3 Results 
5.3.1 Polymer Cytotoxicity Studies 
The MTT assay was carried out on RPE cells treated with PAA or PAA 
modified polymers to determine the polymer concentration at which 50% of the 
cells population were viable (IC50). Polymers with higher IC50 values have a lower 
cytotoxic effect. The cytotoxicity profiles of all polymers are shown in Figure ‎5.3. 
All polymers showed cell viability higher than 75% at 1.3x10-2 mg mL-1 or lower, 
and less than 15% cell viability at 1.0x10-1 mg mL-1 or higher. The IC50 of RPE 
cells treated with PAA and modified PAA is shown in Table ‎5-2. The IC50 values of 
Da10 and Pa5-MPEG were significantly higher (t-test, p < 0.05) when compared to 
the IC50 of PAA. 
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Table ‎5-2: IC50 values for RPE cells treated with PAA and modified PAA polymers (3.9 x 10
-4 
- 0.4 
mg mL
-1
) for 24 h. 
Polymer 
IC50 value on RPE cells 
(mg mL-1) x 10-2 (mean ± S.D., 
n = 4) 
IC50 of modified PAA / IC50 of 
PAA  
PAA 3.4 ± 0.5 - 
Pa5 2.9 ± 0.5 0.85 
Pa5-MPEG 4.5 ± 0.4 1.32 
Ch5 3.7 ± 1.2 1.09 
Da10 4.9 ± 0.6 1.4 
 
Figure ‎5.3: MTT results for percentage cell viability of RPE cells exposed to PAA, Pa5, Pa5-MPEG, 
Ch5 and Da10 (Data represented as mean, error bars represent range, n = 4). 
 
The PrestoBlue® toxicity studies showed cell viability of at least 54% for all 
studied polymers at 1.3x10-2 mg mL-1 (Figure ‎5.4). This finding is comparable to 
the result obtained from the RPE cells using MTT assay at 2.5x10-2 mg mL-1. The 
PrestoBlue® toxicity test also showed Pa5-MPEG had higher cell viability (80%) 
than all other polymers (<20%) at 2.5x10-2 mg mL-1. A comparison between the 
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IC50 of PAA and PAA modified polymers obtained using MTT and PrestoBlue
® 
tests are shown in Table ‎5-3. The IC50 of PAA and PAA modified polymers 
obtained using PrestoBlue® test were similar to the values obtained using the MTT 
assay. 
 
Figure ‎5.4: PrestoBlue
®
 results for percentage cell viability of corneal epethilal cells (HCE-S) 
exposed to PAA, Pa5, Pa5-MPEG and Da10 (Data represented as mean, error bars represent range, 
n = 4). 
 
Table ‎5-3: IC50 values for RPE and HCE cells treated with PAA and modified PAA polymers. 
Polymer 
IC50 value on RPE cells 
(mg mL-1) x 10-2 (mean ± S.D., 
n = 4) 
IC50 value on HCE cells 
(mg mL-1) x 10-2 (mean ± S.D., 
n = 4) 
PAA 3.4 ± 0.5 1.9 ± 0.3 
Pa5 2.9 ± 0.5 2.0 ± 0.3 
Pa5-MPEG 4.5 ± 0.4 4.7 ± 0.2 
Ch5 3.7 ± 1.2 - 
Da10 4.9 ± 0.6 1.4 ± 0.1 
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5.3.2 Permeation Enhancer Cytotoxicity Studies  
The toxicity of two enhancers used in chapter four was tested on RPE using 
the MTT assay, the results of tween 80 and L-glutamic acid are shown in Figure 
5.5. The cytotoxicity of the chitosan could not be performed due to it being poorly 
soluble in cell culture medium pH 7.4. The acetate buffer (pH5) used to dissolve 
chitosan was not a suitable medium since cells were not viable in an acidic 
medium after 24 h. Tween 80 at a concentration of 0.13 mg mL-1 allowed 51% cell 
viability, whereas higher concentrations resulted in less than 10% cell viability at 
all concentrations tested. L-glutamic acid showed cell viability of 86% or more at 
any of the concentrations tested. 
 
Figure ‎5.5: MTT results for percentage cell viability of RPE cells exposed to Tween 80 and L-
Glutamine acid (Data represented as mean, error bars represent range, n = 4). 
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5.4 Discussion 
The toxic effect of PAA and hydrophobically modified PAA were tested on 
HCE-S and RPE cell lines using two cell viability assays.  
The MTT assay showed the modification of PAA had minute impact on the 
cytotoxicity of the polymers to RPE cells. Nevertheless, both Da10 and Pa5-MPEG 
had higher IC50 values (i.e. are less cytotoxic) than PAA. The PAA and PAA 
modified polymers were highly toxic in comparison to other common polymers 
used in ocular drug deliver such as chitosan (no toxicity up to 2 mg mL-1) or 
poly(D,L-lactide-co-glycolide) (PLGA) which have been found to be nontoxic in 
ocular tissues (Kompella & Edelhauser, 2011; Sarmento & das Neves, 2012). The 
increase in IC50 of Pa5-MPEG might be due to the presence of polyethylene glycol, 
which is known for it is low toxicity (Fruijtier-Pölloth, 2005) and has been used to 
decrease the cytotoxicity of other polymers via conjugation of polyethylene glycol 
(PEGylation). Mao et al. reported that the PEGylation of different molecular weight 
trimethyl chitosan (TMC) polymers decreased the cytotoxicity of TMC in a L929 
cell line to a great extent.  The authors also reported lower toxicity of TMC with the 
increase in the PEG molecular weight and grafting percentage (Mao et al., 2005). 
The increase in IC50 of Da10 on the other hand might be due to the higher 
modification percentage in comparison to the rest of the polymers. The 
modification percentage is directly linked to the number of primary amine groups in 
the polymer; the higher modification percentage the lower the number of primary 
amine groups. Reports have shown modification of the primary amines on the 
polymer backbone results in a lower toxicity than the parent polymer (Aravindan, 
Bicknell, Brooks, Khutoryanskiy & Williams, 2009; Thomas & Klibanov, 2002). 
Thompson et al. (Thompson, Tetley, Uchegbu & Cheng, 2009) also reported that 
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modification of the primary amine groups on PAA polymer with palmitoyl 
decreased its cytotoxicity in Caco-2 cells by 2-3 fold compared to the parent 
polymer. The authors explained that the lower toxicity of the palmitoyl modified 
PAA polymers (Pa2.5 and Pa5) is due to the fact it has fewer primary amine groups 
in comparison to unmodified PAA. They further supported this finding by 
converting primary amine groups to tertiary amine groups via methyl 
quaternisition, resulting in a 15 fold increase in the IC50. The different trend 
observed in this study (minute impact on the cytotoxicity profile) compared to 
Thompson et al. (2-3 fold increase in the IC50) is possibly due to the different cell 
lines used in the two experiments. Yeung et al. has shown human glial (SVG) cells 
were 11 times more sensitive than RPE (ARPE19) cells when cells were exposed 
to TA for one day (Yeung, Chan, Chiang, Pang & Lam, 2003). Similar findings 
were reported by Nastiti in which he revealed that BALB/c 3T3 cell line was more 
sensitive than RPE cell line (ARPE 19) in response to 24 h exposure to TA 
(Nastiti, 2007).  
The presence of water (up to 10% v/v) in the culture medium as a 
consequence of diluting the polymer solution (sections  5.2.7 and ‎5.2.8.1) would 
change the osmolality of the medium, and hence this might have an effect on cell 
viability. The particle size and the stability of the formulation in culture medium 
were not tested in this work. Proteins deposition on the particulate surface might 
have impact on the surface charge and hence particle stability. 
The low impact of hydrophobic modification on the IC50 of RPE cells found 
in this work is in good agreement with the findings of Hoskins (Hoskins, 2010). 
Hoskins observed little difference between the IC50 of PAA modified polymer (Ch5 
and Da10) and the unmodified PAA backbone when assessed in Caco-2 cell line. 
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The PAA, Da10 and Ch5 had IC50 values of 2.3x10
-2, 2.5x10-2 and 3.7x10-2 mg mL-
1, respectively. Although the author used different cell line, the IC50 values were 
comparable to the IC50 values found in this work. 
The MTT assay was also used to study the cytotoxicity effect of the 
enhancers used in chapter four on the RPE cell line only (due to the limited 
availability of the human corneal epithelial cells). The results showed that both 
tween 80 and L-glutamic acid were non-toxic at the concentrations applied in the 
permeation enhancer studies performed in chapter four. However, RPE 
percentage cell viability decreased with increasing concentration of tween 80. 
Although PAA modified polymers were significantly more cytotoxic than tween 80, 
the latter at 0.01% (w/v) had a very low solubilising capacity (19 µg mL-1 as 
demonstrated in chapter three) compared to the PAA modified polymers. In order 
to achieve comparable solubilising capacity to the PAA modified polymers much 
higher tween 80 concentrations would have to be used and hence it will result in a 
higher toxicity, with the RPE cells displaying less than 10% cell viability. 
The MTT assay is considered to be a cytotoxic end point assay, as the 
formazan crystals formed from the reduction of the MTT salt must be solubilized 
with dimethyl sulfoxide (DMSO) or HCl/isopropanol. The aforementioned 
solubilisers destroy the cells under investigation and therefore time course 
experiments cannot be carried out (Rampersad, 2012). PrestoBlue® reduced by 
dehydrogenases and reductases and does not require an intermediate electron 
acceptor; this might the reason behind the reported higher sensitivity of resazurin 
based assays. Unlike MTT, PrestoBlue® is a non-toxic dye (Larson, Doughman, 
Gregerson, & Obritsch, 1997) and it is stable in culture media, which enables the 
continuous in-vitro measurement of cell proliferation or delayed cytotoxic effect. 
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Furthermore, the PrestoBlue® dye does not require a long incubation time in 
comparison to the MTT assay, a typical incubation time for toxicity test being 
between 10 min to 2 h (Allen et al., 2013; Baehring et al., 2013; Nikolajski, 
Wotschadlo, Clement, & Heinze, 2012). The PrestoBlue® assay overcomes the 
previously mentioned limitations of the MTT assay. In addition, it offers 
advantages over the MTT assay such as being a one step protocol and having 
higher sensitivity (Hamid, Rotshteyn, Rabadi, Parikh & Bullock, 2004; "Invitrogen," 
2013). The reported PrestoBlue® sensitivity is 12 cells per well in comparison to 
1000 cell per well for the MTT assay (Boncler, Różalski, Krajewska, Podsędek & 
Watała, 2013; "Invitrogen," 2013).  
 There are a few publications reporting this assay (Allen et al., 2013; 
Baehring et al., 2013), however none of these reports have used PrestoBlue® on 
corneal or RPE cell lines, hence the feasibility of using the PrestoBlue® assay in 
corneal epithelial cells has been demonstrated in this work. In this study the 
PrestoBlue® assay showed comparable polymer cytotoxicity results to the one 
obtained using the MTT assay on the RPE cell line at low and high polymer 
concentrations (1.3x10-2 mg mL-1 and concentrations higher than 5x10-2 mg mL-1). 
However, unlike the MTT assay at 2.5x10-2 mg mL-1 the PrestoBlue® assay 
showed Pa5-MPEG had considerably higher cell viability compared to the other 
tested polymers. This may be due to the higher sensitivity of the PrestoBlue® 
assay.  
5.5 Conclusion 
The cytotoxicity of the Pa5 and Ch5 polymers were not significantly (t-test, p 
> 0.05) changed in comparison to the PAA in both RPE and corneal epithelia cells 
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lines. Despite the fact that Da10 and Pa5-MPEG had significantly (t-test, p < 0.05) 
higher IC50 the IC50 of PAA, they had little impact on the safety profile of PAA.  
The RPE and corneal epithelial cells are useful cell lines to test the toxicity 
of new materials or delivery systems targeting the posterior and anterior segment 
of the eye. Both MTT and PrestoBlue® assays can be used to determine the 
cytotoxicity of the polymers. However, PrestoBlue® would appear to offer some 
advantages over the MTT assay in terms of simplicity and shorter incubation time. 
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6.1 Discussion 
The first amphiphilic polymers (block copolymers) were prepared in early 
1950s (Velichkova & Christova, 1995). In the early 1980s, amphiphilic polymers 
were shown to form nano sized self-assemblies (SA) and exhibit potential as 
hydrophobic drug solubilisers (Hoskins, Lin & Cheng, 2012). A decade later in the 
1990s, extensive research had been conducted to explore the ability of these 
nanoparticles to encapsulate ophthalmic drugs and overcome ocular physiological 
barriers (Alonso, 2004; Liu, Jones & Gu, 2012). Polymeric nanoparticles have 
been reported to prolong drug residence time in the eye (Bourges et al., 2003; 
Chaiyasan, Srinivas & Tiyaboonchai, 2013; Nagarwal, Kumar & Pandit, 2012) and 
to increase corneal drug permeability, through the epithelial uptake of drug loaded 
nanoparticles and via altering the corneal epithelia cells tight junctions (Contreras-
Ruiz et al., 2011; Enriquez de Salamanca et al., 2006). In order to prepare nano 
sized SA, four amphiphilic polymers (Pa5, Pa5-MPEG, Ch5 and Da10) were 
synthesised by attaching three hydrophobic groups namely, palmitoyl, cholesteryl 
and dansyl (Pa, Ch and Da) and a hydrophilic (MPEG) group onto a 
poly(allylamine) backbone. The four comb-shaped amphiphilic polymers were 
synthesised with a high yield (>81%) and good reproducibility. The presence of the 
attached groups was confirmed and quantified using elemental analysis, DSC and 
NMR spectroscopy. The DSC thermograms of the Pa5, Ch5 and Da10 amphiphilic 
polymers revealed the amorphous nature of the aforementioned polymers, 
whereas the Pa5-MPEG polymer had a crystalline nature. The 
1H NMR and 
elemental analysis confirmed the presence of the attached Pa, Ch, Da and MPEG 
groups onto a poly(allylamine) backbone and showed that the percentage mole 
modification (8.9% Pa, 6.2% Ch, 3.4% MPEG and 9.6% Da) of the attached 
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moieties was similar to the initial feed ratios (5% initial feed ratio for Pa, Ch and 
MPEG, 10% initial feed ratio for Da).  
The formation of SA of the amphiphiles in aqueous media was confirmed 
using PCS, TEM and a hydrophobic probe (pyrene). The study demonstrated that 
the type of moiety attached onto the PAA backbone had a significant influence on 
the CAC, SA hydrodynamic size and the SA surface charge. In an aqueous 
environment all four amphiphiles were capable of forming spontaneous nano SA 
comprising of a hydrophobic inner core (Figure ‎6.1). The SA were shown to have a 
hydrodynamic diameter of 114-314 nm. The 5% hydrophobically modified 
polymers (Pa5, Ch5 and Pa5-MPEG) formed uniform single size population 
aggregates, whereas the 10% modified polymer (Da10) had a bimodal size 
distribution. The bimodal size distribution of Da10 was due to the presence of small 
compact assemblies (approximately 40 nm) formed due to greater hydrophobic 
interactions, alongside larger loose assemblies (100-400 nm) (Chiu, Chern, Lee & 
Chang, 1998; Wang, Tan, Huang, Che & Du, 2009). The Ch5 amphiphilic polymer 
had the lowest CAC (0.0052 mg mL-1) and the lowest core polarity in comparison 
to Pa5 (0.011 mg mL
-1) and Pa5-MPEG (0.027 mg mL
-1).  
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Figure ‎6.1: Schematic diagram showing the formation of the polymeric SA’s from amphiphilic 
polymers in aqueous media.  
 
The SA formed in aqueous media were able to load high concentrations 
(1263, 910, 744 and 455 µg mL-1 for Da10, Pa5-MPEG, Ch5 and Pa5 polymers, 
respectively) of a poorly water soluble drug (TA) compared to the inherent 
aqueous solubility of TA and compared to the concentrations achieved using 
conventional solubilisers. The Da10, Pa5-MPEG, Ch5 and Pa5 TA-SA enhanced the 
TA aqueous solubility by 92, 65, 52 and 32-fold, respectively. The TA-SA 
formulations were simple to manufacture in comparison to other polymeric 
nanoparticles, in which multistep and time consuming preparation methods are 
required (Rao & Geckeler, 2011), facilitating the possibility of scaling up to 
industrial scale and most importantly the fabrication avoids the use of organic 
solvents, eliminating undesirable in-vivo effects such as toxicity. The mean 
hydrodynamic diameters of the TA-SA formulations had a size range of 200–334 
nm and a positive surface charge of 21-46 mV. The small size and positive charge 
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of the TA-SA formulations are ideal for a potential formulation to overcome 
physiological and anatomical barriers of the anterior and posterior segments of the 
eye, as the retention and permeation across ocular tissues is reportedly 
dependent on the size and charge of nanoparticles (Koo et al., 2012; Liu, Jones & 
Gu, 2012; Pathak & Thassu, 2009). Research on the use of poly(D,L-lactide-co-
glycolide) (PLGA) nanoparticles has revealed that the uptake of small size PLGA 
nanoparticles (100 nm) was found to be higher than larger nanoparticles (800 nm) 
in primary cultured rabbit conjunctival epithelial cells (Qaddoumi et al., 2004), and 
thus the higher cellular uptake of smaller nanoparticles resulted in higher drug 
delivery enhancement. The size of particles also plays a significant role in 
penetrating the retinal tissues; intravitreal injection of 2 µm, 200 nm and 50 nm 
polystyrene spheres into rabbit eyes revealed that the 2 µm microspheres were 
unable to penetrate the retina, while both the 200 and 50 nm nanospheres were 
capable of penetrating the retinal tissue (Sakurai, Ozeki, Kunou & Ogura, 2001). 
Hence, utilisation of a nanoparticle size allows the potential to affect potential 
distribution in the retinal tissue and RPE cells or localisation in the vitreous humour 
when applied intravitreally. The size of nanoparticles also determines their 
diffusivity across the vitreous humour. For example, Xu et al. have shown that 
nanoparticles with a diameter of 1190 nm or larger had restricted movement in 
bovine vitreous humour regardless of their surface chemistry.  In contrast smaller 
nanoparticles (510 nm) were able to freely diffuse across the vitreous humour (Xu 
et al., 2013). The size of the TA-SA should therefore allow the SA to move freely 
across the vitreous humour and penetrate the retinal tissue (Sakurai, Ozeki, 
Kunou & Ogura, 2001; Xu et al., 2013). The positive charge of the TA-SA is 
desirable in order to increase TA pre-corneal retention time through interactions 
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with negatively charged mucins at the corneal surface (Li, Zhuang, Wang, Sui & 
Pan, 2012; Mitra, 2003). Also the movement of nanoparticles in the vitreous 
humour has been shown to be dependent on the surface charge. Positively 
charged nanoparticles were found to localise into the three dimensional collagen 
fibrils network of the vitreous humour when compared to their negatively charged 
counterparts (Kim, Robinson & Csaky, 2009; Koo et al., 2012). In comparison to 
negatively charged nanoparticles immobilized positively charged nanoparticles 
injected in the vitreous humour stay suspended for a longer period before 
migrating to the retina and aqueous humour (Mains & Wilson, 2013; Sakurai, 
Ozeki, Kunou & Ogura, 2001). Consequently cationic nanoparticles cleared slower 
than anionic nanoparticles via the trabecular meshwork, blood vascular system 
(i.e. ciliary body (Kim & Csaky, 2010)) and cells capable of engulfing and clearing 
the nanoparticles (i.e. phagocytes by the astrocytes of the internal limited 
membrane of the retina (Mains & Wilson, 2013)).  
The ability of the SA to encapsulate TA and the in-vitro release of TA from 
the TA-SA formulations were dependent on the type of hydrophobic group 
attached onto PAA backbone and the modification percentage. The Ch5, Pa5 and 
Pa5-MPEG TA-SA’s formulations were able to achieve sustained in-vitro release of 
TA over 47 h, whilst the Da10 TA-SA formulation achieved sustained release over 
145 h. The higher TA entrapment and longer release time of Da10 TA-SA 
formulation in comparison to the 5% hydrophobically modified TA-SA formulations 
(Pa5, Ch5 and Pa5-MPEG) was due to the higher modification percentage of the 
dansyl moiety and better TA-dansyl moiety compatibility. Unlike Pa5, Pa5-MPEG 
and Ch5 polymers modified with alkyl or cyclic ring pendant groups, Da10 consists 
of an aromatic pendant group which can potentially form two hydrogen bonds and 
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π binding with TA. As a result of the high TA affinity to the hydrophobic domain 
(dansyl group) (Chang et al., 2012), the Da10 formulation had the highest TA 
solubilisation and was capable of releasing TA in a sustained manner for a longer 
period of time. The drug release from the SA formulations can potentially be 
controlled by selecting the appropriate pendant groups grafted onto the polymers. 
The variation in TA release time is beneficial as it allows drug release profiles to 
be tailored according to the targeted site. Ocular formulations applied topically and 
targeting the anterior segment should be retained at the ocular surface long 
enough to ensure sustained drug release but should also release the drug at a 
rate faster than the drug clearance rate. In addition, topical ocular formulations 
should not interfere with vision or cause irritation. On the other hand, to minimise 
the application frequency of formulations applied through invasive injections, it 
would be preferred that the posterior formulations release drugs at a slow rate to 
maintain prolonged therapeutic activity. The Da10 TA-SA formulation is more 
suitable than Pa5, Pa5-MPEG and Ch5 TA-SA formulations for posterior drug 
delivery, as the Da10 TA-SA formulation prolonged TA release. In contrast, Pa5, 
Pa5-MPEG and Ch5 TA-SA formulations (release approximately 100% of TA load 
in two days) are more suitable for topically applied formulations targeting the 
anterior segment of the eye, as the Da10 formulation released approximately 100% 
of TA load in six days, which is much higher than the residence time of a topically 
instilled formulation in the eye (typically less than 24 h).  
In order to test the ocular permeability of the developed TA-SA formulations 
and other potential formulations a porcine in-vitro eye model was developed and 
was found fit for purpose. The developed eye model mimicked the posterior 
segment of the eye by employing posterior porcine ocular tissues, and is based on 
Chapter 6: General Discussion 
 
223 
 
the well-established in-vitro permeation system, the Franz cell, which is cost-
effective and relatively quick to set up in comparison to other in-vitro eye models 
such as the perfused eye model or cell culture model (De Coo, Zonnenberg & 
Trap, 1993; Reichl, Döhring, Bednarz & Müller-Goymann, 2005). Little has been 
done to develop and validate an in-vitro eye model fit for the purpose of 
permeation studies. Typically in-vitro permeation eye models test the permeability 
of ocular tissues using buffer solutions as receiver fluids in a diffusion cell such as 
Ussing chambers or Franz cells (Araujo, Garcia, Mallandrich, Souto & Calpena, 
2012; Kadam, Cheruvu, Edelhauser & Kompella, 2011; Loch et al., 2012; Mora et 
al., 2005; Olsen, Edelhauser, Lim & Geroski, 1995; Thakur, Kadam & Kompella, 
2011). Sink conditions for poorly water soluble drugs could not be maintained in 
these models over long experimental durations using buffer solutions alone. The 
development process included selecting a suitable receiver fluid in order to 
maintain sink conditions for TA over the duration of the experiment. TA permeation 
studies performed on porcine posterior ocular tissues using various receiver fluids 
showed that up to 10% of ethanol in modified Dulbecco’s buffer solution could be 
used as a receiver fluid without significantly altering the permeability of the tissue, 
through the co-permeation of TA by the effect of solvent drag. Partial validation of 
the developed in-vitro porcine eye model included assessing tissues barrier 
integrity using tritiated water and assessing and comparing the permeability of four 
hydrophilic markers across human and porcine scleral tissues. The barrier integrity 
of frozen porcine posterior ocular tissue was found to be similar to the barrier 
integrity of fresh tissue as demonstrated by the TA and 3H2O permeation studies. 
Hence, the use of frozen tissue is a practical alternative and more convenient 
option to using fresh tissue (fresh tissue typically has limited availability due to it 
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not being easily obtained from slaughterhouses in large amounts and it requires 
controlled transport conditions which are time consuming and costly). It was found 
that determining the permeation of tritiated water through porcine ocular tissue 
over a 15 min period can be used to assess the tissue barrier integrity, and can be 
used to normalise the flux of model compounds across porcine posterior tissues. 
Tritiated water has previously been used in monitoring the barrier integrity of 
tissues, in particular human skin and nails (Brown et al., 2009; Lawrence, 1997). 
The normalisation allows the compensation of the inherent variability due to non-
uniformity thickness between tissue samples and thus this increases the reliability 
of the in-vitro eye model. The normalisation has a significant advantage as the 
exact thickness of the scleral tissue is hard to measure, due to the sclera not 
having a uniform thickness across the entire eye and therefore makes it 
impractical to cut a uniform section. The four markers had similar permeability in 
both human and porcine scleral tissues when the scleral thickness at the equator 
was considered (the kp values of FSS, 4, 10 and 20 kDa FITC-dextran normalised 
by the equator thickness of human scleral tissues were 1.5 x 10-5, 0.6 x 10-5, 5.0 x 
10-6 and 4.9 x 10-6  cm.h-1, respectively, whereas the normalised kp values of 
porcine scleral tissues were 1.6  x 10-5, 0.6 x 10-5, 7.7 x 10-6 and 7.3 x 10-6 cm.h-1, 
respectively) and permeability decreased with increasing molecular weight of the 
marker. The inverse relationship and the abrupt decline in the permeability of 
various compounds and their molecular weights has been reported using bovine 
scleral tissue by Maurice et al. (Maurice & Polgar, 1977) and human sclera tissue 
by Olsen et al. (Olsen, Edelhauser, Lim & Geroski, 1995). The similarity in 
permeability of the markers between the two species (human and porcine) 
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indicates the suitability of porcine scleral tissues as an alternative to human scleral 
tissue. 
The nano size TA-SA formulations were tested on the in-vitro porcine eye 
model described above to study and compare the permeability of TA from TA-SA’s 
and a TA suspension. The TA-SA formulations did not significantly increase TA 
flux (approximately 0.6 µg.cm-2.h-1) across posterior porcine ocular tissues and 
human scleral tissue when compared to TA suspension (approximately 0.5 µg. cm-
2.h-1), indicating that the nano sized TA-SA did not permeate across the scleral 
tissues. This finding can be explained by the passive diffusion of penetrants in 
between the free spaces of the collagen bundles (intracollagen pathways), which 
is the main determinant of the rate and size of the penetrants traversing across the 
sclera. The distance between human scleral fibres (intracollagen pathways, centre 
to centre) is approximately 60 nm (Edwards & Prausnitz, 1998; Fatt & Weissman, 
1992) and hence the TA-SA (200–334 nm) were unable to travers across the 
sclera. This is supported by the results published by Amrite et al. (Amrite, 
Edelhauser, Singh & Kompella, 2008), in which the workers reported quantifiable 
permeation of the 20 nm nanoparticles across bovine sclera, whereas the 200 nm 
nanoparticles were showing not to penetrate through the scleral tissue. The fact 
that no enhancement of TA permeation across posterior porcine ocular tissues 
(sclera, choroid and retina)  was observed using the TA-SA was similar to results 
obtained from the chemical enhancer studies performed on human and porcine 
scleral tissues. In these studies the enhancers showed no significant 
enhancement effect on human and porcine scleral tissues permeability. Even 
though TA-SA formulation could not penetrate the posterior tissues, they might be 
of interest for ophthalmic topically administered formulations as corneal epithelium 
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cells uptake nanoparticles and positively charged nanoparticles increase drug 
retention time when topically applied at the front of the eye (De Campos et al., 
2003; De la Fuente et al., 2010). The uptake of nanoparticles by the corneal 
epithelium cells is reported to improve ocular bioavailability of the drug and 
prolong the therapeutic action (Aksungur et al., 2011; Hippalgaonkar, Adelli, 
Hippalgaonkar, Repka & Majumdar, 2013; Nagarwal, Kumar & Pandit, 2012). 
Such an effect would be useful for treating persistent and chronic diseases such 
as endophthalmitis and glaucoma. 
Testing TA-SA formulations on corneal tissue using buffer solution was not 
possible due to the severe corneal swelling over the duration of the experiment (24 
h). An in-vitro anterior eye permeation model was developed by employing porcine 
corneal tissue in modified Franz cells. A suitable receiver fluid consisting of a de-
swelling agent (5% w/v 500 kDa Dextran) was developed for the corneal model so 
as to prevent swelling of the cornea and to maintain the thickness of the corneal 
tissue over the duration of the experiment. The storage conditions had an impact 
on the corneal permeability in that the permeability of stored corneas increased 
with the increase in duration of storage time (the flux rate of FSS across fresh 
corneal tissue increased from 0.44 µg.cm−2.h−1 to 32.2 and 75.84 µg.cm−2.h−1 after 
one and two weeks storage, respectively). This finding (increased corneal 
permeability with the increase in duration of storage time) might explain the lack of 
difference in marker permeability across stored corneas in the presence of 
permeation enhancers. The stored corneas might not be susceptible to permeation 
enhancement in comparison to fresh corneas due to the damaged epithelium 
layers or loosen corneal tight junctions as a result of storage. The percentage of 
damaged corneal endothelial cells in organ culture medium and dextran containing 
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medium increases with storage time and is affected by the storage and transport 
media employed (Borderie, Baudrimont, Lopez, Carvajal & Laroche, 1997; Pels, 
Beele & Claerhout, 2008). The presence of de-swelling agent (500 kDa dextran) 
has been shown to cause an 8.4% loss in the number of endothelia cells after two 
days and severe epithelial injuries and lysis of keratinocytes after four days 
(Borderie, Baudrimont, Lopez, Carvajal & Laroche, 1997). This highlights the 
importance of developing an in-vitro corneal model using fresh corneas which is 
able to mimic the in-vivo response at a fraction of the cost of in-vivo studies. 
Two ocular cell lines (RPE and HCE) and two cytotoxicity assays (MTT and 
PrestoBlue®) were investigated in order to determine the toxicity of potential 
formulations or excipients. The hydrophobically modified polymers used in the TA-
SA had similar toxicity profiles in the RPE cells as the unmodified PAA. The IC50 of 
the modified polymers were relatively low (2.9x10-2 - 4.9x10-2 mg mL-1) which 
suggest a higher toxicity of these polymers in comparison to other common 
polymers used in ophthalmic drug deliver such as PLGA (nontoxic (Kompella & 
Edelhauser, 2011)) or chitosan (no toxicity up to 2 mg mL-1 (Sarmento & das 
Neves, 2012)). The two cytotoxicity assays were able to determine the toxicity of 
the polymers in the ocular cell lines. However, the PrestoBlue® method is simpler 
than the MTT method and has a shorter incubation time. 
The importance of this work relies on providing a partial validated eye 
model to test potential ocular formulation. The developed eye model has 
significance to the pharmaceutical industry and can be refined and further 
validated to produce precise and accurate prediction of in-vivo the potential 
formulation permeability 
. 
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6.2 Future Work 
The hydrophobic drug (TA) was not tested on corneal tissue due to severe 
corneal swelling and high lag time. The corneal swelling was resolved by the 
addition of 5% dextran 500 kDa to the receiver fluid; however an analysis method 
quantifying the hydrophobic drug in the de-swelling medium was not been 
developed. In the future, it would be desirable to investigate various separation 
techniques such as liquid extraction, solid phase extraction or centrifugation to 
separate the hydrophobic drug from the matrix of the receiver fluid especially the 
500 kDa Dextran (the 500 kDa interferes with the HPLC column, resulting in an 
increased pressure due to partial blockage of the column). Once a quantification 
assay of the hydrophobic drug has been developed and validated, polymeric SA 
entrapping the hydrophobic drug should be tested on corneal tissues.  
In this work, TA (hydrophobic drug) was used to study the loading capacity 
of the polymeric SA, it would be beneficial to encapsulate other hydrophobic drugs 
and determine their loading capacity and their in-vitro release. In the future it 
would be desirable to carry out short and long term stability tests on aqueous and 
freeze dried formulations, in order to determine the shelf life of these formulations. 
Nanoparticles have previously been shown to facilitate penetrant permeation 
across corneal tissue by altering the tight junctions between the epithelia cells or 
by promoting cellular uptake of nanoparticles (Hippalgaonkar, Adelli, 
Hippalgaonkar, Repka & Majumdar, 2013; Tiyaboonchai, 2003). Testing the drug-
SA on corneal tissue is crucial as these formulations might enhance the drug 
permeability across the corneal tissue and provided different results from the 
posterior tissues. 
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A longer experiment duration in the developed in-vitro corneal model is 
required to investigate drugs with high corneal lag time. The developed in-vitro eye 
model did not examine the effect of long experiment duration on the viability of the 
corneal epithelia cells or the looseness of the tight junctions after permeation 
studies. The corneal tissue should be examined and compared to a control at the 
end of the permeation study. Furthermore the effect of any anatomical change on 
the permeation should be determined. 
This study showed prolonged corneal storage time might either decrease 
cell viability or loosen tight junctions between the epithelia cells as indicated by the 
increase in marker permeation with the increase in storage time. Further work 
should determine whether the increase in corneal permeability is due to damage in 
epithelia cells or due to loose tight junctions. Other corneal storage conditions 
should be investigated in order to minimise changes in corneal barrier integrity and 
maintain cell viability and tight junctions. 
The toxicity of the amphiphilic polymers was determined on RPE cell lines; 
however neither the toxicity of the hydrophobic drug nor the formulations was 
determined in this study. Performing in-vitro intracellular localisation studies to 
determine the mechanism of cellular uptake in the cell would be useful as this 
might provide information about the fate of the drug and polymer. 
In conclusion, four pendant groups were attached to a PAA backbone 
resulting in four amphiphilic polymers. These amphiphilic polymers formed 
spontaneous nano-polymeric SA in aqueous media. A poorly-water soluble drug 
(TA) was loaded into the nano-polymeric SA with a significantly higher drug 
loading than its saturated aqueous solubility or that achieved through the use of 
conventional solubilisers such as cremophor® EL and tween® 80. The solubilising 
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capacity, SA size and surface charge and drug release can be controlled by 
selecting the appropriate pendant groups to graft onto the polymers. A porcine in-
vitro eye model was developed and found to have good correlation with the human 
in-vitro model providing strong evidence that the porcine in-vitro eye model can be 
used to screen potential formulations. The in-vitro model can assess hydrophobic 
and hydrophilic drug permeation through posterior ocular tissues and hydrophilic 
drugs through the corneal tissue. The drug loaded SA (TA-SA) did not significantly 
increase TA flux through human or porcine scleral tissues. However these SA 
might be of interest for ophthalmic topically administered formulations due to their 
small size and positive charge. In future, the developed in-vitro porcine eye model 
can be used to screen various formulations or enhancers targeting both the 
anterior and the posterior segment of the eye before testing in-vivo. 
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Appendix A 
Markers Permeations Fluxes 
Table 1: Summary of the flux of 10 kDa FITC-Dextran added to various enhancers and elevated temperature 
through human corneal and scleral tissues and porcine scleral tissue. 
Enhancer 
Human Cornea 
Flux ± S.D. 
(µg.cm−2.h−1) 
Human Sclera 
Flux ± S.D. 
(µg.cm−2.h−1) 
Porcine Sclera 
Flux ± S.D. 
(µg.cm−2.h−1) 
Control 83.5 ± 40.3 362.4 ± 119.5 105.0 ± 27.5 
0.1% Glutamic Acid 29.6 ± 10.4 387.0 ± 156.3 157.8 ± 62.4 
0.001% Tween 80 155.3 ± 68.5 280.8 ±  96.2 109.4 ± 40.8 
0.01% Tween 80 134.8 ± 52.2 334.8 ± 135.8 150.0 ± 23.9 
45 °C 187.5 ± 80.6 425.1 ± 222.1 152.3 ± 33.1 
Pa5 polymer 92.2 ± 3.8 256.1 ± 119.1 122.0 ± 41.9 
Acetate Buffer pH 5 121.6 ± 88.6 
423.3 ± 169.6 
 
124.4 ± 41.1 
0.5% Chitosan 51.7 ± 13.9 449.0 ± 65.8 123.7 ± 42.2 
 
Table 2: Summary of the flux of fluorescein sodium salt, 4, 10 and 20 kDa FITC-Dextran through 
human and porcine ocular tissues. 
Marker 
Sclera Cornea 
Human 
Flux ± S.D. 
 (µg.cm−2.h−1) 
Porcine 
Flux ± S.D. 
 (µg.cm−2.h−1) 
Human 
Flux ± S.D. 
 (µg.cm−2.h−1) 
Porcine 
Flux ± S.D. 
 (µg.cm−2.h−1) 
Fluorescein 
sodium salt 
188.0 ± 35.9 99.5 ± 15.8 128.5 ± 10.9 
 
27.5 ± 5.9 
4 KDa FITC-
Dextran 
745.0 ± 153.5 352.0 ± 93.0 201.0 ± 27.0 
 
28.2 ± 7.6 
10 KDa FITC-
Dextran 
434 ± 105 299.6 ± 55.7 49.4 ± 19.5 30.6 ± 9.0 
20 KDa FITC-
Dextran 
426 ± 164 284.6 ± 154.9 53.9 ± 18.4 42.1 ± 25.8 
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Appendix B 
STANDARD OPERATING PROCEDURE (SOP) – ORGAN CULTURE 
STORAGE OF CORNEAS 
 
A. Purpose 
Deceased donor selection guidelines for tissue donors allows for the storage of 
corneas in organ culture media. This is mainly performed for donor eyes where the 
donor has either recovered from a systemic infection within two weeks of death or 
suffered from a bacterial infection at the time of death. This procedure defines the 
steps to be taken when storing corneoscleral buttons in organ culture media.   
 
B. Definitions 
Septic  Term used by the eye bank to define the status of a donor that had a 
bacterial infection at the time of death or within two weeks prior to 
death. All septic donations must be stored in organ culture media.  
 
C. Materials and equipment 
Procedure labels  
Media thaw label  
Corneal storage label  
Tissue labels (created by the eye bank database) 
1 x bottle of Povidone Iodine 5% w/v (or 3 x bottles of eye drops) 
1 x bottle of Normal Saline 0.9% w/v 
1 x bottle of Framycetin 0.5% v/v 
1x bottle 70% Alcohol for storage of sclera in alcohol (if required) 
1 x corneal excision pack containing a trephine, 2 forceps, 2 scissors, scalpel 
1 x blue eye bank pack containing a tray, 4 large gallipots, 2 small gallipots (not 
required for this procedure), gauze swabs 
1x sterile suture 
2 x organ culture media (defrosted) 
2 x sampling caps  
1 x sterile microbiology tube  
6 x sterile pots (for sclera storage – if required)  
4 x TSA settle plates for environmental monitoring 
1 x sterile gloves  
Donor eyes in containers 
Donning gloves, clean room suit, mask, clean room boots, sterile gloves 
Sterile alcohol spray. 
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D. Safety Concerns 
Cornea preparation and transfer and all microbiology testing must be carried out in 
class two biological cabinets in the GMP Grade B room. Personnel protective 
equipment provided (cleanroom clothing, gloves and masks) as described in 
MLEB SOPC 2.2 and C2.3 must be worn during processing of tissue.  
Only one donation should be processed at a time. The cabinet and work surfaces 
should be emptied and cleaned before a second donation is processed.  
The tissue label should be applied to the organ culture bottle before they are taken 
into the grade B room.   
 
E. Responsibilities  
The Eye Bank Technicians for performing the procedure as described and report 
any deviations. The Eye Bank Manager to ensure that the Technicians are trained 
to perform the procedure. 
 
F. Procedure 
Corneal button storage - Preparation of media  
The media is stored at -20°C and should be thawed at ambient room temperature 
(~4hrs) or at 30°C using the water bath (~30mins). Water in water bath should be 
supplemented with a water bath cleanse solution prior to heating – this will remove 
any microbes from the water. Sufficient time should be allowed to thaw the media 
before the processing of tissue begins, as introduction of the cornea to media not 
thawed sufficiently may cause damage to the endothelial cells.  
On removal from the freezer a ‘media thaw label’ must be applied providing the 
following information  
 Date of removal  
 Time of removal  
 Operator 
The media cannot be refrozen once thawed, but will remain suitable for use for up 
to five days when stored at +4°C and remains unopened. Media not used within 
this timeframe must be destroyed  
 
Corneal button dissection  
Prior to entering the cleanroom suite ensure room pressures are within the 
required range and recorded on the Room Pressure Log (this is a daily activity, the 
pressure may have already been recorded, but it is good practice to visually check 
the pressure reading before entering the cleanroom suite).  
 
In preparation room: 
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1. Place batch labels from items on the batch record for organ culture storage 
form 
2. Disinfect hands with alcohol gel 
3. Put on gloves. 
4. Spray alcohol and wipe inside of pass through  
5. Place items in lower section of pass through. Spray or wipe with sterile 
alcohol. 
6. Where sterile products are double wrapped – remove the outer packing 
layer and place into the pass through without touching the inner packaging. 
 
Move through areas: 
7. Move to entrance of change room 2  
8. Change into clean room apparel as per MLEB SOP C2.2  
 
In the cleanroom  
9. Move into processing room and remove items from clean room pass 
through. 
10. Check safety cabinet pressure is correct and wipe / spray interior surface 
with sterile alcohol. 
11. Wipe area to layout equipment on work surface. 
12. Place and expose environmental monitoring settle plates as per MLEB SOP 
I1.1  
13. Open blue pack out into cabinet and create a sterile field. 
14. Open all other sterile equipment onto the sterile field.  
15. Spray down all non sterile products with ethanol and place into the cabinet 
adjacent to the sterile field. 
16. Open and fill (non-touch) gallipots with: 
i. Framycetin 
ii. Saline x 2 
iii. Povidone iodine 
17. Put on second pair of sterile gloves to begin the processing session.  
18. Transfer globes into the first pot of povidine iodine using forceps.  
19. Discard pots and forceps. 
20. Eyes soaked as follows: 
i. Povodine iodine x 3 minutes 
ii. Then saline wash 
iii. Framycetin x 3 minutes 
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iv. Final rinse in saline. 
An alarm clock is provided to ensure that time limits are not exceeded, and 
should be used in all cases.  
Note: Should Framycetin not be available use Gentamycin as alternative or take 
advice from Pharmacy (Gentamycin dilution – 4 vials (80mg/2ml) per 100mls 
sterile NaCl). An additional 3 minutes in Framycetin/Gentamycin can be performed 
if the donor had systemic sepsis prior to death. 
21. Invert the media gently a number of times, remove the tamper proof cap 
from the organ culture media, leave the cap over the bottle top until the 
cornea button is ready to be added to the media. Note – this is a single use 
cap so will be discarded and replaced with a new cap once the button has 
been added to the media.  
22. Place a knot in the end of the suture in preparation to suspend the cornea. 
23. Remove 1 globe from final saline wash. 
24. Wrap a sterile gauze swab round the globe. Hold the globe gently. 
25. Dissect off conjunctiva. 
26. Incise 360 degrees about 4-5 mm from the limbus with the trephine, and 
knife and complete with corneal scissors. Adjust tension if ciliary body 
bulges. 
Important: 
 Maintain the anterior chamber as long as possible. 
 Do not distort the cornea. 
 Do not touch the endothelium  
27. Lift cornea, with minimal distortion, prepare the cornea for suspension in the 
media using the suture through the sclera. Note – work from the epithelium 
side in to ensure the endothelial surface is protected from the suture.  
28. Once the cornea is at the end of the thread use the suture to secure the 
cornea to the side of the gray sampling cap bung, take the thread from the 
inside of the cap to the outside close the bung.  
29. Lower the cornea in to the media, take care not to touch the outer surface 
of the bottle. Close container with a sterile sampling cap. Make sure the 
cornea is suspended half way into the media and is not touching the bottom 
or to close to the top of the media. Media will be removed as part of the 
microbiology testing and may lead to exposure of the cornea if suspended 
to close to the top of the bottle.  
30. Take a sample of the sclera for microbiology testing and place into the 
designated sterile tube.  
 
 
Important – sclera storage  
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Sclera can be stored for transplant if infection at the time of death was  
 - not eye related 
 - not systemic  
 - not viral   
 
31. If sclera is to be stored follow MLEB/SOP E1.5 or E1.7. Place all internal 
eye structures into a separate container for transfer to research or 
appropriate discard.  
32.  Repeat for second eye  
33. Place all used equipment, wrappings and materials in bottom shelf of pass 
through. 
34. Place ocular tissue on top shelf of pass through. 
35. Remove all rubbish and tidy room and wipe down surfaces and safety 
cabinet with disinfectant and sterile alcohol spray. 
36. Leave corneal storage room and go to second change area to remove 
clean suit and boots – according to MLEB/SOP C2.4 Leaving grade B and 
C areas 
 
In preparation room: 
37. Remove containers with corneas from pass through d (and scleral tissue if 
prepared).  
38. Add the corneal storage label to each of the organ culture bottles and 
record the following information  
a. Date of storage  
b. Time of storage  
c. Operator 
39. Place organ culture bottles into the +31°C incubator designated as the 
‘quarantine one’.  
40. Remove equipment, wrappings and instruments from pass through d. Clean 
pass through with sterile Alcohol spray and low lint wipes. 
41. The labelled tissue containers (sclera and retina if research if applicable) 
and batch record form is placed on the top shelf of pass through a. 
42. Clinical waste should be placed on the lower shelf to be moved into the 
receiving room for disposal. 
43. The preparation room is tidied and the work surface is wiped down with 
disinfectant and sterile alcohol. 
44. The technician then moves to change room 1.  
In the receiving room: 
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45. Place labelled sclera containers in quarantine tray into the quarantine 
refrigerator  
46. Remove clinical waste bag and place in clinical waste bin 
47. Remove waste fluid bottle and dispose of fluids in trap waste. 
48. Clean waste trap, sink and surface areas (including pass through a) using 
alcohol spray. 
 
In office 
49. Update donor file with time of storage and processing comments. 
50. Place notes and batch record form in file and place file in tissue in 
quarantine (organ culture). 
51. Update the donor database and add date of 7 day microbiology test in the 
lab diary.  
 
Maximum storage period and microbiology testing  
52. Microbiology testing must be carried out on day seven (or later) of storage – 
see MLEB SOP E1.11 Microbiology testing of corneas in organ culture 
53.  The maximum storage time for corneas in organ culture is 28 days. This 
can be extended to 30 days on agreement form the Eye Bank Manager.  
54. Corneas must be stored at +31°C +/-2°C whilst in organ culture media. If 
the temperature exceeds 37°C at any point the graft will no longer be 
deemed suitable for corneal grafting. 
 
G. Records to be kept 
All records will be kept for 30 years from the use or disposal of the tissue.  
 
H. Copies of forms 
MLEB FORM Batch record for organ culture storage  
MLEB/FORM Organ culture processing and microbiology results form  
 
I. References  
HTA Directions  
Manufacturer Guidelines – Eurobio  
MLEB SOP C2.2 People moving from preparation room to cleanrooms 
MLEB SOP C2.3 People moving from receiving room area to preparation area 
MLEB SOP I1.1 Sessional monitoring 
MLEB SOP E1.11 Microbiology testing of corneas in organ culture 
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MLEB SOP C2.4 Leaving Grade B and Grade C areas 
MLEB SOP E1.5 Preparing and storing sclera in alcohol 
 
